


| | | | |
|---|---|--|--|
| Form PTO-1390 (REV 11-98) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTORNEY'S DOCKET NUMBER 480848.9002* |
| TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 | | | US. APPLICATION NO. (If known, see 37 CFR 1.5) 09/830837 |
| INTERNATIONAL APPLICATION NO. PCT/CA99/01058 | INTERNATIONAL FILING DATE 04 November 1999 | PRIORITY DATE CLAIMED 04 November 1998 | |
| TITLE OF INVENTION MAMMALIAN SUBTILISIN/KEXIN ISOZYME SKI-1: A PROTEIN CONVERTASE WITH A UNIQUE CLEAVAGE SPECIFICITY | | | |
| APPLICANT(S) FOR DO/EO/US SEIDAH, Nabil; CHRETIEN, Michael; MARCINKIEWICZ, Mieczyslaw; LAAKSONEN, Reijo; DAVIGNON, Jean | | | |
| <p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input checked="" type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11. to 16. below concern document(s) or information included:</p> <ol style="list-style-type: none"> <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98 and Form 1449. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input checked="" type="checkbox"/> Other items or information: Copy of Form PCT/IB/308 dated 11 May 2000 Confirming Transmittal of the International Application to the US as Designated Office; Postcard | | | |

| | | | | | |
|---|--------------|---|--|--|----|
| U.S. APPLICATION NO. 09/830837 | | INTERNATIONAL APPLICATION NO. PCT/CA99/01058 | | ATTORNEY'S DOCKET NUMBER 480848.9002* | |
| 17. [X] The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$760.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00 | | | | CALCULATIONS PTO USE ONLY | |
| ENTER APPROPRIATE BASIC FEE AMOUNT = | | | | \$970.00 | |
| Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)). | | | | \$ | |
| CLAIMS | NUMBER FILED | NUMBER EXTRA | RATE | | |
| Total claims | 54 -20 = | 34 | X \$18.00 | \$612.00 | |
| Independent claims | 7 -3 = | 4 | X \$78.00 | \$312.00 | |
| MULTIPLE DEPENDENT CLAIM(S) (if applicable) | | | + \$260.00 | \$ | |
| TOTAL OF ABOVE CALCULATIONS = | | | | \$1894.00 | |
| [X] Applicant hereby claims reduction by 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28). | | | | \$947.00 | |
| SUBTOTAL = | | | | \$947.00 | |
| Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.429(f)). | | | | + \$ | |
| TOTAL NATIONAL FEE = | | | | \$947.00 | |
| Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property | | | | + \$ | |
| TOTAL FEES ENCLOSED = | | | | \$ | |
| | | | | Amount to be refunded | \$ |
| | | | | Charged | \$ |
| a. [] A check in the amount of \$ <u>00</u> to cover the above fees is enclosed. b. [X] Please charge my Deposit Account No. <u>17-0055</u> in the amount of \$947.00 to cover the above fees. A duplicate copy of this sheet is enclosed. c. [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>17-0055</u> . A duplicate copy of this sheet is enclosed. | | | | | |
| NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status. | | | | | |
| SEND ALL CORRESPONDENCE TO: Quarles & Brady LLP 411 East Wisconsin Ave. Milwaukee, WI 53202-4497 | | | <div style="text-align: center;">  SIGNATURE Jean C. Baker NAME 35,433 REGISTRATION NUMBER </div> | | |

10 Reps. PC 18 OCT 2001

EXPRESS MAIL LABEL NO. EL777022284US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

USSN: 09/830,837
Applicant: SEIDAH ET AL.
Int'l Appl. No.: PCT/CA99/01058
Int'l Filing Date: 04 November 1999
Priority Date: 04 November 1998
Title: MAMMALIAN SUBTILISIN/KEXIN ISOZYME SKI-1:
A PROTEIN CONVERTASE WITH A UNIQUE
CLEAVAGE SPECIFICITY
Docket No.: 480848.90026

Box PCT
Asst. Commissioner for Patents
Washington, D.C. 20231

STATEMENT OF CONTENTS OF COMPUTER READABLE
SEQUENCE LISTING DISK AND PAPER COPY


Dear Sir:

The content of the attached Sequence Listing for the above-identified U.S. patent application, containing SEQ ID Nos: 1 - 76, and the content of the enclosed diskettes, labeled Seidah et al., does not include matter which goes beyond the content of the application as filed and that the information recorded on the data carrier is identical to the written sequence listing.

Respectfully submitted,

October 18, 2001

By:


Jean C. Baker
QUARLES & BRADY LLP
411 East Wisconsin Avenue
Milwaukee, WI 53202
Reg. No.: 35,433
(414) 277-5709

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **SEIDAH et al.** Docket No.: 480848.9002*
Serial No.: **Unassigned** Filed: **Concurrently herewith**
Int'l appln No.: **PCT/CA99/01058** Int'l filing date: **04 Nov 1999**
Title: **MAMMALIAN SUBTILISIN/KEXIN ISOZYME SKI-1: A
PROPROTEIN CONVERTASE WITH A UNIQUE CLEAVAGE
SPECIFICITY**

PRELIMINARY AMENDMENT

Box PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In connection with the above-identified application filed herewith, please enter the following preliminary amendment:

IN THE CLAIMS:

Please amend Claims 3, 10, 11, 15, 16, 21, 25, 28-30, 35 AND 36 as follows:

3. The proteic fragment of claim 2, wherein said part has a molecular weight of about 14 Kda and forms a tight complex with the soluble fragment of SKI-1 [as defined in claim 1].

10. An isolated nucleic acid encoding a proteic fragment as defined in [any one of claims 4 to 6] claim 4.

11. A recombinant vector comprising the nucleic acid defined in [any one of claims 7 to 10] claim 7.

15. A recombinant host cell comprising the recombinant vector defined in [any one of claims 11 to 14] claim 11.

16. A method of producing a proteic fragment of SKI-1 enzyme, which comprises the steps of:

culturing a recombinant host cell expressing a nucleic acid as defined in [any one of claims 7 to 10] claim 7 in a cell growth and expression-supportive culture medium; and recovering said proteic fragment of SKI-1 in the culture medium.

21. A method of inhibiting the activity of a subtilisin-kexin isoenzyme named SKI-1, which comprises the step of contacting SKI-1 with the inhibitor [defined in any one] of [claims 4 to 6, 8 and 10] claim 4 or an isolated nucleic acid encoding the inhibitor.

25. A peptide as defined in [any one of claims 22 to 24] claim 22 which is labelled.

28. The use of a peptide as defined in [any one of claims 22 to 27] claim 22 for monitoring the activity of a subtilisin-kexin isoenzyme named SKI-1.

29. The use as defined in [any one of claims 22 to 27] claim 22 for screening inhibitors of a subtilisin-kexin isoenzyme named SKI-1.

30. The use as defined in [any one of claims 22 to 27] claim 22 for screening a subtilisin-kexin isoenzyme named SKI-1.

35. The use as defined in claim 33 [or 34], wherein said inhibitor is defined in [any one of claims] claim 2, 4 to 6, 8 and 10].

36. A composition comprising a SKI-1 fragment as defined in [any one of claims] claim 1 [to 6, or a nucleic acid defined in any one of claims 7 to 10, or a recombinant vector as defined in any one of claims 7 to 10, or a recombinant vector as defined in any one of claims 11 to 14].

Please add the following claims:

38. (New Claim) A composition comprising an SKI-1 fragment as defined in claim 2.

39. (New Claim) A composition comprising a SKI-1 fragment as defined in claim 3.

40. (New Claim) A composition comprising a SKI-1 fragment as defined in claim 4.

41. (New Claim) A composition comprising a SKI-1 fragment as defined in claim 5.

42. (New Claim) A composition comprising a SKI-1 fragment as defined in claim 6.

43. (New Claim) A composition comprising a nucleic acid as defined in claim 7.

44. (New Claim) A composition comprising a nucleic acid as defined in claim 8.

45. (New Claim) A composition comprising a nucleic acid as defined in claim 9.

46. (New Claim) A composition comprising a nucleic acid as defined in claim 10.

47. (New Claim) A composition comprising a recombinant vector as defined in claim 7.

48. (New Claim) A composition comprising a recombinant vector as defined in claim 8.

49. (New Claim) A composition comprising a recombinant vector as defined in claim 9.

50. (New Claim) A composition comprising a recombinant vector as defined in claim 10.

51. (New Claim) A composition comprising a recombinant vector as defined in claim 11.

52. (New Claim) A composition comprising a recombinant vector as defined in claim 12.

53. (New Claim) A composition comprising a recombinant vector as defined in claim 13.

54. (New Claim) A composition comprising a recombinant vector as defined in claim 14.

REMARKS

The above amendments are being made to eliminate multiple dependencies in the claims of this application.

No fee is believed necessary to enter this amendment. However if a fee is necessary, please charge Deposit Account 17-0055.

Applicant respectfully requests that the preliminary amendment described herein be entered into the record prior to examination and consideration of the above-identified application.

QUARLES & BRADY LLP

BY: Jean C. Baker
Jean C. Baker, Reg. No. 35,433

Date: May 1, 2001

QUARLES & BRADY
411 East Wisconsin Avenue
Milwaukee WI 53202-4497
U.S.A.
(414) 277-5709

10 OCT 2001

I hereby certify that this correspondence is being deposited with the United States Postal Services on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231
Date of Signature and Deposit: Jan C. Baker 10/18/01

Attorney of Record

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Nabil G. Seidah, et al.
Serial No.: 09/830,837
Filed: April 30, 2001
For: MAMMALIAN SUBTILISIN/KEXIN ISOZYME SKI-1:
A PROPROTEIN CONVERTASE WITH A UNIQUE
CLEAVAGE SPECIFICITY
Group Art Unit: --
Examiner: --

Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sir:

In the matter of the above-identified case, Applicants wish to make the following amendments.

In the Specification:

1. Please amend paragraph 2, page 2, to read as follows:

It was further discovered by Cheng, D. *et al.* (1999) J. Biol. Chem. 274.22805-22812 that an enzyme called S1p, is capable of cleaving sterol-regulatory element-binding proteins (SREBPs), which function to control lipid biosynthesis and uptake in animal cells. Upon cleavage, SREBPs are released from cell membranes for translocation to the nucleus, where they activate transcription of genes involved in the biosynthesis and uptake of cholesterol and fatty acids. S1p and the present enzyme or the same. Therefore, for diseases involving

overexpression of these genes as well as any other disease involving SKI-1 activity, it is contemplated that any inhibitor of SKI-1 would be useful in their treatment

2. On page 27, please amend Paragraph 1, as follows:

Genetic and biochemical evidence indicates that SKI-1/S1p is the protease that cleaves sterol-regulatory element-binding proteins (SREBPs) which functions to control lipid biosynthesis and uptake in animal cells { Sakai, J. et al. (1998) *Molecular Cell* 2, 505-514; Cheng, D. et al. (1999) *J. Biol. Chem.* 274, 22805-22812; Toure, A. et al. (1999) In: *Peptides for the New Millennium: Proceedings of the 16th American Peptide symposium*}. SKI-1 and SREBPs play critical roles in the feedback pathways by which cholesterol suppresses transcription of genes encoding HMG CoA reductase and other enzymes of cholesterol biosynthesis as well as the low density lipoprotein (LDL) receptor. A SKI-1 inhibitor would be of use under clinical conditions in which there is not sufficient down regulation of SREBP dependent transcription by sterols. For example, in the Nieman-Pick group of diseases a high sphingomyelin content of cells leads to an increase in proteolysis of SREBP-2 and a subsequent increase in cholesterol biosyntheses { Scheek, S. et al. (1997) *Proc. Natl. Acad. Sci. USA* 94, 11179-11183; Spence, M.W., and Callahan, J.W. (1989) *Sphingomyelin-cholesterol lipidoses: The Nieman-Pick Group of Diseases. In The Metabolic Basis of Inherited Disease*) Scriver, C.R., Beaudet, A.L., Sly, W.S., and Valle, D., editors), McGraw-Hill Publ. Co., 6th edition, chapter 66, 1655-1676; Sviridov, D. (1999) *Histology & Histopathology* 14 (1): 305-319 }. Perhaps of greater significance, nuclear SREBP-1c protein levels were significantly elevated in mouse models for non-insulin dependent diabetes, *ob/ob* and *aP2* SREBP-1c mice, which

was associated with elevated mRNA levels for known SREBP target genes involved in the biosynthesis of fatty acids (Schimomura, I. *et al.* J. Biol. Chem. 1999; 274:30028-30032).

3. On page 50, please amend the last paragraph to read:

Results of immunocytochemistry performed in mouse lacrimal glands provides evidence for the presence of SKI-1 and APP in the same cells types, including intralobular duct epithelial cells and some acinar cells (Fig. 26). The finding of SKI-1 in the lacrimal gland suggests the possibility of developing a diagnostic assay analyzing tears; perhaps based on two-dimensional polyacrylamide gel electrophoresis for disease diagnosis { Moley, M.P. *et al.* (1997) *Electrophoresis* 18, 2811-2815; Glasson, M.J. *et al.* (1998) *Electrophoresis* 19, 852-855; Grus, F.H., and Augustin, A.J. (1999) *Electrophoresis* 20, 875-880; Iskeleli, G. *et al.* (1999) *CLAO Journal*, 25:101-104;

4. On page 72, please amend Example 1, 3. to read as follows:

Seidah, N.G., Mbikay, M., Marcinkiewicz, M., & Chretien, M. (1998) in *Proteolytic and Cellular Mechanisms in Prohormone and Proprotein Processing*, ed. Hook, V.Y.H. (R.G. Landes Company, Georgetown, TX), pp. 49-76.

5. On page 72, please amend Example 1, 4., to read as follows:

Ling, N., Burgus, R., & Guillemin, R. (1976) *Proc. Natl. Acad. Sci. USA* **73**, 3942-3946.

6. On page 74-75, please amend Example 2, 10., to read as follows:

Seidah, N.G., Mbikay, M., Marcinkiewicz, M. and Chretien, M., The mammalian precursor convertases: paralogs of the subtilisin/kexin family of calcium-dependent serine proteinases. In: Hook, V.Y.H. (Ed.), *Proteolytic and Cellular Mechanisms in Prohormone and Proprotein Processing*. R.G. Landes Company, Georgetown, TX, USA, 1998, pp. 49-76.

7. On page 75, please amend Example 2, 13., to read as follows:

Hallenberger, S., Moulard, M., Sordel, M., Klenk, H.D., and Garten, W. – The role of eukaryotic subtilisin-like endoproteases for the activation of human immunodeficiency virus glycoproteins in natural host cells. – *Journal of Virology* 1997;71; 1036-1045.

8. On page 77, please amend Example 3, 4th reference, to read as follows:

Ling, N., Burgus, R., and Guillemin, R. (1976) *Proc. Natl. Acad. Sci. USA* **73**, 3942-3946.

9. On page 78, please amend Example 3, 21st reference, to read as follows:

Rittenhouse, J., and Marcus, F. (1984) *Anal. Biochem.* **138**, 442-448

10. On page 79, please amend Example 3, 35th reference, to read as follows:

Zhong, M., Munzer, J.S., Basak, A., Benjannet, S., Mowla, S.J., Decroly, E., Chretien, M. and Seidah, N.G. (1999) *J. Biol. Chem.* **274**:33913-33920.


No fees are believed necessary to enter this amendment.
However, if any fees are necessary, please charge Deposit Account
17-0055.

Respectfully submitted,

Nabil G. Seidah, et al.

October 18, 2001

By:


Jean C. Baker
QUARLES & BRADY LLP
411 East Wisconsin Avenue
Milwaukee, WI 53202
Reg. No.: 35,433
(414) 277-5709

MARKED PAGES SHOWING AMENDMENTS MADE

WO 00/26348

- 2 -

PCT/CA99/01058

It was further discovered by [Chang] Cheng, D. *et al.* (1999) J. Biol. Chem.

274.22805-22812 that an enzyme called S1p, is capable of cleaving sterol-regulatory element-binding proteins (SREBPs), which function to control lipid biosynthesis and uptake in animal cells. Upon cleavage, SREBPs are released from cell membranes for translocation to the nucleus, where they activate transcription of genes involved in the biosynthesis and uptake of cholesterol and fatty acids. S1p and the present enzyme or the same. Therefore, for diseases involving overexpression of these genes as well as any other disease involving SKI-1 activity, it is contemplated that any inhibitor of SKI-1 would be useful in their treatment.

Genetic and biochemical evidence indicates that SKI-1/S1p is the protease that cleaves sterol-regulatory element-binding proteins (SREBPs) which functions to control lipid biosynthesis and uptake in animal cells { Sakai, J. et al. (1998) *Molecular Cell* 2, 505-514; Cheng, D. et al. (1999) *J. Biol. Chem.* 274, 22805-22812; Toure, A. et al. (1999) In: *Peptides for the Now Millennium: Proceedings of the 16th American Peptide symposium*}. SKI-1 and SREBPs play critical roles in the feedback pathways by which cholesterol suppresses transcription of genes encoding HMG CoA reductase and other enzymes of cholesterol biosynthesis as well as the low density lipoprotein (LDL) receptor. A SKI-1 inhibitor would be of use under clinical conditions in which there is not sufficient down regulation of SREBP dependent transcription by sterols. For example, in the Nieman-Pick group of diseases a high sphingomyelin content of cells leads to an increase in proteolysis of SREBP-2 and a subsequent increase in cholesterol biosyntheses { Scheek, S. et al. (1997) *Proc. Natl. Acad. Sci. USA* 94, 11179-11183; Spence, M.W., and Callahan, J.W. (1989) *Spingomyelin-cholesterol lipidoses: The Nieman-Pick Group of Diseases. In The Metabolic Basis of Inherited Disease*) Scriver, C.R., Beaudet, A.L., Sly, W.S., and Valle, D., editors), McGraw-Hill Publ. Co., 6th edition, chapter 66, [1655-1675] 1655-1676; [Svirirodov] Sviridov, D. (1999) *Histology & Histopathology* 14 (1): 305-319 }. Perhaps of greater significance, nuclear SREBP-1c protein levels were significantly elevated in mouse models for non-insulin dependent diabetes, *ob/ob* and *aP2* SREBP-1c mice, which was associated with elevated mRNA levels for known SREBP target genes involved in the biosynthesis of fatty acids (Schimomura, I. et al. *J. Biol. Chem.* 1999; 274:30028-30032).

Results of immunocytochemistry performed in mouse lacrimal glands provides evidence for the presence of SKI-1 and APP in the same cells types, including intralobular duct epithelial cells and some acinar cells (Fig. 26). The finding of SKI-1 in the lacrimal gland suggests the possibility of developing a diagnostic assay analyzing tears; perhaps based on two-dimensional polyacrylamide gel electrophoresis for disease diagnosis { Moley, M.P. et al. (1997) Electrophoresis 18, 2811-2815; Glasson, M.J. et al. (1998) Electrophoresis 19, 852-855; Grus, F.H., and Augustin, A.J. (1999) Electrophoresis 20, 875-880; Iskeleli, G. et al. (1999) [Electrophoresis 20, 875-880 }.] CLAO Journal, 25:101-104;

Seidah, N.G., Mbikay, M., Marcinkiewicz, M., & Chretien, M. (1998) in *Proteolytic and Cellular Mechanisms in Prohormone and [Neuropeptide Precursor] Proprotein Processing*, ed. Hook, V.Y.H. (R.G. Landes Company, Georgetown, TX), pp. 49-76.

Ling, N., Burgus, R., & Guillemin, R. (1976) *Proc. Natl. Acad. Sci. USA* **73**, [3042-3046] 3942-3946.

10. Seidah, N.G., Mbikay, M., Marcinkiewicz, M. and Chretien, M., The mammalian precursor convertases: paralogs of the subtilisin/kexin family of calcium-dependent serine proteinases. In: Hook, V.Y.H. (Ed.), Proteolytic and Cellular Mechanisms in Prohormone and [Neuropeptide Precursor] Proprotein Processing. R.G. Landes Company, Georgetown, TX, USA, 1998, pp. 49-76.

13. Hallenberger, S., Moulard, M., Sordel, M., Klenk, H.D., and Garten, W. - The role of eukaryotic subtilisin-like endoproteases for the activation of human immunodeficiency virus glycoproteins in natural host cells. - Journal of Virology 1997;71; [1036-1455] 1036-1045.

Ling, N., Burgus, R., and Guillemin, R. (1976) *Proc. Natl. Acad. Sci. USA* **73**, [3042-3046] 3942-3946.

[Rittenhose] Rittenhouse, J., and Marcus, F. (1984) *Anal. Biochem.* **138**, 442-448

Zhong, M., Munzer, J.S., Basak, A., Benjannet, S., Mowla, S.J., Decroly, E.,
Chretien, M. and Seidah, N.G. (1999), J. Biol. Chem. [(in press)] 274:33913-33920.

26-02-2001

- 76 -

13. The recombinant vector of claim 12, which comprises a promoter expressible in a target cell wherein expression of said nucleic acid is desirable.

14. The recombinant vector of claim 12, which comprises an inducible promoter.

15. A recombinant host cell comprising the recombinant vector defined in any one of claims 11 to 14.

16. A method of producing a proteic fragment of SKI-1 enzyme, which comprises the steps of:

10 culturing a recombinant host cell expressing a nucleic acid as defined in any one of claims 7 to 10 in a cell growth and expression-supportive culture medium; and recovering said proteic fragment of SKI-1 in the culture medium.

17. A method for cleaving a substrate for SKI-1 enzyme, which comprises the step of:

15 a) contacting said substrate with a SKI-1 enzyme which has 1) an amino acid sequence defined by amino acids 18 to 1052 of any one of SEQ ID Nos: 2, 4, 6 and an active variant thereof, or 2) a SKI-1 soluble fragment as defined in claim 1, or 3) a catalytic part of a) or b), or 4) a complex as defined in claim 3, for a time sufficient and in conditions adequate for such cleavage to occur,

with the proviso that said substrate is not a sterol-regulatory element-binding protein (SREBP).

20 18. A method for producing a protein or a peptide from a proteic precursor which is an enzymatic substrate for SKI-1 enzyme, which comprises the steps of:

25 a) contacting said proteic precursor with a SKI-1 enzyme which has 1) an amino acid sequence defined by amino acids 18 to 1052 of any one of SEQ ID Nos: 2, 4, 6 and an active variant thereof, or 2) a SKI-1 soluble fragment as defined in claim 1, or 3) a catalytic part of a) or b), or 4) a complex as defined in claim 3, for a time sufficient and in conditions adequate for such cleavage to occur; and

b) recovering said protein or peptide;

- 77 -

with the proviso that said substrate is not a sterol-regulatory element-binding protein (SREBP).

19. The method of claim 17, which takes place in a cell or in the presence of a cellular population and wherein step a) comprises the step of transfecting a cell with a nucleic acid
5 expressing said SKI-1 enzyme.

20. The method of claim 19, wherein said cell expresses said proteic precursor or is transfected with a nucleic acid expressing said proteic precursor.

21. A method of inhibiting the activity of a subtilisin-kexin isoenzyme named SKI-1, which comprises the step of contacting SKI-1 with the inhibitor defined in any one of claims
10 4 to 6, 8 and 10.

22. A peptide of at least 7 amino acids capable of binding to and of being cleaved by SKI-1 catalytic site, comprising the following general formula:



wherein Xaa₁, 2, 3 and Z are any amino acid

15 J is an alkyl or aromatic hydrophobic amino acid

n is 1, 2 or 3

O is an acidic amino acid,

with the proviso that the peptide does not comprise the sequence Lys
- Arg - Phe - Val - Phe - Asn - Lys - Ile - Glu.

20 23. A peptide as defined in claim 22, wherein Xaa₂ is Lys, Leu, Phe or Thr.

24. A peptide as defined in claim 23 which has the sequence:



25. A peptide as defined in any one of claims 22 to 24 which is labelled.

26. A peptide as defined in claim 25 which is fluorogenic.

26-02-2001

- 78 -

27. A peptide as defined in claim 26 which is

Abz-Val-Phe-Arg-Ser-Leu-Lys-Tyr-Ala-Glu-Ser-Asp-Tyr(NO₂),

wherein

Abz is orthoaminobenzoic acid, and

5 Tyr(NO₂) is 3-nitrotyrosine.

28. The use of a peptide as defined in any one of claims 22 to 27 for monitoring the activity of a subtilisin-kexin isoenzyme named SKI-1.

29. The use as defined in any one of claims 22 to 27 for screening inhibitors of a subtilisin-kexin isoenzyme named SKI-1.

10 30. The use as defined in any one of claims 22 to 27 for screening a subtilisin-kexin isoenzyme named SKI-1.

31. The use of a peptide of at least 7 amino acids capable of binding to and of being cleaved by SKI-1 catalytic site, comprising the following general formula:



15 wherein Xaa₁, 2, 3 and Z are any amino acid


J is an alkyl or aromatic hydrophobic amino acid

n is 1, 2 or 3

O is an acidic amino acid

for monitoring the activity of a subtilisin-kexin isoenzyme named SKI-1.

20 32. The use of a peptide of at least 7 amino acids capable of binding to and of being cleaved by SKI-1 catalytic site, comprising the following general formula:



wherein Xaa₁, 2, 3 and Z are any amino acid

AM 34 AMDT

- 79 -

J is an alkyl or aromatic hydrophobic amino acid

n is 1, 2 or 3

O is an acidic amino acid

for screening inhibitors or substrates of a subtilisin-kexin isoenzyme named SKI-1.

5 33. The use of an inhibitor of the activity of a subtilisin-kexin isoenzyme named SKI-1 in the making of a medication for treating a disease involving an overexpression of a SKI-1 or a SKI-1 substrate.

10 34. The use as defined in claim 33, wherein said disease is associated with any one of hypercholesterolemia, high levels of fatty acids, lipids or farnesyl pyrophosphate, liver steatosis, Ras-dependent cancer, restenosis and amyloid protein formation.

35. The use as defined in claim 33 or 34, wherein said inhibitor is defined in any one of claims 2, 4 to 6, 8 and 10.

15 36. A composition comprising a SKI-1 fragment as defined in any one of claims 1 to 6, or a nucleic acid defined in any one of claims 7 to 10, or a recombinant vector as defined in any one of claims 7 to 10, or a recombinant vector as defined in any one of claims 11 to 14.

20 37. The use of a SKI-1 enzyme as encoded by nucleic acids to 18 to 1052 of SEQ ID NOs: 1, 3 or 5, or of a catalytic part that is unique to SKI-1 enzyme, or of an active variant thereof, the nucleic acid of the variant sharing at least 70% homology with the nucleic acid defined in SEQ ID NOs.: 1, 3 and 5 and hybridizing therewith under stringent hybridization conditions, for cleaving a proteic precursor, with the proviso that said proteic precursor is not a sterol-regulatory element-binding protein (SREBP).

TITLE OF THE INVENTION:

Mammalian subtilisin/kexin isozyme SKI-1: a proprotein convertase with a unique cleavage specificity

5 FIELD OF THE INVENTION:

This invention relates to a serine proteinase capable of converting proteic precursors into mature proteins; particularly a serine proteinase capable of cleaving at non-basic amino acid residues.

10 BACKGROUND OF THE INVENTION:

Limited proteolysis of inactive precursors to produce active peptides and proteins is an ancient mechanism to generate biologically diverse products from a finite set of genes. Most often, such processing occurs at either single or dibasic residues, as a result of cleavage by a family of mammalian serine proteinases related to bacterial subtilisin and yeast kexin(1, 2). These enzymes, known as pro-protein convertases (PCs), participate in the tissue-specific intracellular processing of precursors at the consensus (R/K)-(X)_n-R↓ sequence, where X is any amino acid except Cys and n = 0, 2, 4 or 6 (1-3). PCs have been implicated in the production of various bioactive polypeptide hormones, neuropeptides, enzymes, growth factors, adhesion molecules, cell surface receptors and surface glycoproteins of infectious agents such as viruses and bacteria (1-3).

Less commonly, bioactive products can also be produced by limited proteolysis at amino acids such as Leu, Val, Met, Ala, Thr, Ser and combinations thereof (3). This type of cellular processing has been implicated in the generation of bioactive peptides such as α- and γ-endorphin (4), the C-terminal glycopeptide fragment 1-19 of pro-vasopressin (5), anti-angiogenic polypeptides such as platelet factor 4 (6) and angiostatin (7), the metalloprotease ADAM-10 (8), site 1 cleavage of the sterol receptor element binding proteins (9), as well as in the production of the Alzheimer's amyloidogenic peptides Aβ40, 42 and 43 (10). Processing of this type occurs in the endoplasmic reticulum (ER) (9), or late along the secretory pathway, within secretory granules (4, 5), at the cell surface, or in endosomes (6-8, 10). So far, the proteinases responsible for these cleavages have not been unambiguously identified.

Since mammalian convertases process precursors at either single or pairs of basic residues, we hypothesised that a distinct, but related, enzyme(s) may generate

polypeptides by cleavage at non-basic residues. To test that idea, we employed an RT-PCR strategy similar to the one used to identify the PCs (11), except that we used degenerate oligonucleotides closer to bacterial subtilisin than to yeast kexin. This approach resulted in the isolation of a cDNA fragment encoding a putative subtilisin-like enzyme from human cell lines. This partial sequence was identical to a segment of a human myeloid cells-derived cDNA reported by Nagase *et al.* (12). A role for this putative subtilase remained undefined up to the present invention.

It was further discovered by Chang, D. *et al.* (1999) J. Biol. Chem. 274:22805-22812 that an enzyme called S1p, is capable of cleaving sterol-regulatory element-binding proteins (SREBPs), which function to control lipid biosynthesis and uptake in animal cells. Upon cleavage, SREBPs are released from cell membranes for translocation to the nucleus, where they activate transcription of genes involved in the biosynthesis and uptake of cholesterol and fatty acids. S1p and the present enzyme or the same. Therefore, for diseases involving overexpression of these genes as well as any other disease involving SKI-1 activity, it is contemplated that any inhibitor of SKI-1 would be useful in their treatment.

SUMMARY OF INVENTION:

We show that the sequences of the rat, mouse and human orthologues of this putative type-I membrane-bound subtilisin-kexin-isoenzyme, which we called SKI-1, exhibit a high degree of sequence conservation. Tissue distribution analysis by both Northern blots and *in situ* hybridization (ISH) revealed that SKI-1 mRNA is widely expressed. A stable transfectant of human SKI-1 in HK293 cells allowed the analysis of its biosynthesis and intracellular localization. We present data demonstrating that SKI-1 cleaves at a specific Thr¹ residue within the N-terminal segment of human pro-brain-derived neurotrophic factor (proBDNF). SKI-1 is the first identified secretory mammalian subtilisin/kexin-like enzyme capable of cleaving a proprotein at non-basic residues.

Therefore in accordance with the present invention, there is provided a soluble proteic fragment of a subtilisin-kexin isoenzyme named SKI-1 which has the amino acid sequence defined by amino acids 187 to 996 of any one SEQ ID NOs: 2, 4 and 6, a variant thereof, or an enzymatically active part thereof.

It is further an object of this invention to provide a proteic fragment of SKI-1 enzyme, which has the amino acid sequence defined by amino acids 18 to 137 of any one of SEQ ID NOs: 2, 4 and 6, a variant thereof, or a part thereof, which is a pro-segment capable of binding with amino acids 18 to 1052 of SKI-1 in whole or in part.

5 A part of this pro-segment has a molecular weight of about 14 KDa and forms a tight complex with the soluble fragment of SKI-1.

The pro-segment is an inhibitor of SKI-1 activity.

To improve its inhibitory activity, the pro-segment sequence is modified to prevent further enzymatic processing in a cell expressing said proteic fragment.

10 The modification includes amino acid substitution, deletion or rearrangement. Nucleic acids encoding any of the above SKI-1 forms are also objects of this invention.

Recombinant vectors and hosts comprising these nucleic acids are also objects of this invention.

The recombinant vectors are preferably expression vectors.

15 The recombinant vectors comprise a promoter expressible in a target cell wherein expression of said nucleic acid is desirable, be it for a therapeutic or manufacturing purposes.

The recombinant vectors may also comprise an inducible promoter.

20 It is further an object of this invention to provide a method of producing a proteic fragment of SKI-1 enzyme, which comprises the steps of:

culturing a recombinant host cell expressing a SKI-1 nucleic acid in a cell growth and expression-supportive culture medium; and recovering the proteic fragment of SKI-1 in the culture medium.

25 There is also provided a method for cleaving a proteic precursor which is an enzymatic substrate for SKI-1 enzyme, which comprises the step of:

a) contacting the proteic precursor with a SKI-1 enzyme which has an amino acid sequence defined by amino acids 18 to 1052 of SEQ ID Nos: 2, 4 or 6, or a variant thereof, or the soluble form, for a time sufficient and in condition adequate for such cleavage to occur.

30 The cleavage may be provoked *in vivo* or *in vitro*, e.g. serving a therapeutic purpose or an industrial protein manufacturing use.

For the purpose of producing a protein or a peptide from a proteic precursor which is an enzymatic substrate for SKI-1 enzyme, the method would further comprise the step of:

b) recovering and purifying the protein or peptide.

The method may be performed in cell-free assays, or may take place in a cell or in the presence of a cellular population, and wherein step a) comprises the step of transfecting a cell with a nucleic acid expressing a SKI-1 protein.

5 The cell may express said proteic precursor or may be transfected with a nucleic acid expressing the proteic precursor.


A method of silencing the expression or the activity of SKI-1 enzyme on a proteic precursor, which comprises the steps of:

10 contacting the enzyme or a nucleic acid encoding the enzyme with a ligand molecule which binds to the enzyme or to the nucleic acid, thereby interfering with the binding of the enzyme to the proteic precursor or with the expression of the nucleic acid encoding the enzyme, is also an object of this invention.

The ligand molecule may comprise an antisense nucleic acid to the nucleic acid encoding SKI-1, a pro-segment of a precursor protein encoding SKI-1, a SKI-inhibitor, 15 a peptide mimicking a proteic precursor SKI-1 binding site, or an antibody molecule directed against SKI-1, or one which generates an inactive SKI-1 mutant form.

The pro-segment is a polypeptide extending from amino acids 17 to 137 of SEQ ID NOs: 2, 4, 6, or a variant thereof or an inhibitory part thereof.

20 We also provide a peptide of at least 7 amino acids capable of binding to and of being cleaved by SKI-1 catalytic active site, comprising the following general formula:



wherein $\text{Xaa}_{1,2,3}$ and Z are any amino acid

J is an alkyl or aromatic hydrophobic amino acid

25 n is 1, 2 or 3

O is an acidic amino acid.

Preferably Xaa_2 is Lys, Leu, Phe or Thr.

A preferred peptide has the structure:



30 The peptide may be labelled, a fluorogenic label being one of our preferred embodiments.

A fluorogenic peptide which has the following sequence:



has been synthesized.

These peptides can be used for monitoring SKI-1 activity, for screening inhibitors of SKI-1 activity or for screening enhancers of SKI-1 activity.

5 An inhibitor of SKI-1 activity used in the making of a medication for treating a disease involving an overexpression of a SKI-1 or a SK1-1 substrate, is also a further object of this invention, namely the pro-segment modified or not.

The disease may be associated with any one of hypercholesterolemia, high levels of fatty acids, lipids or farnesyl pyrophosphate, liver steatosis, Ras-dependent cancer, restenosis and amyloid protein formation.

10 We also provide a method for detecting SKI-1 activity in a sample, which comprises the steps of contacting the sample with a ligand molecule to SKI-1 protein or nucleic acid, and detecting the formation of a complex between said ligand and SKI-protein or nucleic acid as an indication of the presence of SKI-1 in said sample. The ligand includes molecules such as anti-SKI-1-antibodies or a nucleic acid probes or
15 primers.

Finally is provided a new use for SKI-1 enzyme in whole or in part which is for cleaving substrates not cleaved by other members of the subtilisin-kexin family. Variants of SKI-1 are under the scope of this invention, such variants are encoded by nucleic acids sharing at least 70% homology with the sequences defined in SEQ ID
20 NOs: 1, 3, 5.

DESCRIPTION OF THE INVENTION:

During our search for new members of the subtilisin-kexin family, we obtained two closely related sequences from mouse and rat tissues. When questioning gene
25 data banks to find a match with other known sequences, we found that the human counterpart has been previously cloned and sequenced. However, no specific function for this enzyme was known. We named our new enzyme subtilisin-kexin isoenzyme 1 (SKI-1).

We characterized this enzyme and found that SKI-1 has a unique cleavage site
30 in cognate substrates. One of these substrates is pro-BDNF. Sakai *et al.* have found that another substrate, SREBP-2, which is a sterol-responsive transcription element, was cleaved at a first enzyme processing site by an enzyme which they called site 1 protease (S1p). S1p and SKI-1 appeared to be the same enzyme.

Since SKI-1 is autocatalytically cleaved, this brings to three the number of substrates that are known to be recognized and cleaved by SKI-1. One object of this invention is therefore the use of SKI-1 as a protein processing enzyme.

SKI-1 is ubiquitously distributed and appears to be very well conserved amongst mammalian species. Therefore, variants of SKI-1 are within the scope of this invention. We have indeed identified two species variants of the human enzyme disclosed in gene data banks, and *per se* this is a proof that variants to screen SKI-1 activity exist.

SKI-1 is first located in the endoplasmic reticulum (ER) membrane. Upon processing the pro-segment of pro-SKI-1 is removed and SKI-1 is thus activated. SKI-1 is further processed to remove the transmembrane domain that keeps it integrated in the ER membrane, which generates a SKI-1 soluble form that is directed into the secretory pathway and which remains active. The soluble active form is indeed retrievable in culture media as well as the pro-segment. The pro-segment is itself also processed into shorter fragments. One of these fragments has an apparent molecular weight of about 14 KDa and forms a tight complex with the soluble SKI-1 form. The formation of this complex does not hinder the activity of the enzyme. It is known that the pro-segment of pro-protein convertases is inhibitory *in vitro* to the activity of the convertases. We demonstrate for the first time hereinbelow that such a behaviour occurs in an *ex vivo* model. SKI-1 pro-segment also has such an inhibitory activity. We predict that a SKI-1 pro-segment that would be modified to prevent the pro-segment processing will be an even better SKI-1 inhibitor. Such a modification is made by converting an enzyme recognition and cleavage site into a non-cleavable sequence. Such modification is intended to cover amino acid substitutions, deletions or re-arrangements to provide a SKI-1 pro-fragment that has an improved inhibitory activity.

The nucleic acids encoding all the above SKI-1 forms (soluble, pro-segment and sub-fragments, modified or not) are under the scope of this invention. Recombinant vectors and hosts comprising these nucleic acids are also objects of this invention. More particularly, expression vectors capable of producing the different SKI-1 forms are preferred. The expression vectors comprise promoter sequences which govern the expression of the nucleic acids. The promoter may be compatible with the cell wherein the expression of the nucleic acid is sought, be it for a therapeutic purpose or for the industrial production of SKI-1. The promoter may also be an inducible promoter which needs an exogenous inducing agent to activate the expression. For


the production of any SKI-1 form, a recombinant host cell may be used and is cultured in a culture medium which supports cell proliferation and the expression of the nucleic acids. Under suitable conditions, the SKI-1 form of interest is expressed and may be conveniently recovered from the culture medium.

5

A general method for cleaving a proteic precursor is also an object of this invention. SKI-1 whole active enzyme or its soluble form or catalytically active fragments or variants are added to a proteic precursor which is a SKI-1 substrate, in conditions adequate for enzymatic precursor processing (cleavage) to occur. This method may be performed *in vivo* for curing a SKI-1 deficiency or *in vitro* for the industrial preparation of active proteins. In the latter case, the processing may be performed in a cell-free assay, using purified proteic precursors and SKI-1 whole enzyme or derived forms. Alternatively, it may be performed using transfected cells expressing SKI-1 whole enzyme and derived forms. The transfected cells may endogenously express the protein precursor or may be co-transfected to express the same. The transformed cells therefore become a manufacture of mature proteins and/or or SKI-1.

Modification of the SKI-1 activity is further an object of this invention. We have succeeded in inhibiting SKI-1 activity using the SKI-1 pro-segment. Alternative ways to achieve the same results include antisense nucleic acids or oligonucleotides, SKI-1 inhibitors, peptides mimicking a precursor SKI-1 binding site (cleavable or not), which would compete for the binding of SKI-1 to its cognate protein precursor site, and antibodies directed against SKI-1 or its cognate proteic precursor binding site. Another alternative is a genic therapy replacing the active SKI-1 by an inactive mutant form. On the opposite, overexpressing SKI-1 may cure a SKI-1 deficiency. Due to the ubiquitous distribution of SKI-1, it may be useful, even necessary, to target the cell wherein SKI-1 activity is to be modified for such a therapeutic purpose. Such targeting may include conjugating or combining molecules capable of modifying or modulating SKI-1 activity to a ligand capable of targeting the cell of interest. Immunoliposomes are examples of targeting vehicles as well as conjugated ligands-oligonucleotides. Even viral vectors may be made targeting if they express such a targeting ligand at the membrane surface. A targetting ligand serves a selection purpose, leaving substantially intact the non-targetted cells.

Peptides of less than 100 amino acids, more preferably of less than 30 amino acids, mimicking a cognate SKI-1 cleaving site in a proteic precursor have been synthesized and are also objects of this invention. Therefore, a peptide of at least 7 amino acids comprising the following preferred structure is capable of binding to and
 5 of being cleaved by SKI-1 enzyme catalytic site:



wherein $\text{Xaa}_{1,2,3}$ and Z are any amino acid

J is an alkyl or aromatic hydrophobic amino acid

n is 1, 2 or 3

10 O is an acidic amino acid.

Preferably Xaa_2 is Lys, Leu, Phe or Thr.

The preferred peptide has the following sequence:



These peptides may be labelled in such a way that labelled fragments produced
 15 upon cleavage are easily detected and identified. Such labelling include any type of suitable detectable markers. We have developed a fluorogenic peptide which shows a very good affinity for SKI-1. The above preferred peptide has been labelled at its N- and C- terminal ends with an orthoaminobenzoic acid and 3-nitrotyrosine groups, respectively.

20 These peptides as well as cell lines expressing SKI-1 will be especially useful for monitoring SKI-1 activity and for screening inhibitors or substrates and enhancers of SKI-1 activity.

Inhibitors of SKI-1, namely the SKI-1 pro-segment, will be used in the making of a medication for treating a diseasing involving overexpression of SKI-1 or of its
 25 substrate.

Conversely, substrates of SKI-1 will be used in the research field to discover physiological systems involving SKI-1.

Diagnostic methods and kits comprising a ligand to SKI-1 protein or nucleic acid, which is to be contacted with a sample suspected to express SKI-1, is also an
 30 object of this invention. Detection of the formation of a ligand-SKI-1 complex or of a hybridization complex is an indication of the presence or amount of SKI-1 in the sample.

Since we were the first to discover the function of SKI-1 enzyme, the use thereof for cleaving proteic precursors that are not substrates for the other members

of the subtilisin-kexin family is an object of this invention. SKI-1 is intended in this broad use to cover the whole enzyme, a catalytic part thereof and its functional variants. Variants are encoded by anyone of the nucleic acids depicted in SEQ ID Nos: 1, 3 or 5, and any other sequences sharing at least 70% homology therewith, preferably more than 85% homology, under stringent conditions of hybridization.

Having now defined the general teachings of the present invention, reference will be made hereinbelow to specific examples and embodiments as well to the following appended figures, which purpose is to illustrate the invention rather than to limit its scope.

BRIEF DESCRIPTION OF FIGURES:

FIG. 1 shows the comparative protein sequences of SKI-1 deduced from rat, mouse and human cDNAs (SEQ ID NOs 2, 4, and 6, encoded by nucleic acids SEQ ID NOs: 1, 3, and 5, respectively). The position of the predicted end of the 17 aa signal peptide is shown by an arrow. The active sites Asp²¹⁸, His²⁴⁹ and Ser⁴¹⁴, as well as the oxyanion hole Asn³³⁸ are in bold, shaded and underlined characters. The positions of the 6 potential N-glycosylation sites are emphasized in bold. The conserved shaded **CLDDSHRQKDCFW** sequence fits the consensus signature for growth factors and cytokine receptors family. Each of the two boxed sequences was absent in a number of rat clones. The predicted transmembrane segment is in bold and underlined.

FIG. 2 shows a Northern blot analysis of the expression of SKI-1 in adult rat tissues. **[A]** 5 µg of male rat total RNA were loaded in each lane. Molecular sizes are based on the migration of an RNA ladder. The tissues include: adrenal, thyroid, striatum, hippocampus, hypothalamus, pineal gland, anterior (AP) and neurointermediate (NIL) lobes of the pituitary, submaxillary gland, prostate, ovary and uterus. Notice the high level of SKI-1 mRNA in adrenal glands. **[B]** 2 µg of poly-A+ of (male + female) Sprague Dawley rat adult tissues (Bio/Can Scientific) were loaded, which includes: liver, thymus, spleen, kidney, heart and brain. The estimated size of rat SKI-1 mRNA is about 3.9 kb.

FIG. 3 shows *in situ* hybridization (15 H) of rSKI-1 mRNA in a 2 day old rat. ISH is shown at anatomical resolution on X-ray film using an [³⁵S]-labeled antisense riboprobe [A-C] and sense control riboprobe [D]. Abbreviations: *Adr* - adrenal gland; *Cb* - cerebellum; *cc* - corpus callosum; *Cx* - cerebral cortex; *H* - heart; *Int* - intestine; *K* - kidney; *Li* - liver; *Lu* - lungs; *M* - muscles; *Mol* - molars; *OT* - olfactory turbinates; *Pit* - pituitary gland; *Rb* - ribs; *Ret* - retina; *Sk* - skin, *SM* - submaxillary gland; *Th* - thymus. Magnification x 4; scale bar (in D) = 1 cm.

FIG. 4 illustrates the biosynthetic analysis of SKI-1 in HK293 cells. Stable transfectants expressing either the pcDNA3 vector alone or one that expresses SKI-1 (clone 9) were pulse-labeled for 4h with [³⁵S]Met. Media and cell lysates were immunoprecipitated with either a SKI-1 antiserum (Ab: SKI; against aa 634-651) or a pro-SKI-1 antiserum (Pro). The stars represent the 4 specific intracellular proteins (Mr 148, 120, 106 and 98 kDa) immunoprecipitated with the SKI-1 antiserum. In these transfected cells, only the 148 kDa band is recognized by the Pro-antiserum. A 98 kDa immunoreactive SKI-1s protein is also detectable in the medium.

FIG. 5 shows hSKI-1 immunoreactivity in stably transfected HK293 cells. Representation of the comparative double fluorescence staining using a SKI-1 antiserum (directed against aa 634-651) [A] and [B] and FITC-labeled WGA [A'] and [B'] in control [A, A'] and LME-treated [B, B'] cells is shown. Thin arrows emphasize the observed punctate staining which is enhanced in the presence of LME. Large arrows point to the coincident staining of SKI-1 and WGA. Magnification x 900; bar (in B') = 10 µm.

FIG. 6 shows the processing of proBDNF by SKI-1. [A] COS-7 cells were infected with vv:BDNF and either vv:WT (-) or vv:SKI-1 in the presence of either vv: PIT or vv:PDX. The cells were metabolically labeled with [³⁵S]Cys-Met for 4h and the media (M) and cell lysates (C) were immunoprecipitated with a BDNF antiserum, prior to SDS-PAGE analysis. The autoradiogram shows the migration positions of proBDNF (32 kDa), the 28 kDa BDNF produced by SKI-1 and the 14 kDa BDNF. [B] Microsequence analysis of the [³⁵S]Met-labeled 32 kDa proBDNF (maximal scale 1000 cpm) and [H]Leu-labeled 28 kDa BDNF (maximal scale 250 cpm), revealing a Met at sequence position 3 and Leu at positions 2, 13 and 14, respectively.

FIG. 7 shows the *in vitro* processing profile of proBDNF by SKI-1. **[A]** pH dependence of the processing of proBDNF by SKI-1. The SKI-1 enzyme preparation was compared to that obtained from the media of Schwann cells infected with the wild type virus (WT) as control. **[B]** Inhibitor profile of the processing of proBDNF to the 28 kDa BDNF by the same SKI-1 preparation as in **[A]**. The reaction was performed overnight at 37°C, pH 6.0. Notice that only PMSF (0.5 mM PMSF+50 µM pAPMSF), o-phenanthroline (5 mM), and EDTA (10 mM) effectively inhibited SKI-1 cleavage of proBDNF.

FIG. 8 shows the *in situ* hybridization translating SKI-1 mRNA expression in the pituitary gland of an adult rat using specific [³⁵S]radiolabeled antisense (*SKI* AS) and control sense (*SKI* SS) riboprobes. The hybridization signal was detected in the anterior (AL), intermediate (IL) and posterior pituitary lobe (PL). Most of the labeling was confined to endocrine cells in AL and IL and to some pituicytes in the PL. Magnification x 5; bar (in b) = 1 mm.

FIG. 9 shows the *in situ* hybridization translating the presence of SKI-1 mRNA sites in the skin of a newborn two days old (p2) rat using antisense (*SKI* AS) and control sense (*SKI* SS) riboprobes. The hybridization signal was detected in the stratum germinativum (small vertical arrows in SGe), in both outer and inner hair sheath (medium arrows) and in some cells within the dermis (D). Other abbreviations: HB - hair bulb, SC - stratum corneum, SGr - stratum granulosum. Magnification x 80.

Fig. 10 shows the *in situ* hybridization (ISH) distribution of SKI-1 mRNA in the rat central nervous system (CNS). ISH distribution pattern in the CNS of adult rat demonstrates a higher concentration of SKI-1 mRNA within a grey matter (GM and all structures indicated with capital letters) vs the white matter (WM) including corpus callosum (cc). Representative brain structures are shown in sagittal (a); horizontal (b) and coronal plane (c - f) after hybridization with antisense SKI-1 riboprobe (a - e) and control sense riboprobe (ssRNA in f). As shown at anatomical level this type of mRNA distribution is highly reminiscent to a type of pan-neuronal gene distribution pattern. As complementary to this figure a Table 1 demonstrates at cellular level the predominance of neuronal SKI-1 mRNA expression over glial SKI-1 mRNA expression. Magnification x 4; bar (in a) = 1 cm. Abbreviations: **CA1** - area 1 of cornus Ammonis; **CA3** - area 3 of cornus Ammonis; **Cb** - cerebellum; **cc** - corpus callosum; **Ch PI** - choroid plexus; **Cx** - cerebral cortex; **GD** - gyrus dentatus; **GM** - grey matter; **Hip** - hippocamp; **Hy** - hypothalamus; **OI** - olfactory bulb; **Str** - striatum; **WM** - white matter.

Fig. 11 shows the *in situ* hybridization (ISH) distribution of SKI-1 mRNA in the rat peripheral nervous system (PNS) trigeminal ganglion (TriG). ISH distribution pattern in the CNS of adult rat demonstrates a higher concentration of SKI-1 mRNA within a region of cell bodies (large arrows) over the region of supportive Schwann cells (small arrows). ISH was performed using antisense (SKI-1 as in a) and sense (SKI-1 ss) riboprobes. Magnification x 12.

Fig. 12 shows the distribution of SKI-1, mRNA and/or protein, in the region of spinal cord (SpC) and in the related dorsal root ganglion (DRG) and dorsal root (DR).

Demonstrated are the region of neuronal cell bodies in the DRG (SKI-1 mRNA) and the region of nerve terminals in the dorsal horn of the spinal cord (layer I and II) characterized by a especial density of SKI-1 protein.

A) Schematic drawing depicting the position of layer I and II in the dorsal horn as well as that of the related DRG and DR.

B) SKI-1 mRNA revealed by *in situ* hybridization labeling (thin arrows) in the DRG using antisense riboprobes (SKI-1 AS).

C) Control hybridization in the DRG using sense riboprobes (SKI-1 SS).

D) Immunocytochemical localization of SKI-1 (brown staining) within layer I and II of the dorsal horn and in the dorsal root (DR) suggesting the sensory afferents arriving from DRG. Neuronal and glial nuclei are stained on blue. Magnification x 300.

E) Immunoreactivity of SKI-1 (thin arrows) detected around neuronal somata (large arrows) within layer II of the dorsal horn at high magnification (x 1,500). Pattern of immunoreactive spots is reminiscent to that of axo-somatic or axo-dendritic nerve terminals.

F) Northern blot revealing the concentrations of 4 kb SKI-1 mRNA in different tissues including dorsal root ganglia (DRG) and spinal cord (SpC). Abbreviations: I - layer I of the dorsal horn; II - layer II of the dorsal horn; **Adr** - adrenal gland; **Cb** - cerebellum; **Cx** - cerebral cortex; **Hip** - hippocamp; **DH** - dorsal horn; **DR** - dorsal root; **DRG** - dorsal root ganglion; **SpC** - spinal cord; **Stom** - stomach and **Thyr** - thyroid gland.

Fig. 13 shows the farnesyl diphosphatase mRNA levels in HK 293 cells treated with (+)lipids (cholesterol and 25-hydroxycholesterol) or without lipids (-). 1-2 = wild type cells, 3-4 = SREBP-1 overexpressors, 5-6 = a pool of 3 different clones overexpressing SREBP-1 and Pro-SKI-1 ; clones 4,6,9.

Fig. 14 shows the fatty acid synthase mRNA levels in HK 293 cells treated with (+) lipids (cholesterol and 25-hydroxycholesterol) or without lipids (-). 1-2 = wildtype cells, 3-4 = SREBP-1 overexpressors, 5-6 = a pool of 3 different clones overexpressing SREBP-1 and Pro-SKI-1; clones 4,6,9.

5 Fig. 15 shows the HMG CoA reductase mRNA levels in HK 293 cells treated with lipids (box A) or without lipids (box B). 1 = wild type cells, 2 = vector only cells, 3 = SREBP-1 overexpressor cells, 4 = SREBP-1 and ProSKI-1 overexpressor cells (high SREBP expression, clone 6), 5 = SREBP-1 and ProSKI-1 overexpressor cells (low SREBP expression, clone 9).

10 Fig. 16 shows the HMG CoA reductase and farnesyl diphosphatase mRNA levels in Hk 293 cells in different clones overexpressing SREBP-1 (1-5) or SREBP-1 and ProSki-1 (clone 4, clone 6, clone 9). Cells were treated with fetal calf serum.

Fig. 17 shows the nuclear SREBP-1 in HK 293 cells in absence of lipids. Mature SREBP is processed in the ER and translocated into the nucleus. 1 = wild type cells,
15 2 = vector only cells, 3 = SREBP-1 overexpressors, 4 = SKI-1 antisense cells, 5 = ProSki + SREBP-1 overexpressors clone 6, 6 = ProSKI + SREBP-1 overexpressors clone 9.

Fig. 18 shows the processing of cytoplasmic SREBP-1 in HK 293 cells. 50 µg of protein per lane was separated in 6 % (above) and 10 % (below) SDS-PAGE gels.
20 Uncut SREBP-1 (proSREBP-1) and intermediate SREBP-1 (intSREBP-1) cleaved by SKI-1 are indicated with arrows. Cell lines express ProSKI-1 (pSKI), SKI-1 anti-sense (SKI-1 as), SREBP-1, or ProSKI-1 and SREBP-1 (pSKI + SRE), or control vector (pcDNA3), as indicated. Analysis was performed in the presence (+ sterols) or absence of sterols (- sterols).

25 Fig. 19 [A] is a schematic representation of the structure of FL-SKI-1 and its truncation mutant BTMD-SKI-1. The various SKI-1 domains depicted are, respectively, the signal peptide, pro-segment, catalytic domain, and the C-terminal region comprising a cytokine receptor/growth factor motif, a transmembrane domain and a cytosolic tail. The positions of polypeptides used to produce SKI-1-specific antisera (Ab: P, N and
30 S) are also displayed. Fig. 19 [B] shows the biosynthetic analysis of SKI-1. VV:FL-SKI-1, BTMD-SKI-1 (bSKI-1) or control VV:WT infected LoVo cells were pulse-labeled with [³⁵S]Cys for 3h. Media were immunoprecipitated with either Ab:S or Ab:P and then resolved by SDS-PAGE on an 8 % gel followed by autoradiography. Arrows point to the migration positions of the 100 kDa BTMD-SKI-1 (bSKI-1), the 98 kDa shed form

(sSKI-1) as well as the 14 kDa prosegment product. Fig. 19 [C] shows a Western blot analysis of the overexpressed BTMD-SKI-1. Samples from VV:WT or BTMD-SKI-1 infected BSC 40 cells (left and middle panel) were processed as described in "Experimental Procedures" and run on an 8 % SDS-PAGE reducing gel. Following electrotransfer to PVDF membranes, protein bands were visualized via ECL detection using primary rabbit antisera Ab:S or Ab:N. Purified BTMD-SKI-1 (right panel, *) was obtained from a Ni²⁺ affinity resin as described in "Experimental Procedures", then processed as described above. A mixture of Ab:S and Ab:P were used as primary antisera. Elution buffer was used as a control (CTL).

Fig. 20 shows the biosynthetic analysis of the rate of zymogen processing and the fate of the prosegment of SKI-1. LoVo cells overexpressing VV:FL-SKI-1 were pulse-labeled with [³H]Leu for 15 min and then chased for 2h (P15C2h), or pulsed for 2h in the presence or absence of BFA (P2h). Cell lysates were immunoprecipitated with Ab:P, resolved by SDS-PAGE on a 14 % gel and autoradiographed. The migration positions of the major ~26, 24, 14, 10 and 8 kDa prosegments are emphasized.

Fig. 21 illustrates the purification and identification of secreted recombinant pro-SKI-1. [A] Media obtained from HK293 cells stably expressing FL-SKI-1 were concentrated and sequentially applied to C4 semi-preparative column (*not shown*) followed by a C4 analytical RP-HPLC columns, and then eluted by the indicated linear CH₃CN gradient.

[B] The fractions labeled I-IV were collected and analyzed by Western blotting using the primary antiserum Ab:P. [C,D] Proteins contained in fraction IV were separated on a 10 % SDS-PAGE reducing gel. Following electrotransfer, the proteins were stained with Ponceau Red. The immunoreactive 14 kDa and non-immunoreactive but colored ~ 4.5 kDa [D] polypeptides were excised and submitted to N-terminal sequencing (X represents an undefined residue). [E] Mass spectrometric analysis by MALDI-TOF spectrometry of fraction IV. The C-terminal residues sites believed to corresponding to the three ~14 kDa polypeptides are underlined, whereas the expected (potential) cleavage sites are indicated by dashed arrows.

Fig 22 shows the processing of proSKI-1 autocatalytic prosegment candidate sequences by purified, shed SKI-1. The proposed prosegment C-terminal mutant 17 aa peptide IV [A] and 15 aa peptide IX [B] were digested for 18 h with metal chelation chromatography-purified BTMD-SKI-1. The cleavage products were separated by RP-HPLC using a 5 µm analytical Ultrasphere C18 column (Beckman) as described under "Experimental Procedures". The peptides contained in all but two peaks were identified

by mass spectrometry. The unidentified peaks are attributable to contaminating activities seen in WT/empty vector controls.

Fig. 23 shows the processing of proBDNF and SREBP-2 peptides by BTMD-SKI-1. The 14 aa peptide I [A] and 27 aa peptide II [B] were digested with BTMD-SKI-1 for 150 and 60 min, respectively. The cleavage products were separated by RP-HPLC using a 5 μ m analytical Ultrasphere C18 column (Beckman) as described under "Experimental Procedures". The peptides contained in the major peaks were identified by mass spectrometry and amino acid analysis (*not shown*).

Fig. 24 shows the pH and Ca²⁺ activation profile of BTMD-SKI-1. BTMD-SKI-1 from VV-infected BSC40 cells was assayed as described under "Experimental Procedures" using a binary buffer system consisting of MES and HEPES, along with peptides I or II for the pH profile [A], and peptide II for the Ca²⁺ profile [B]. The results represent the average \pm SD (indicated as error bars) of three separate determinations.

Fig. 25 is a X-ray film autoradiography showing in situ hybridization pattern for SKI-1 mRNA (A) and APP mRNA (B) at the anatomical plane in sagittal section from a 4-day mouse. Note similarity of distribution of SKI-1 and APP. A significant concentration of both SKI-1 and APP mRNA is revealed in the brain (Br), apinal cord (SpC), dorsal root ganglia (DRG), kidney (Ki), skin (Sk) submaxillary gland (SM) and bone tissue (B).

Fig. 26 shows the comparative distribution of SKI-1 and APP in different regions of lacrimal gland of adult male mouse shown by immunocytochemistry. Peripherally located lobes display immunoreaction for both SKI-1 (A) and APP (B) in acinar cells. In the centrally located lobes the immunoreaction for SKI-1 (C) and APP (D) is confined to single cells distributed through the acini (medium arrows) and to intralobular ducts (long arrows).

Fig. 27 illustrates the inhibition of proNGF processing. Rat Schwann cells were infected with either VV:POMC (antigen control), or co-infected with VV:NGF and either VV:POMC (control), VV:PDX, VV:ppFurin or VV:ppPC7. The cells were then pulse-labeled with [³⁵S]Met for 4h and the media immunoprecipitated with an NGF antiserum. The migration positions of the 35 kDa proNGF and the 13.5 kDa NGF are shown.

Fig. 28 illustrates the inhibition of proBDNF processing by furin. Western blot analysis of non-transfected (NT) COS-1 or cells transfected with pcDNA3 recombinants of proBDNF as control (BDNF) or together with recombinants expressing sense (S) or antisense (AS) ppPC7 or ppFurin. The secreted products resolved by SDS-PAGE were analyzed with a BDNF-specific antiserum [Santa Cruz].

Fig. 29 shows the biosynthetic analysis of the fate of the prosegment of SKI-1.

(A) Zymogen processing of [³H] Leu SKI-1 in LoVo cells. LoVo cells overexpressing vaccinia virus full length SKI-1 were pulse-labeled for 15 min with [³H] Leu and then chased for 2h (P15C2h). Cell lysates were immunoprecipitated with antibody to the prosegment, resolved by SDS-PAGE on a 14% gel and the dried gel autoradiographed. The migration positions of the major 26, 24, 14, 10 and 8 kDa prosegments are emphasized.

(B) Zymogen processing of [³H] Leu SKI-1 in BSC40 cells. BSC40 cells overexpressing vaccinia virus SKI-1 prosegment were pulse-labeled for 30 min with [³H] Leu and then chased for 2h (P30C2h). Cell lysates were immunoprecipitated with antibody to the prosegment, resolved by SDS-PAGE on a 14% gel and the dried gel autoradiographed. The migration positions of the 24 and 14 kDa prosegments are emphasized.

Fig. 30 shows the inhibition of α_4 processing in stable transfectants of Jurkat T cells expressing the mPC5 prodomain mutated at Arg⁸⁴ to Ala. The cell surface proteins of 25×10^6 cells were biotinylated and immunoprecipitated with monoclonal α_4 antibody (HP 2/1). Following SDS gel electrophoresis under reducing conditions and blotting to nitrocellulose the 80 kDa cleavage product was revealed by the chemiluminescence detection of anti-biotin streptavidin horse radish peroxidase.

EXAMPLE 1:

MATERIALS AND METHODS

Polymerase Chain Reaction and Sequencing. Most reverse transcriptase polymerase chain reactions (RT-PCR) were performed using a Titan One Tube RT-PCR system (Boehringer Mannheim) on 1 μ g of total RNA isolated from either a human neuronal cell line (IMR-32), mouse corticotrophic cells (AtT20), or rat adrenal glands using a TRIzol reagent kit (Life Technologies). The active site degenerate primers were: His (*sense*) 5'-GGICA(C,T)GGIACI(C,T)(A,T)(C,T)(G,T)(T,G)IGCIGG-3' and Ser (*antisense*) 5'-CCIG(C,T)IACI(T,A)(G,C)IGGI(G,C)(T,A)IGCIACI(G,C)(A,T)GTICC-3' based on the sequences GHGT(H,F)(V,C)AG and GTS(V,M)A(T,S)P(H,V)V(A,T)G, respectively. The amplified 525 bp products were sequenced on an ALF DNA sequencer (Pharmacia). To obtain the full length of rat and mouse SKI-1, we used PCR primers based on the human (12) and mouse sequences, in addition to 5' (13) and 3' (14) RACE amplifications. To avoid errors, at least three clones of the amplified

cDNAs were fully sequenced. The GenBank accession numbers of the 3788 bp mouse mSKI-1 cDNA and 3895 bp rat rSKI-1 are AF094820 and AF094821, respectively.

Transfection and Metabolic Labeling. Human SKI-1 (nt 1-4338) (12) in Bluescript (a generous gift from Dr. N. Nomura, Kazusa DNA Research Institute, Chiba, Japan; gene name KIAA0091, accession No. D42053) was digested with SacII (nt 122-4338) and inserted into the vector PMJ602. The construct was digested with 5' KpnI/3' NheI, cloned into the KpnI/XbaI sites of pcDNA3 (Invitrogen), and the cDNA transfected into HK293 cells with a DOSPER liposomal transfection reagent (Boehringer Mannheim). A number of stable transfectants resistant to G418 and positive on western blots using a SKI-1 antiserum (*see below*) were isolated, and one of them (clone 9), was further investigated. Cells were pulsed for 4h with [³⁵S]Met and the media and cell lysates immunoprecipitated with SKI-1 antisera directed against either amino acids (aa) 634-651, or aa 217-233, or a pro-SKI-1 antiserum directed against the pro-segment comprising aa 18-188 (Fig. 1). Immune complexes were resolved by SDS-PAGE on a 6% polyacrylamide/Tricine gel (15).

Northern Blots, *in situ* Hybridizations and Immunocytochemistry. Northern blot analyses (16) were done on total RNA from adult male rat tissues using either a TRIzol reagent kit (Life Technologies) or a Quick Prep RNA-kit (Pharmacia) and on polyA⁺ RNA of (male + female) rat adult tissues (Bio/Can Scientific). The blots were hybridized overnight at 68°C in the presence of [³²P]UTP SKI-1 cRNA probes, consisting of the antisense of nucleotides 655-1249 of rat SKI-1 (accession No. AF094821). For ISH, the same rat sense and antisense cRNA probes were doubly labeled with uridine and cytosine 5'-{λ-[³⁵S]thio}triphosphate (16). The distribution of SKI-1 mRNA in different tissues of adult and newborn rat (P1) after emulsion autoradiography was investigated. Relative densities of specific SKI-1 mRNA labeling per cell in selected organs have been measured upon counting of silver grains produced by antisense SKI-1 riboprobes and subtraction of non-specific background produced with sense SKI-1 riboprobes. Countings were made under 1000-fold microscopical magnification in the similar regions of adjacent sections stained with hematoxylin and eosin. Results are the mean (S.E.D. of 10 - 16 readings / cell type. Newborn rats were frozen at - 35°C in isopentane and then cut into 14-μm sagittal cryostat sections (1, 16). After hybridization, all tissue slides were exposed for 4 or 30 days to X-Ray film or emulsion autoradiography, respectively. For immunofluorescence staining we used a rabbit anti-SKI-1 antiserum at a 1:100 dilution and rhodamine-

labeled goat anti-rabbit IgGs diluted 1:20 (16). Red SKI-1 immunostaining was compared with green staining patterns of both fluorescein-labeled concavalin A (ConA; Molecular Probes, OR), an ER marker, or fluorescein-conjugated wheat germ agglutinin (WGA; Molecular Probes, OR), a Golgi marker (17).

5 ***Ex vivo and in vitro* proBDNF Processing.** A vaccinia virus recombinant of human SKI-1 (vv:SKI-1) was isolated as previously described for human proBDNF (vv:BDNF) (15). The vaccinia virus recombinants of the serpins α 1-antitrypsin Pittsburgh (α 1-PIT; vv:PIT) and α 1-antitrypsin Portland (α 1-PDX; vv:PDX) (18) were generous gifts from Dr. G. Thomas (Vollum Institute, Portland, OR). For analysis of the
10 cleavage specificity of hSKI-1, 4×10^6 COS-7 cells were co-infected with 1 pfu/cell of vv:BDNF and either the wild type virus (vv:WT) alone at 2 pfu/cell or with 1 pfu/cell of each virus in the combinations: [vv:SKI-1+vv:WT], [vv:SKI-1+vv:PIT] and [vv:SKI-1+vv:PDX]. At 10h post infection, cells were pulse labeled for 4h with 0.2 mCi [35 S]Cys-Met (Dupont). Media and cell extracts were immunoprecipitated with a BDNF
15 antiserum (19; kindly provided by Amgen) at a concentration of 0.5 μ g/ml. The precipitates were resolved on polyacrylamide gradient gels (13-22%) and the autoradiograms obtained as described (15). Microsequencing analysis was performed on the [35 S]Met-labeled 32 kDa proBDNF and [3 H]Leu-labeled 28 kDa BDNF, as described (20). For *in vitro* analysis, the 32 kDa proBDNF obtained from the media of
20 LoVo cells infected with vv:BDNF was incubated overnight with the shed form of SKI-1 obtained from rat Schwann cells (16) co-infected with vv:SKI-1 and vv:PDX, either at different pHs or at pH 6.0 in the presence of selected inhibitors: pepstatin (1 μ M), antipain (50 μ M), cystatin (5 μ M), E64 (5 μ M), soya bean trypsin inhibitor (SBTI, 5 μ M), 0.5 M phenylmethylsulfonyl fluoride (PMSF) + 50 μ M para-aminophenylmethylsulfonyl
25 fluoride (pAPMSF), o-phenanthroline (5 mM) and EDTA (10 mM). The products were resolved by SDS-PAGE on a 15% polyacrylamide gel, transferred to a PVDF membrane and then probed with a BDNF antiserum (Santa Cruz) at a dilution of 1:1000.

RESULTS

Protein Sequence Analysis of SKI-1. We first aligned the protein sequences within the catalytic domain of PC7 (21), yeast subtilases and bacterial subtilisins, together with that of a novel subtilisin-like enzyme from *Plasmodium falciparum* (J-C. Barale *et al.*, *submitted*). This led to the following choice of conserved amino acids around the active sites His and Ser: GHGT(H/F)(V/C)AG and GTS(M/V)A(T/S)P(H/V)V(A/T)G, respectively. Thus, using degenerate oligonucleotides coding for the sense His and antisense Ser consensus sequences we initiated a series of RT-PCR reactions on total RNA (*see Materials and Methods*) and isolated a 525 bp cDNA fragment from the human neuronal cell line IMR-32. This sequence was found to be 100% identical to that reported for a human cDNA called KIAA0091 (Accession No. D42053) obtained from a myeloid KG-1 cell line (12) and 88 % identical to that of a 324 bp EST sequence (Accession No. H31838) from rat PC12 cells. We next completed the rat and mouse cDNA sequences following RT-PCR amplifications of total RNA isolated from rat adrenal glands and PC12 cells, and from mouse AtT20 cells. Starting from the equivalent rat and mouse 525 bp fragments, the complete sequences were determined using a series of RT-PCR reactions with human-based oligonucleotides in addition to 5' (13) and 3' (14) RACE protocols. As shown in Fig. 1, alignment of the protein sequence deduced from the cDNAs of rat, mouse and human SKI-1 revealed a high degree of conservation. Rat and mouse SKI-1 share 98% sequence identity and a 96% identity to human SKI-1. Interestingly, within the catalytic domain (Asp²¹⁸ to Ser⁴¹⁴) the sequence similarity between the three species is 100%. Analysis of the predicted amino acid sequence suggests a 17 aa signal peptide, followed by a putative pro-segment beginning at Lys¹⁸ and extending for some 160-180 amino acids. The proposed catalytic domain encompasses the typical active sites Asp²¹⁸, His²⁴⁹ and Ser⁴¹⁴ and the oxyanion hole Asn³³⁸. This domain is followed by an extended C-terminal sequence characterized by the presence of a conserved growth factor / cytokine receptor family motif C⁸⁴⁹LDDSHRQKDCFW⁸⁶¹. This sequence is then followed by a potential 24 aa hydrophobic transmembrane segment and a less conserved 31 aa cytosolic tail that remarkably consists of 35% basic residues. Some of the clones isolated from rat adrenal glands suggested the existence of alternatively spliced rSKI-1 mRNAs in which the segments coding for aa 430-483 or 858-901 are absent. Finally, the phylogenetic tree derived from the alignment of the catalytic domain of SKI-1 with subtilases (22) suggests that it is an ancestral protein that is

closer to plant and bacterial subtilases than to either yeast or mammalian homologues (*not shown*).

Tissue Distribution of SKI-1 mRNA. Northern blot analyses of SKI-1 mRNA in adult male rat tissues reveal that rSKI-1 mRNA is widely expressed and is particularly rich in anterior pituitary, thyroid and adrenal glands (Figs. 2A and 8). A Northern blot of polyA⁺ RNA obtained from mixed adult male and female rat tissues also showed a wide distribution and a particular enrichment in liver (Fig. 2B). Similarly, analysis of 24 different cell lines (23) revealed a ubiquitous expression of SKI-1 mRNA (*not shown*).

In situ hybridization data obtained in a day 2 postnatal rat also provided evidence of a widespread, if not ubiquitous distribution of rSKI-1 mRNA. Figure 3 shows at the anatomical level the presence of SKI-1 mRNA in developing skin (see also Figure 9), striated muscles, cardiac muscles, bones and teeth as well as brain and many internal organs. Strong hybridization signals were detectable in the retina, cerebellum, pituitary, submaxillary, thyroid and adrenal glands, molars, thymus, kidney and intestine. Evidence for the cellular expression of rSKI-1 mRNA was obtained from analysis of the relative labeling densities per cell in selected tissues, based on a semiquantitative analysis of emulsion autoradiographies (*not shown*). In the central nervous system (CNS) rSKI-1 mRNA labeling was mostly confined to neurons, whereas ependymal cells, supportive glial cells, such as presumed astrocytes, oligodendrocytes, and microglia, exhibited 5-30 fold less labeling/cell (see Table 1 and Figure 10). In addition, within the peripheral nervous system (PNS) trigeminal ganglia reveal a 5-10 fold greater expression in neurons as compared to presumptive Schwann cells (Figures 11 and 12 and Table 1). Labeling was observed in most of the glandular cells in the anterior and intermediate lobes of the pituitary as well as in the pituicytes of the pars nervosa. A semiquantitative comparison in the adult and newborn rat pituitary gland, submaxillary gland, thymus and kidney demonstrated an overall 2-fold decreased labeling of rSKI-1 mRNA with age (*not shown*).

Biosynthesis of hSKI-1. To define the molecular forms of human SKI-1 and their biosynthesis, we generated both a vaccinia virus recombinant (vv:SKI-1) and a stable transfectant in HK293 cells. Three antisera were produced against aa 18-188 (prosegment), 217-233 and 634-651 of SKI-1. Expression of vv:SKI-1 in 4 different cell lines revealed that the enzyme is synthesized as a 148 kDa proSKI-1a zymogen which is processed into 120, 106 and 98 kDa proteins. In this system, both the 148 and 120

kDa forms are recognized by the Pro-domain antiserum, whereas all 4 forms react with the other two antisera. Processing of the 148 kDa proSKI-1a into the 120 and 106 kDa forms occurs in the ER based on the presence of these proteins in cells pre-incubated with the fungal metabolite brefeldin A (see 24 for refs., *not shown*). The same SKI-1-related forms are also observed in stably transfected HK293 cells following a 4h pulse labeling with [³⁵S]Met (Fig.4). The results reveal the intracellular formation of a secretable 98 kDa form (SKI-1s) recognized by both of the SKI antisera but not by the Pro antiserum. These data demonstrate that the 148 kDa proSKI-1a is N-terminally cleaved into an intermediate 120 kDa form containing part of the prosegment (proSKI-1b) which is then further excised to form a non secretable 106 kDa SKI-1. This suggests that two cleavages occur within the prosegment prior to the formation of the presumably membrane-bound 106 kDa form which is later shed into the medium as a 98 kDa soluble SKI-1s.

Intracellular localization of SKI-1. Double staining immunofluorescence was used to compare the intracellular localization of the stably transfected human SKI-1 in HK293 cells and that of either the ER or Golgi markers ConA and WGA (17), respectively. The data show that SKI-1 exhibits: (i) peripheral nuclear staining, colocalizing with ConA fluorescence, presumably corresponding to the ER (*not shown*); (ii) paranuclear staining colocalizing with WGA fluorescence, suggesting the presence of SKI-1 in the Golgi (Fig. 5A,B) and (iii) punctate staining observed in the cytoplasm and within extensions of a few cells (Fig. 5A). Some, but not all of the punctate immunostaining matched that observed with WGA. This suggests that SKI-1 localizes in the Golgi but may sort to other organelles, including lysosomal and/or endosomal compartments. Since in HK293 cells we observed scant immunoreaction to either cathepsin B or cathepsin D (*not shown*), we could not directly assess the presence of SKI-1 within lysosomes. An indication of lysosomal/endosomal localization was provided by the analysis of SKI-1 immunofluorescence within cells pre-incubated for 4h with 10 mM leucine-methyl ester (LME), a specific lysosomal/endosomal protease inhibitor (25). The results showed a net increase in the proportion of cells exhibiting punctate staining (Fig. 5C) as compared to control cells. Thus, SKI-1 immunoreactivity is enhanced upon LME inhibition of lysosomal/endosomal hydrolases.

Enzymatic Activity and Cleavage Specificity of SKI-1. To prove that SKI-1 is a proteolytic enzyme we examined its ability to cleave five different potential precursor substrates. Our choice was based on the tissue expression pattern of SKI-1 (Figs. 2, 3), which led us to select pro-opiomelanocortin (pituitary), pro-atrial natriuretic factor (heart), HIV gp160 (T-lymphocytes) and based on its neuronal expression, pro-nerve growth factor and pro-brain-derived neurotrophic factor (proBDNF). Cellular co-expression of vv:SKI-1 with the vaccinia virus recombinants of each of the above precursors revealed that only proBDNF could be cleaved intracellularly by SKI-1. Thus, upon expression of vv:BDNF alone in COS-7 cells we observed a partial processing of proBDNF (32 kDa) into the known major 14 kDa BDNF product (15), and the minor production of a previously observed (16; Mowla, S.J. *et al.*, *submitted*) but still undefined 28 kDa product (Fig. 6A). Upon co-expression of proBDNF and SKI-1, a net increase in the level of the secreted 28 kDa BDNF is evident, without significant alteration in the amount of 14 kDa BDNF (Fig. 6A). To examine whether the 28 kDa product results from cleavage at a basic residue or at an alternative site, we first co-expressed proBDNF, SKI-1 and either α 1-PIT or α 1-PDX which are inhibitors of thrombin and PC cleavages, respectively (18, 26). The results show that different from α 1-PIT, the serpin α 1-PDX selectively blocks the production of the 14 kDa BDNF and that neither α 1-PIT nor α 1-PDX affect the level of the 28 kDa product. This demonstrates that α 1-PDX effectively inhibits the endogenous furin-like enzyme(s) responsible for the production of the 14 kDa BDNF (15), but does not inhibit the ability of SKI-1 to generate the 28 kDa product. Thus, it is likely that the generation of the 28 kDa BDNF takes place via an alternate cleavage. Incubation of the cells with the Ca^{2+} ionophore A23187 abolished the production of both the 14 and 28 kDa products (*not shown*), supporting the notion that similar to the PCs (1-3, 24), SKI-1 is a Ca^{2+} -dependent enzyme.

In Fig. 6B, we present the N-terminal microsequence analysis of [^{35}S]Met-labeled 32 kDa proBDNF and [^3H]Leu-labeled 28 kDa BDNF. The sequence of the 32 kDa form revealed the presence of an [^{35}S]Met at position 3 (Fig. 6B), which is in agreement with the proposed sequence of human proBDNF (27) resulting from the removal of an 18 aa signal peptide cleaved at GCMLA¹⁸↓APMK site. The N-terminal sequence of the 28 kDa product revealed a [^3H]Leu at positions 2, 13 and 14 (Fig. 6B). This result demonstrates the 28 kDa BDNF is generated by a unique cleavage at Thr⁵⁷ in the sequence: RGLI⁵⁷↓SLADTFEHVIEELL (27).

To prove that SKI-1 is directly responsible for the production of the 28 kDa BDNF at the novel Thr-directed cleavage, we performed *in vitro* studies. Thus, proBDNF was incubated at various pHs with concentrated media of vv:SKI-1-infected Schwann cells. A similar preparation obtained from wild type vaccinia virus-infected cells served as control. The data show that SKI-1 exhibits a wide pH dependence profile revealing activity at both acidic and neutral pHs between pH 5.5 up to 7.3 (Fig. 7A) but also at pH 4.5 and 8 (*not shown*). Analysis of the inhibitory profile of this reaction revealed that metal chelators such as EDTA and o-phenanthroline, or a mixture of the serine proteinase inhibitors PMSF + pAPMSF effectively inhibit the processing of proBDNF by SKI-1. The inhibition by EDTA is expected since like all PCs, SKI-1 is a Ca^{2+} -dependent enzyme. The unexpected inhibition by 5 mM o-phenanthroline may be due to excess reagent since at 1 mM only 25% inhibition is observed (*not shown*). All other class-specific proteinase inhibitors (aspartyl-, cysteinyl-, and serine proteases- of the trypsin-type) proved to be inactive.

Table 1

| Tissue | Adult | Newborn (PI) |
|---------------------------------|------------------------------|------------------------------|
| | Silver grains/Cell \pm SED | Silver Grains/Cell \pm SED |
| C.N.S. | | |
| <u>Cerebral Cortex</u> | | |
| Neurons, large | 19.7 \pm 5.8 | ND* |
| Neurons, medium & small | 5.7 \pm 2.3 | |
| Astrocytes, presumptive | 0.6 \pm 0.5 | |
| <u>Hippocampus</u> | | ND |
| Neurons, pyramidal | 15.3 \pm 3.9 | |
| Neurons, granules | 23.7 \pm 5.3 | |
| <u>Corpus callosum</u> | | ND |
| Oligodendrocytes, presumpt. | 0.6 \pm 0.6 | |
| <u>Spinal cord</u> | | ND |
| Motorneurons | 27.8 \pm 7.1 | |
| <u>Circumventricular organs</u> | | ND |
| Plexus choroideux | 9.6 \pm 1.9 | |
| Ependyma (III ventr.) | 2.9 \pm 0.8 | |

| | | | |
|----|----------------------------|-----------|-----------|
| 5 | P.N.S. | | ND |
| | <u>Trigeminal ganglion</u> | | |
| | Neurons, large | 14.6 ± 4 | |
| | Satellite cells | 3.8 ± 22 | |
| | Schwann cells, presumpt. | 1.3 ± 1.9 | |
| 10 | <u>Pituitary gland</u> | | |
| | Anterior lobe cells | 4.9 ± 3.6 | 9.3 ± 2.1 |
| | Intermediate lobe cells | 4.1 ± 0.9 | 7.2 ± 1.4 |
| | Posterior lobe pituicytes | 3.6 ± 3.9 | 6.7 ± 4.2 |
| | <u>Thymus</u> | | |
| 15 | Cortical lymphocytes | 4.1 ± 0.7 | 7.1 ± 1.0 |
| | Medullary reticular cells | 2.7 ± 1.0 | 4.4 ± 0.9 |
| | Adipocytes | 0.3 ± 0.6 | ND |
| | Fibroblasts | 0.2 ± 0.1 | ND |
| | <u>Submaxillary gland</u> | | |
| 20 | Epithelial cells | 2.1 ± 1.0 | 3.9 ± 1.7 |
| | Acinar cells | 2.4 ± 1.2 | 4.5 ± 1.7 |
| | <u>Kidney</u> | | |
| | Glomerular cells | 2.8 ± 0.9 | 4.2 ± 0.9 |
| | Convolutated tubules | 4.1 ± 2.7 | 9.8 ± 1.4 |

*ND = not determined

25 DISCUSSION

This work provides the first evidence for the existence of a mammalian secretory Ca^{2+} -dependent serine proteinase of the subtilisin-kexin type that selectively cleaves at non-basic residues. Thus, SKI-1 processes the 32 kDa human proBDNF at an KAGSRGLT↓SL sequence generating a 28 kDa form, which may have its own biological activity (Mowla, S.J. *et al.*, *submitted*). Such a cleavage site is close to the consensus site deduced from a large body of work done with the PCs, whereby an (R/K)-(X)_n-R↓X-(L/I/V), [where n=0, 2, 4 or 6] motif is favored by most PCs (1-3, 28). Note that in the SKI-1 site, P1 Arg is replaced by Thr and an aliphatic Leu is present

at P2', an amino acid also favored by PCs (1-3, 28). Several proteins are known to be cleaved following Thr. These include human anti-angiogenic platelet factor 4 (6; QCLCVKTT↓SQ) and angiostatin (7; KGPWCFTT↓DP), the neuroendocrine α-endorphin (4; KSQTPLVT↓LF), the ADAM-10 metalloprotease (8; LLRKKRTT↓SA), as well as the amyloidogenic peptide Aβ43 (10; VGGVVIAT↓VI).

Interestingly, comparison of the phylogenetically highly conserved sequence of proBDNF revealed an insertion of hydroxylated amino acids (Thr and Ser) just after the identified SKI-1 cleavage site of human proBDNF. Thus, in rat and mouse proBDNF, two threonines are inserted (RGLTTT—SL) and in porcine proBDNF five serines added (RGLTSSSSS—SL) (27). These observations raised a number of questions: (i) do these insertions affect the kinetics of proBDNF cleavage by SKI-1? (ii) does SKI-1 recognize both single and pairs of Thr and Ser and combinations thereof? (iii) is the presence of a basic residue at P4, P6 or P8 important for cleavage? and (iv) similar to enzymes cleaving at basic residues (29), does the possible phosphorylation at specific Thr or Ser residues affect substrate cleavability by SKI-1? Answers to these questions are provided hereinbelow.

Biosynthetic analysis of the zymogen processing of proSKI-1 demonstrated a two-step ER-associated removal of the pro-segment (Fig. 4). Furthermore, analysis of the [³⁵SO₄]-labeled SKI-1 demonstrated only the presence of sulfated 106 and 98 kDa forms but not that of either the 148 or 120 kDa forms recognized by the Pro-segment antiserum (*not shown*). Since sulfation occurs in the *trans* Golgi network, this confirms that the removal of the pro-segment occurs in the ER. Like furin and PC5-B (1-3, 24) the membrane bound 106 kDa SKI-1 is transformed into a soluble 98 kDa form that is released into the medium by an as yet unknown mechanism. The secreted 98 kDa SKI-1s is enzymatically active since it processes proBDNF *in vitro* (Fig. 7). Numerous attempts to sequence the SDS-PAGE purified [³H]Leu and Val-labeled 148 kDa and 98 kDa forms, resulted in ambiguous results, suggesting that SKI-1 is refractory to N-terminal Edman degradation. Presently, we cannot define the two zymogen cleavage sites leading to the sequential formation of the 120 kDa proSKI-1b and 106 kDa SKI-1 deduced by pulse (Fig. 4) and pulse-chase studies (*not shown*). Examination of the pro-segment sequence (Fig. 1), the species-specific proBDNF motif potentially recognized by SKI-1 (*see above*), and the alignment of SKI-1 with other subtilases (22), suggests two possible conserved sites: RNNPSS⁹⁵↓DYPS and RHSS¹⁸²↓RRLL.

Both sites predict a cleavage after pairs of Ser with either a P6 or a P4 Arg, respectively.

Phylogenetic structural analysis of the predicted amino acid sequence of SKI-1 reveals that this serine proteinase is closer to plant and bacterial subtilases than it is to yeast and mammalian PCs. The 100% conservation of the catalytic domain sequence, although striking and suggestive of an important function, is not far from the 98% similarity between human and rat PC7 (3, 21). The sequence C-terminal to the catalytic domain of SKI-1 is very different from that of any of the known PCs. In fact, although PCs have a typical P-domain critical for the folding of these enzymes (for reviews see 1-3), we did not find the hallmark sequences (3, 30) of the P-domain within the SKI-1 structure. Instead different from the PCs, we find a conserved growth factor/cytokine receptor motif of which functional importance will need to be addressed, especially since this motif is partly missing in alternatively spliced forms (Fig. 1). Finally, the highly basic nature of the cytosolic tail of SKI-1 (Fig. 1) may be critical for its probable cellular localization within endosomal/lysosomal compartments (Fig. 5), similar to the importance of basic residues for the accumulation of the α -amidation enzyme PAM in endosomal compartments (Milgram, S.L., *personal communication*).

The wide tissue distribution of SKI-1 mRNA transcripts suggests that this enzyme processes numerous precursors in various tissues. Furthermore, the observed developmental down-regulation of the level of its transcripts also suggests a functional importance during embryonic development. The fact that SKI-1 can cleave C-terminal to Thr and possibly Ser residues suggests that, like the combination of PCs and carboxypeptidases E and D (31), a specific carboxypeptidase may also be required to trim out the newly exposed C-terminal hydroxylated residues. Such a hypothesis may find credence in a report suggesting that the amyloidogenic A β 43 (ending at Thr) may be transformed *in vitro* into A β 42 and A β 40 by a brain-specific carboxypeptidase(s) (32).

A recent report demonstrated the existence of a soluble subtilisin-like enzyme exhibiting a 29% sequence identity to SKI-1 in *Plasmodium falciparum* merozoites (PfSUB-1). This enzyme localizes to granular-like compartments and presumably cleaves at a Leu↓Asn bond (33). In that context, SKI-1 may represent the first member of an as yet undiscovered mammalian family of proteinases implicated in the limited proteolysis of proproteins at sites other than basic amino acids that may differ by their intracellular localization and cleavage specificity.

EXAMPLE 2

Genetic and biochemical evidence indicates that SKI-1/S1p is the protease that cleaves sterol-regulatory element-binding proteins (SREBPs) which functions to control lipid biosynthesis and uptake in animal cells { Sakai, J. et al. (1998) *Molecular Cell* 2, 505-514; Cheng, D. et al. (1999) *J. Biol. Chem.* 274, 22805-22812; Touré, A. et al. (1999) In: *Peptides for the Now Millennium: Proceedings of the 16th American Peptide symposium* }. SKI-1 and SREBPs play critical roles in the feedback pathways by which cholesterol suppresses transcription of genes encoding HMG CoA reductase and other enzymes of cholesterol biosynthesis as well as the low density lipoprotein (LDL) receptor. A SKI-1 inhibitor would be of use under clinical conditions in which there is not sufficient down regulation of SREBP dependent transcription by sterols. For example, in the Nieman-Pick group of diseases a high sphingomyelin content of cells leads to an increase in proteolysis of SREBP-2 and a subsequent increase in cholesterol biosynthesis { Scheek, S. et al. (1997) *Proc. Natl. Acad. Sci. USA* 94, 11179-11183; Spence, M.W., and Callahan, J.W. (1989) *Sphingomyelin-cholesterol lipidoses: The Nieman-Pick Group of Diseases. In The Metabolic Basis of Inherited Disease* (Scriver, C.R., Beaudet, A.L., Sly, W.S., and Valle, D., editors), McGraw-Hill Publ. Co., 6th edition, chapter 66, 1655-1675; Svirirodov, D. (1999) *Histology & Histopathology* 14 (1): 305-319 }. Perhaps of greater significance, nuclear SREBP-1c protein levels were significantly elevated in mouse models for non-insulin dependent diabetes, *ob/ob* and *aP2* SREBP-1c mice, which was associated with elevated mRNA levels for known SREBP target genes involved in the biosynthesis of fatty acids (Shimomura, I. et al. *J. Biol. Chem.* 1999; 274:30028-30032).

In addition, the inhibition of the SREBP- dependent transcription of farnesyl diphosphate synthase, like HMG-CoA reductase and farnesyl-protein transferase inhibitors, by inhibition of farnesyl pyrophosphate biosynthesis could potentially be useful to treat a number of diseases such as Ras-dependant cancers and restenosis (Reference - United States Patent 5,925,651). With regard to a potential treatment for restenosis, HMG-CA reductase inhibitors decrease smooth muscle (SMC) cell migration and proliferation, and induce SMC apoptosis { Bellosta, S. et al. (1998) *Atherosclerosis* 137, S101-S109; Guijarro, C. et al. (1998) *Circulation Research* 83, 490-500 }.

As mentioned above, inhibition of PC activity seems to offer new therapeutical targets. Unfortunately, previous attempts using inhibitory peptides have failed either

due to cytotoxicity of used agents or poor targeting ^{17;18}. We have focused on the inhibitory properties of PC prosegments in order to find a safe and effective way for enzyme silencing.

To study the effect of the SKI-1 prosegment (ProSki-1) on the SREBP processing and mediated transcriptional activity we isolated a cDNA fragment covering the 188 amino acids that make up the signal peptide and the prosegment of SKI-1 including the predicted cleavage site RRLL¹⁷⁶. This autocatalytic cleavage site was confirmed by mass spectral analysis and amino acid sequencing by other investigators ¹⁹. We isolated stable cell lines overexpressing SREBP-1 (neo resistance) and ProSki-1 plasmid (zeo resistance). A background SREBP-1 overexpression was used in order to improve detection of nuclear NH₂-terminal segment of SREBP in immunoblot experiments.

The effect of ProSki-1 on target gene mRNA: mRNA expression in HK293 cells was studied by Northern blotting as described in the methods section. In wild type (wt), vector only, and SREBP overexpressor cells in presence of lipids the mRNA levels were low for all studied genes: LDL-receptor, HMG-CoA reductase, farnesyl diphosphate (FDP) (Fig. 13), and fatty acid synthase (FAS) (Fig. 14). However, when these cells were treated with media containing no cholesterol a clear increase was observed in mRNA expression for all these genes, as demonstrated in earlier studies. Interestingly, corresponding mRNA levels were greatly reduced in both conditions in cells overexpressing ProSKI-1 and SREBP-1 suggesting that SREBP mediated transcription can be blocked efficiently by the prodomain mediated inhibition of the SKI-1 protease (Figs. 13 and 14). The effect was observed in early passages of previously frozen cell lines. However, when the same clones were kept in culture for future passages, in contrast to earlier findings the target gene mRNA levels were now normal or even higher than in control cells. (Figure 15). This finding suggests that cells can adapt to new conditions and maintain their lipid homeostasis even without SREBP mediated regulation and synthesis. This finding was supported in another experiment with several cell lines overexpressing SREBP-1 or SREBP-1 and ProSki-1 (Fig. 16). While HMG CoA reductase and farnesyl diphosphatase varied markedly between different cell lines containing only SREBP-1 (Fig. 16, lanes 1-5), mRNA levels measured from cells overexpressing ProSki-1 and SREBP-1 (Fig. 16, lanes cl4, cl6, and cl9) showed no variation and were higher than in SREBP-1 cells.

The effect of ProSKI-1 on nuclear SREBPs: Western blot experiments were performed to illustrate the effect of ProSKI-1 on SREBP-1 processing in these cells. After staining with an antibody against the NH₂-terminal end of SREBP-1 a band around 60 kDa appeared on blots of nuclear extracts (Fig. 17), as demonstrated earlier by other investigators^{2,3}. As expected, only a weak signal was detected in presence of sterols. In absence of sterols a significant increase was observed, especially in SREBP-1 cells. Only minute amounts of nuclear SREBPs were detected when ProSKI-1 was present suggesting that sterol mediated proteolysis of SREBPs is efficiently blocked in these cells in presence of ProSKI-1 (Figure 17 shows the data from clones 6 {lane 5} and 9 {lane 6}).

The inhibitory effect of ProSKI-1 was further demonstrated by studying the processing of cytoplasmic full length SREBP-1 (proSREBP-1) (Fig. 18). The processing of proSREBP-1 by SKI-1 / S1P into intermediate (intSREBP-1) forms shown previously by other investigators¹⁹, was clearly demonstrated in clones overexpressing SREBP-1. Significantly, in cell lines overexpressing SREBP-1 together with the inhibitory prodomain of SKI-1 (pSKI + SRE) accumulation of the proSREBP-1 was observed and formation of the intermediate form(s) of SREBP-1 was abolished. These results, along with the observed reduction in nuclear SREBP (Fig. 17), indicate that ProSKI-1 efficiently inhibits SKI-1 protease activity and blocks SREBP processing in mammalian cells. In addition, the specificity of ProSKI-1 inhibition was studied by using a substrate not processed by SKI-1 (neurotrophin-3; NT-3). Both the level and furin-derived processing of NT-3 were unaffected by the presence of ProSKI-1 (*not shown*). These results suggest that ProSKI-1 is SREBP- and pro-BDNF- specific and that it does not affect other secretory proteins which are not substrates for SKI-1.

In these experiments a pro-domain was successfully used for the first time as a subtilase inhibitor *in vivo*. ProSKI-1 seems to be a promising therapeutical tool for SREBP-mediated pathologies, which may or may not be directly related to cholesterol or fatty acid homeostasis. For instance SREBP-dependent isoprenoids, such as farnesol and geranylgeraniol, have been shown to associate e.g. with endothelial nitric oxide synthetase (eNOS)²⁰⁻²³, vascular smooth muscle proliferation and migration as well as ras-protein mediated cell proliferation²⁴⁻²⁸. Furthermore, links to PPAR- γ mediated signaling system including adipocyte differentiation and insulin resistance have already been reported²⁹⁻³³. This novel prosegment approach to inhibit enzyme activity will certainly also inspire other investigators in different fields, since it may be

possible to specifically inhibit other enzymes with this prosegment technology leading to new treatments for a variety of diseases. On the other hand, these results provide new data supporting the existence of an SREBP-independent, but lipid dependent (Fig. 3) control of the lipid homeostasis in human cells, although the alternative sensor of lipids under these conditions is currently unknown.

Materials and Methods

Materials:

Cell Culture: HK293 cells were maintained as monolayers in Dulbecco's modified Eagle's medium containing 100 units / ml penicillin and 100 µg / ml streptomycin sulfate (medium A) supplemented with 10 % fetal calf serum. 24 hours before RNA and protein extractions medium A was supplemented with 5 % lipoprotein deficient serum, 50 µM mevalonate (Sigma), 50 µM compactin (Sigma) and with no sterols or 1 µg/ml of 25-hydroxy-cholesterol and 10 µg/ml of cholesterol. 4 hours before protein extraction 25 µg/ml N-acetyl-leuciny-leuciny norleucinal was added. Total RNA was isolated with Trizol (Gibco BRL) reagent according to the instructions of the manufacturer. In order to extract proteins cells were washed and collected in PBS with protease inhibitors (). After addition of buffer A (Triton x 100 1 %, 50 mM tris maleate, 2 mM CaCl₂, inhibitor cocktail (), and ALLN) cells were mixed with pipette and allowed to swell on ice for 20 minutes. Then the solution was centrifuged for 5 minutes at 15 000 rpm and supernatants representing membrane proteins were collected and stored until analyzed at -70 °C. Remaining pellets were resuspended in Buffer B (20 mM Tris pH 7.9, 400 mM NaCl, 1mM EDTA, 1mM EGTA, and protease inhibitors). Samples were shaken at 4 °C for 1 hour and centrifuged and the supernatant was frozen in aliquots at -70 °C.

Plasmid constructions: SKI-1 prosegment containing aa 1-188 was isolated by PCR using following oligonucleotides: [5' GGA TCC GAA GAA ACA TCT GGG CGA CAGA 3'] and [5' CTC GAG GGC TCT CAG CCG TGT GCT 3'] and cloned into PCR 2.1 TA cloning vector for sequencing. After that it was subcloned into the pcDNA_{3zeocin} vector (Invitrogen) (BamHI / HindIII sites) for transfections.

SREBP-1 in bluescript IISK (ATCC 79810) subcloned into Sall / BamHI sites of the pcDNA_{3geneticin}.

Transfections: HK293 cells were plated at a density of 5x10⁵ / 60 mm dish in medium A with 10 % fetal calf serum and were cultured until they were 40-60 % confluent. The cells were then transfected with 10 µg plasmid DNA (pcDNA_{3neo}, pcDNA_{3neo}-SREBP-1,

pcDNA_{3neo}-SREBP-1 and pcDNA_{3zeo}-ProSKI-1) using Lipofectin reagent (Life Technologies, city, state) according to manufactures instructions. On day two medium containing appropriate selection agents (800 µg/ml Geneticin for pcDNA_{3neo}, x00 µg/ml Zeocin for pcDNA_{3zeo}) were added. The medium was changed every two days until
 5 defined colonies were evident. Colonies were isolated and formed stable cell lines were analyzed by immunoblotting with ProSKI-1 and SREBP-1 antibodies.

Northern blotting: 20 µg of total RNA was electrophoretically separated in an 1.0 % agarose gel, and transferred to Hybond N⁺ filters (Amersham, city, state) by capillary blotting. After transfer filters were crosslinked by UV irradiation in a Stratalinker
 10 (Stratagene). Filters were prehybridized at 42 °C for 1 hour and hybridized with random labeled ³²P cDNA probes for 16-20 hours. Ultrahyb buffer (Ambion) was used. After hybridization filters were washed and exposed to film for indicated time and bands were quantified by densitometry. Following primer pairs were used to clone
 15 cDNA probes: HMG CoA reductase [5' GAG GAA GAG ACA GGG ATA AAC 3'] [5' GGG ATA TGC TTA GCA TTG AC 3'], farnesyl diphosphate [5' AGC CCT ATT ACC TGA ACC TG 3'], [5' GAA TCT GAA AGA ACT CCC CC 3'], Fatty acid synthase [5' TTC CGA GAT TCC ATC CTA CG 3'], [5' TGC AGC TCA GCA GGT CTA TG 3'], Acetyl CoA carboxylase [5' TCT CCT CCA ACC TCA ACC AC 3'], [5' CCA GCC TGT CAT CCT CAA TAT C 3'], SREBP-1 [5' GGA GCC ATG GAT TGC ACT TTC 3'], [5'
 20 AGG AGC TCA ATG TGG CAG GA 3'], LDL-receptor [5' 3'], [5' 3']. Amplification products were cloned into pGEM (Promega) and sequenced. 18S cDNA was purchased from Ambion.

Immunoblot analysis: 50 µg of nuclear extract and membrane fractions were separated in an SDS-PAGE gel. After electrophoresis proteins were transferred to a
 25 nitrocellulose membrane. Membranes were stained with appropriate primary SREBP-1 (Santa Cruz), ProSki-1 and secondary antibodies. After washing chemiluminescent substrate (Santa Cruz) was added, and membranes were exposed to x-ray film for 1-30 min. Gels were calibrated with prestained molecular weight markers (New England Biolabs).

EXAMPLE 3

The soluble SKI-1 isoform, collected from cell media, was used to study the *in vitro* cleavage properties of this enzyme on a number of synthetic substrates. In addition, we present data on the *in vitro* inhibitory character of three prosegment

constructs of SKI-1, which we obtained as bacterial recombinant proteins. Moreover, we examined the processing of hSKI-1 in LoVo cells infected with a VV recombinant as well as in a stable transfectant of HK293 cells (10).

EXPERIMENTAL PROCEDURES

Vaccinia Virus Recombinant of BTMD-SKI-1 - The preparation of a soluble form of hSKI-1 involved the initial amplification by polymerase chain reaction (PCR) of a 1250 base pair (bp) product encompassing nucleotides (nts) 491-1740 of the hSKI-1 cDNA (12), which includes the initiator methionine. The sense (s) and antisense (as) oligonucleotides were 5' GTGACCATG-AAGCTTGTCAACATCTGG 3' and 5' ACACTGGTCCCTGAGAGGGCCCGGCA 3', respectively. This completely sequenced fragment, which had been inserted into the PCR2.1 TA cloning vector (Invitrogen), was first digested with NotI and AclI. It was then ligated with the similarly digested full-length hSKI-1 cDNA 3.5 kb product, resulting in a product called 5' hSKI-1-FL. In order to obtain a soluble form of hSKI-1 with a hexa-His sequence just before the stop codon, PCR amplification was carried out using the sense and antisense oligonucleotides: 5' ATTGACCTGGACAAGGTGGTG 3' and 5' G G A T C C T C T A G A T C A G T G G T G G T G G T G G - TGGTGGTGCTCCTGGTTGTAGCGGCCAGG 3'. This resulted in a 165 bp fragment encoding the C-terminal sequence PGRYNQE⁹⁹⁷-(H₆)* (10). Following digestion with 5' EcoNI and 3' XbaI, the product was ligated to the aforementioned and similarly digested 5' hSKI-1-FL. This cDNA, coding for BTMD-SKI-1 ending with a hexa-His sequence, was then transferred to the BamH1/XbaI site of the (VV) transfer vector PMJ601. A recombinant was then isolated as previously reported (13). The VV recombinant of full-length hSKI-1 has been described (10).

Biosynthetic Analyses - Seventeen hours following infection with 2 pfu each of VV:SKI-1 and VV:BTMD-SKI-1 recombinants, human LoVo cells (3 x 10⁶) were radiolabeled with 500 µCi of [³H]Leu for 2h or pulsed for 15 min followed by a chase of 2h, in the presence or absence of 5 µg/ml of the fungal metabolite brefeldin A (BFA) as described (10,14). Media and cell lysates were immunoprecipitated with SKI-1 antiserum directed against either aa 634-651, or the prosegment comprising aa 18-188 (10). Immune complexes were resolved by SDS-PAGE on an 8% or 14% polyacrylamide/Tricine gel (10) and the dried gels autoradiographed (10,14). All biosynthesis experiments were performed at least twice.

Isolation and Purification of Recombinant hSKI-1 Prosegments - Three N-terminal fragments of hSKI-1 were isolated by PCR using a common (s) oligonucleotide [5' GGATCCGAAGAAACATCTGGGCGACAGA 3'] and one of three (as) oligonucleotides [5' CTCGAGGGAGAGGCTGGCTCTTCG 3'], [5' CTCGAGGGGCTCTCAGCCGTGTGCT 3'] or [5' CTCGAGTGTCTGGGCAACCTGGGCGCGGG 3']. These prosegment fragments, ending at aa 169, 188, and 196 (10), were cloned in the PCR 2.1 TA cloning vector for sequencing. Then they were transferred into the BamHI / XhoI sites of the bacterial expression vector pET 24b (Novagen). These recombinants were transformed into the *E. Coli* strain BL21. Protein expression was induced with 1mM isopropyl β -D-thiogalactoside and the cultures were grown for 3h at 37°C. The cell pellets were sonicated on ice in a binding buffer containing 6M guanidine-HCl (Novagen) until a clear solution was obtained. The clarified and filtered solution was then applied to a nickel affinity column (Novagen) and eluted with 500 mM imidazole. The eluates were dialyzed overnight at 4°C against 50 mM sodium acetate (pH 7). The protein precipitate was solubilized with glacial acetic acid, filtered through a 0.45 μ m disk and further purified on a 5 μ m C4 column (0.94 x 25 cm; Chromatographic Sciences Company Inc; CSC) by reverse-phase high performance liquid chromatography (RP-HPLC). The purity was assessed by Coomassie staining and the identity of the products verified by mass spectrometry on a Matrix Assisted Laser Desorption Time of Flight (MALDI-TOF) Voyageur DE-Pro instrument (PE PerSeptive Biosystems). The amounts of prosegments were determined by quantitative amino acid analysis (13).

Expression and Purification of Recombinant BTMD-SKI-1 - Following infection of BSC40 cells (75×10^6 cells) with 2 pfu/cell of recombinant VV:BTMD-SKI-1, the cells were washed and incubated at 37 °C for 18h in a serum-free minimal essential medium (MEM; Life Technologies). Media (45 ml) were then dialyzed, concentrated 20-fold to 2.2 ml on Centriprep-30's (Amicon) and stored at -20 °C in 40 % glycerol. For purification², the concentrated media were applied to a Ni^{2+} affinity resin (Novagen) or a Co^{2+} affinity resin (Clontech Laboratories) as described by the manufacturer. After two washes with 5 mM imidazole, the protein was eluted with 200 mM imidazole and tested for enzymatic activity and immunoreactivity by Western blot (*see below*).

Western Blot Analyses - Aliquots of partially purified BTMD-SKI-1 were separated by 8 or 12 % SDS-PAGE followed by electro-transfer of the proteins onto polyvinylidene fluoride (PVDF) membranes (Schleicher and Schuell). These

membranes were probed with an antiserum directed against either SKI-1 [aa 217-233 (Ab:N) or aa 634-651 (Ab:S)] or pro-SKI-1 [(aa 18-188 (Ab:P)]. Protein bands were visualized by enhanced chemiluminescence (ECL) (Boehringer Mannheim).

Purification, N-terminal Sequencing and Mass Spectrometric Analysis of the

- 5 *Secreted Recombinant Prosegment(s) of hSKI-1* - Concentrated media obtained from either VV:BTMD-SKI-1 infected BSC40 cells or from a stable transfectant of full-length hSKI-1 in HK293 cells (10) were loaded onto an RP-HPLC 5 μ m C4 column (0.94 x 25 cm) (Vydac). Proteins were eluted at 2 ml/min using a 1 %/min linear gradient (15-70 %) of 0.1 % aqueous trifluoroacetic acid (TFA)/CH₃CN with monitoring at 210 nm. The products were analyzed by Western blotting, after which the immunoreactive fractions were further purified on a CSC 5 μ m C4 column (0.2 x 25 cm). Mass values were obtained by MALDI-TOF spectrometry using the ¹matrix 3,5 dimethoxy-4-hydroxycinnamic acid (Aldrich Chemical Co). For N-terminal sequencing, fraction IV proteins (Fig. 21A) were separated by SDS-PAGE, transferred to Immobilon-P membranes, and stained with Ponceau Red. The 14 and 5 kDa bands were excised and sequenced using an Applied Biosystems Model 477 sequenator operating in the gas-phase mode (15).

- Synthesis of Peptide Substrates* - All Fmoc amino acid derivatives (L-form), the coupling reagents, and the solvents for peptide synthesis were purchased from PE Biosystems Inc. (Framingham, Mass, USA), Calbiochem (San Diego, Ca, USA), or Richelieu Biotechnologies (Montréal, QC, Canada). The various linear synthetic peptides and internally quenched fluorogenic (Q-) substrates reported in this article are: (I) **hproBDNF(50-63)**: KAGSRGLTSLADTF, (II) **hSREBP-2(504-530)**: GGAHDSDQHPHSGSGRSVLSFESGSGG, (III) **hSKI-1(174-191)**: WHATGRHSSRLLRAIPR, (IV) **hSKI-1(174-188+LE)**: WHATGRHSSRLLRALE, (V) **hSKI-1(182-188+LE)**: SRLLRALE, (VI) **hSKI-1(156-172)**: WQSSRPLRRASLSLGSG, (VII) **hSKI-1(187-201)**: RAIPRQVAQTLQADV; (VIII) **hSKI-1(128-136)**: PQRKVFRSL; (IX) **hSKI-1(128-142)**: PQRKVFRSLKYAESD; (X) **Q-hSKI-1(132-142)**: Abz-

¹ Although we managed to produce limited quantities of partially purified SKI-1 using metal chelating resins, there was insufficient enzyme to carry out full kinetic analyses. However, since the medium of WT virus-(or control vector)-expressing cells produced no significant peptide hydrolysis (with the exception of peptides VIII and IX), we mainly used the concentrated media of BSC40 cells infected with VV:BTMD-SKI-1. Thus, the metal chelation-purified enzyme served mainly to verify that the enzyme from concentrated media behaved similarly to this form. We therefore confirmed all of the peptide cleavage sites, the SREBP-2 pH optimum, and the Ca²⁺ requirement presented below.

VFRSLKYAESD-Y(NO₂)-A; (XI) **Q-hSKI-1(134-142)**: Abz-RSLKYAESD-Y(NO₂)-A. Except for the first two peptides, which were purchased from the Sheldon Biotechnology Institute (McGill University, QC, Canada), all other peptides were synthesized with the carboxy-terminus in the amide form. Peptides III-XI were prepared on a solid phase peptide synthesizer (Pioneer model, PE Biosystems) using either 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) / N-hydroxybenzotriazole (HOBT) or HATU (O-[7-azabenzotriazol-1-yl]-N,N,N',N'-tetramethyluronium hexafluorophosphate) / diisopropyl ethyl amine (DIEA)-mediated Fmoc chemistry with PAL-PEG unloaded resin and the standard side chain protecting groups (16). For the incorporation of the two unnatural amino acids [Abz and Y(NO₂)], an extended coupling cycle was used instead of either the standard or fast cycles.

Purification, Analysis, and Digestion of Peptide Substrates - The crude peptides were purified by RP-HPLC using a semi-preparative CSC-Exsil C18 column (2.5 x 25 cm). Monitoring at 210 nm, the peptides were eluted with a 1 %/min linear gradient (5 % to 60 %) of aqueous 0.1 % TFA/CH₃CN at 2 ml/min and. The peptide purity and concentration were determined by quantitative amino acid analysis (16). The identity of each purified peptide was confirmed by MALDI-TOF spectrometry using the matrix α -cyano 4-hydroxycinnamic acid (Aldrich Chemical Co).

For digestions, each peptide was typically reacted at 37 °C with 10 μ l of the concentrated enzyme preparation in a buffer consisting of 50 mM HEPES (N-2-Hydroxyethyl Piperazine-N'-2 EthaneSulfonic acid) (ICN Biomedicals Inc), 50 mM MES (2-[N-Morpholino] EthaneSulfonic acid) (Sigma Chem Co.), and 3 mM Ca²⁺-acetate (pH 6.5). The digestion products were separated by RP-HPLC on a Beckman 5 μ m Ultrasphere C18 column (0.2 x 25 cm) and eluted with a 1 %/min linear gradient of aqueous 0.1 %TFA/CH₃CN (5-45 %) at a flow rate of 1 ml/min. The collected peptides were characterized by mass spectrometry and amino acid composition, which was also used to quantitate the amount of various substrates and products. The digestions of the quenched fluorogenic peptides were analyzed by RP-HPLC using a dual UV (210 nm) and fluorescence (excitation and emission wavelengths of 320 and 420 nm, respectively) detector (Rainin).

pH Optimum, Calcium-Dependence and Inhibitor Profile - The protocols used were essentially the same as reported previously (13). Stocks of the buffer described above were adjusted to pH 5.0-8.5 at 0.5 unit increments by addition of either acetic acid or sodium hydroxide. In order to investigate the calcium requirement of SKI-1,

increasing concentrations of Ca^{2+} -acetate were used ranging from 0 to 10 mM. For inhibition studies, the enzyme in the reaction buffer was preincubated with the desired agents for 30 min prior to addition of peptide II.

$K_{m(\text{app})}$, $V_{\text{max}(\text{app})}$ and $K_{i(\text{app})}$ determinations - Following digestion reactions with increasing substrate concentrations, the products were separated by RP-HPLC. The rate of substrate hydrolysis was obtained from the integrated peak areas of the chromatograms. $K_{m(\text{app})}$ and $V_{\text{max}(\text{app})}$ values were estimated using nonlinear regression analysis (Enzfitter software; Elsevier Biosoft, Cambridge, UK) of plots of the hydrolysis rate vs the substrate concentration. For apparent inhibitor constant [$K_{i(\text{app})}$] determinations, variable inhibitor concentrations within the range of 15-70 % inhibition were used at three concentrations of peptide IV ranging from 0.6 to 3.5 times the $K_{m(\text{app})}$ value. The $K_{i(\text{app})}$ values were estimated from Dixon plots as described (16). For the two quenched peptides, kinetic parameters were determined as described (17).

RESULTS

SKI-1 Overexpression, Purification, Biosynthesis, and Prosegment Processing

We have previously shown that overexpression of full-length SKI-1 (FL-SKI-1) in HK293 cells results in shedding of a 98 kDa form (sSKI-1) of this enzyme into the medium (10). Based on this finding, we engineered a soluble form of SKI-1 (BTMD-SKI-1), ending at residue 997, to which we added a hexa-His sequence at the C-terminus (Fig. 19A). In a comparative biosynthetic analysis, shown in Fig. 19B, LoVo cells were infected with the SKI-1 virus constructs VV:FL-SKI-1, VV:BTMD-SKI-1, and wild type virus (VV:WT). After labeling the cells for 3h with [^{35}S]Cys, proteins in the media were immunoprecipitated with an antiserum directed against either the prosegment of SKI-1 (Ab:P) or an internal SKI-1 sequence (Ab:S). In both cases, a protein of ~14 kDa co-immunoprecipitated with the 98 kDa sSKI-1 or the 100 kDa BTMD-SKI-1 (bSKI-1, Fig. 19B) that was not seen with VV:WT infections. Since Ab:P was raised against a recombinant SKI-1 prosegment peptide and has been shown previously to detect the SKI-1 zymogen (10), we concluded that the ~14 kDa peptide is most likely derived from the cleaved prosegment (the full-length prosegment is ~24 kDa – see below). The fact that it co-immunoprecipitated with the enzyme under denaturing conditions suggests a strong interaction between SKI-1 and this region of its prosegment. The actual stoichiometry of enzyme-to-prosegment is not clear from this experiment, since it was carried out using two different antisera and denaturing conditions. We also observed that some of the 100 kDa BTMD-SKI-1 is cleaved into

a 98 kDa form similar to that found with FL-SKI-1 (Fig. 19B). This conversion is presumably carried out by endogenous "shedding enzymes" (10,18) that can act on both forms of SKI-1, although C-terminal sequencing would be needed to confirm this hypothesis.

5 Western blot analyses of media now obtained from BSC40 cells infected with VV:BTMD-SKI-1 also revealed a secreted ~100 kDa immunoreactive band (Fig. 19C). The same band was detected using either an antiserum against the N-terminal region of the SKI-1 catalytic domain (Ab:N) or one against a more C-terminal region (Ab:S). When Ab:P was mixed together with Ab:S and used to probe the metal affinity column-
10 purified SKI-1 preparation (indicated by the * in Fig. 19C), we were able to again detect the ~14 kDa prosegment fragment, further supporting our hypothesis that it forms a strong association with the enzyme. (It should be noted that although a mixture of Ab:S and Ab:P was used in order to detect both proSKI-1 and BTMD-SKI-1 simultaneously, when either Ab:N or Ab:S were used alone, only the 100 kDa or 14 kDa species were
15 observed, respectively (*not shown*)).

In order to evaluate the rate of zymogen processing and the fate of the prosegment, LoVo cells overexpressing VV:FL-SKI-1 were pulse-labeled with [³H]Leu for 15 min and then chased for 2h. Figure 20 shows an SDS-PAGE analysis of the cell
20 lysates immunoprecipitated with Ab:P (left panel). At least five immunoreactive polypeptides (molecular masses of ~26, 24, 14, 10 and 8 kDa) which were not present in controls infected with VV:WT, were detected. In order to further define in which organelle(s) this processing occurred, LoVo cells infected with VV:FL-SKI-1- were pulse-labeled with [³H]Leu for 2h in the presence or absence of BFA (Fig. 20, right
25 panel). In both cases, the same five major, intracellular, immunoreactive prosegment forms could still be detected. Since the fungal metabolite BFA is known to disassemble the Golgi complex and cause the ER to fuse with the *cis*, *medial* and *trans* Golgi (but not the *trans* Golgi network, TGN) (19), this result strongly implies that the initial zymogen processing of proSKI-1 occurs early along the secretory pathway. Possible
30 locations include the ER or *cis* Golgi, as was previously reported (10). Moreover, further processing of the prosegment into yet smaller fragments also occurs in these organelles.

To further characterize the prosegment of SKI-1, we took advantage of a stable transfectant of FL-SKI-1 in human HK293 cells that we had made previously (10). This system has the added advantage that the possibility of VV overexpression artifacts

influencing the processing of the prosegment is eliminated. Concentrated culture medium from these cells (serum-free) was purified via RP-HPLC using first a semi-preparative C4 column (*not shown*) followed by an analytical C4 column (Fig. 21A). The eluted fractions were analyzed by Western blot using Ab:P (Fig. 21B).

5 Immunoreactive peptides ranging from ~4.5-24 kDa were apparent. N-terminal sequencing of the very abundant ~14 kDa protein in fraction IV (Fig. 21C) revealed a major sequence starting at Gly¹⁸ of pre-proSKI-1 (10,12). This clearly defines the signal peptidase cleavage site as LVVLLC¹⁷↓GKKHLG, which is one aa before that predicted by signal peptidase cleavage site algorithms (10,11). The N-terminal sequence of the
10 ~4.5 kDa polypeptide (Fig. 21D) revealed that it starts at Pro¹⁴³, indicating a cleavage at the sequence KYAESD¹⁴²↓PTVPCNETRWSQK. This fragment is most likely the product of cleavage between Asp and Pro that may be caused by the acidic conditions encountered in either RP-HPLC, Edman sequencing (20), or sample preparation for SDS-PAGE analysis (21). An unexpected benefit of this cleavage was our finding that
15 phenylthiohydantoin (PTH)-Asn¹⁴⁸, which occurs in the putative N-glycosylation site AsnGluThr was readily detected in this sequence. Thus, the predicted N-glycosylation site Asn¹⁴⁸ within the prosegment of SKI-1 is not employed, at least in this expression system. This conclusion was also supported by the prosegment's resistance to endo H and endo F digestion (*not shown*). Of the two eukaryotic subtilases known to contain
20 a potential N-glycosylation AsnGluThr site, *i.e.* kexin (22) and SKI-1 (10), it appears that at least the latter's prosegment is not N-glycosylated. Finally, the separation of the above prosegment fragments from mature SKI-1 using RP-HPLC (Fig. 21A,B) and non-reducing SDS-PAGE (*not shown*), suggests that none of the Cys residues in the prosegment (10) are linked by disulfide bridges to the rest of the enzyme.

25 As a preliminary means of characterizing the SKI-1 prosegment fragments, MALDI-TOF analysis (Fig. 21E) of fraction IV from Fig. 21B was carried out. Three major molecular ions of masses 13,351, 13,518, and 13,685 Da were detected, with an expected error of ± 25 Da for this mass range. Combined with the previous N-terminal sequencing results of the ~14 kDa peptide (Fig. 21C), these mass values indicate that
30 this peptide has heterogeneous C-termini that are derived from cleavages near the sequence RKVERSLK¹³⁷, as indicated in Fig. 21E. In fact this region contains three potential SKI-1 cleavage sites (8) with an R or K at the P4 position and either an F, R or K at the P1 position. Although the calculated molecular masses of 13,339, 13,496 and 13,696 for the polypeptides G¹⁷KK---RKVF¹³³, G¹⁷KK---RKVFR¹³⁴ and G¹⁷KK---

RKVFRSL¹³⁶, respectively, match within experimental error (± 22 Da) the observed masses in Fig. 21E, these assignments should only be taken as a first indication (see below). Moreover, the predicted G¹⁷KK---RKVFRSL¹³⁶ fragment does not correspond to the expected SKI-1 cleavage motif of a basic residue at the P4 position. Hence, this secreted peptide could result either from cleavage at G¹⁷KK---RKVFRSL¹³⁶ or, more likely, at G¹⁷KK---RKVFRSLK¹³⁷ Lys¹³⁷ followed by basic carboxypeptidase cleavage of the C-terminal Lys (23). Since we were unable to obtain consistent mass spectra of the ~4.5 kDa polypeptide that was sequenced in Fig. 21D, we could not use this technique to approximate its C-terminus, which presumably corresponds to the C-terminus of the processed SKI-1 pro-segment. We therefore resorted to synthetic peptide cleavage as a tool to accurately define potential prosegment cleavage sites.

Analysis of Synthetic Prosegment-derived Peptide Cleavages - Based on our detection of ~26 and 24 kDa SKI-1 prosegment products (Fig. 20), as well as on a mutagenesis study of SREBP-2 cleavage sites (8), we synthesized three SKI-1 prosegment peptides encompassing potential, C-terminal, autocatalytic cleavage sites (10,11). All contain Arg at P4 and either Leu, Lys, Ala or Phe at P1 (peptides III, VI and VII shown in Table II-A). Of these peptides containing only native sequences, the only one with detectable cleavage by SKI-1-containing concentrated medium (from either VV:BTMD-SKI-1-infected BSC40 cells or SKI-1 transfected HK293 cells) was peptide III (WHATGRHSSRRLL¹⁸⁶↓RAIPR) (see Table II-A). No cleavages were observed when VV:WT-infected or empty vector-transfected media were used (*not shown*). Metal chelation chromatography-purified enzyme further supported that this cleavage is effected by SKI-1 (Fig. 22A; peptide III), and the products were positively identified via mass spectrometry.

Similarly, based on the mass spectrometry data in Fig. 21E, we synthesized two peptides (VIII and IX) encompassing the putative internal processing site(s) of the SKI-1 prosegment. Both were cleaved at multiple locations by SKI-1-containing concentrated medium from HK293 transfectants (*not shown*). Further analysis revealed that one of these cleavages, corresponding to PQRKVF¹³³↓RSL, was as prevalent in empty vector-transfected HK293 medium as in SKI-1-transfected medium (see Table III-A, peptide VIII). In contrast, the PQRKVFRSLK¹³⁷↓YAESD cleavage was only seen in SKI-1-containing medium. This cleavage was also confirmed using metal chelation chromatography-purified enzyme (Fig. 22B; peptide IX) and mass spectrometry to identify the products. However, also clearly visible are the PQRKVF¹³³↓RSLKYAESD

cleavage products. We acknowledge that there could be residual contaminating proteases in our purified SKI-1 preparations (minor bands were visible on colloidal gold-stained membranes of SKI-1 preparations). Thus, while we are confident that SKI-1 cleaves its prosegment at the C-terminal WHATGRHSSRRLL¹⁸⁶↓RAIPR site and at the internal PQRKVFRSSLK¹³⁷↓YAESD site, our data do not allow us to rule out SKI-1-mediated cleavage at the PQRKVF¹³³↓RSSLKYAESD site.

Comparing the simple cleavage rates of the SKI-1 prosegment internal and C-terminal sites, we observed that the former was vastly superior to the latter (*not shown*). We also noticed that the peptides best processed by SKI-1 contain an acidic residue at the P3' or P4' substrate site, whereas those that did not appeared to be cleaved poorly or not at all (Table III-A). Moreover, we had previously established that SKI-1 does not cleave the fluorogenic peptides RGLT-MCA, RGLTT-MCA and RSVL-MCA (10), which lack P' residues. Based on these observations, we asked if replacing the Ile and Pro residues at P3' and P4' of the C-terminal prosegment processing site would significantly improve the SKI-1-mediated cleavage of peptide III. Thus, we synthesized two mutants of this peptide (peptides IV and V, the latter truncated by 8 aa at the N-terminus) in which the Ile and Pro residues at P3' and P4' were replaced by Leu and Glu, respectively. As shown in Table II-B, this change significantly improved the processing of these peptides, such that we were able to determine $V_{\max(\text{app})} / K_{m(\text{app})}$ values. The approximately two-fold difference in these values for peptides IV and V further suggests that determinants N-terminal to the P4 position may also play a role in substrate specificity. The SKI-1 specificity of these peptide cleavages was also verified using metal chelation chromatography-purified enzyme (when VV:WT-infected or empty vector-transfected media were used, no peptide processing was observed).

In Vitro Kinetic Properties of SKI-1: Comparative Analysis of Synthetic Peptide Cleavages - In a previous report (10), sSKI-1 was shown, to cleave the 32 kDa proBDNF into a 28 kDa form at the RGLT↓SL sequence *in vitro* with a pH optimum close to neutrality. Similar to PCs (1-3), we suggested that SKI-1 might be a Ca²⁺-dependent enzyme since the calcium ionophore A23187 inhibited the *ex vivo* cleavage of proBDNF (10). In order obtain kinetic analyses of defined SKI-1 substrates, we examined a 14 aa peptide spanning the hproBDNF processing site (10), K⁵⁰AGSRGLT↓SLADTF⁶³ (peptide I) and a 27 aa hSREBP-2-related peptide (8), G⁵⁰⁴GAHDSQHPHSGSGRSVL↓SFESGSGG⁵³⁰ (peptide II). Concentrated SKI-1-

containing medium (from either VV:BTMD-SKI-1-infected BSC40 cells or SKI-1 transfected HK293 cells) was reacted with these peptides at pH 6.5, followed by MALDI-TOF mass spectrometric analysis of the RP-HPLC-purified products. The expected cleavages were confirmed and did not occur using WT-/empty vector-derived media (Fig. 23). Again, the metal chelation chromatography-purified enzyme generated the same products as the concentrated media (not shown). We then demonstrated that the optimal pH and calcium concentrations for efficient cleavage of the hSREBP-2 peptide (II) are pH 6.5 and 2 mM Ca^{2+} , respectively (Fig. 24). Interestingly, the pH optimum observed with the the proBDNF peptide (I) is sharper than that obtained with peptide II. In the former case, the enzyme still retains about 30% of its activity at pH 5.0 and 55 % of its activity at pH 8.5 (Fig. 24A). Similar results for the pH optimum of peptide II cleavage were obtained with metal chelation-purified BTMD-SKI-1 (*not shown*). In contrast, however, the pH optimum of peptide IX with the purified enzyme was 8.0, with no activity detectable below pH 5.5.

A summary of the kinetic analyses of the synthetic proBDNF (peptide I) and SREBP-2 (peptide II) cleavages by SKI-1 is shown in Table II-B. Both peptides are cleaved at comparable kinetic efficiencies with $V_{\text{max(app)}} / K_{\text{m(app)}}$ values of 0.002 and 0.004 h^{-1} , respectively. In comparison, the $V_{\text{max(app)}} / K_{\text{m(app)}}$ value estimated with peptide IV is 5-10-fold higher than those obtained with peptides I and II (Table II-B). The N-terminal truncation of peptide IV from 17 to 9 aa (peptide V, Table II-A) caused a 4-fold reduction in catalytic efficiency (Table II-B).

Table III shows the inhibitor profile of SKI-1, in which it is clear that this enzyme is quite sensitive to metal chelators such as EDTA and to the calcium chelator EGTA. In addition, the transition metals Cu^{2+} and Zn^{2+} , but not Ni^{2+} or Co^{2+} , inhibit the enzyme at mM concentrations. As reported using the 32 kDa proBDNF (10), assays with the synthetic SREBP-2 peptide demonstrated that the metal chelator o-phenanthroline becomes inhibitory at concentrations above 1 mM. The other non-chelator inhibitors tested had minimal or no effects on SKI-1 activity.

In order to develop a convenient *in vitro* assay for SKI-1, we designed a number of internally quenched fluorogenic substrates and tested their cleavage efficacy by SKI-1. The two best peptides encompassed the processing site RSLK↓ within the hSKI-1 prosegment (peptides X and XI, Table II-A). Mass spectrometric analysis confirmed that both peptides were cleaved at the RSLK↓ site by shed SKI-1 derived from HK293 cell transfects, but not by medium obtained from HK293 empty vector transfectants.

This processing generated the fluorescent N-terminal peptides Abz-VFRSLK or Abz-RSLK, and a non-fluorescent C-terminal peptide YAESDY(NO₂)-A (*not shown*). Measurements of kinetic parameters demonstrated that peptides X and XI are about 3- and 16-fold better substrates than the C-terminal prosegment peptide IV (Tables I-B and III), suggesting that the shorter peptide XI may be the best SKI-1 substrate tested to date. This cleavage was completely abolished in the presence of 10 mM EDTA, in agreement with the Ca²⁺-dependence of SKI-1 activity (Fig. 24B).

SKI-1 Inhibition by its Prosegment - One important question remaining is whether the SKI-1 prosegment functions as an inhibitor of its enzymatic activity, analogous to the prosegments of other subtilases (3). We thus prepared prosegment constructs, designated ending near the proposed C-terminal processing site RRLL¹⁸⁶ (Fig. 22A): PS1; extending to Leu¹⁶⁹; PS2, extending to Ala¹⁸⁸; and PS3, extending to Leu¹⁹⁷. To each C-terminus we coupled a hexa-His tag. These prosegment constructs were expressed in bacteria and purified by Ni²⁺-chelation chromatography followed by RP-HPLC (*see Experimental Procedures*). The purity of these prosegments was confirmed by SDS-PAGE/Coomassie staining and aa analysis (*not shown*). A summary of the inhibitory potency of each prosegment using peptide IV as a substrate is shown in Table V. Kinetic analysis using Dixon plots (15) indicated a competitive inhibition mechanism (*not shown*). Although PS2 exhibits the best apparent inhibitory constant ($K_{i(app)} = 97$ nM), PS3 ($K_{i(app)} = 127$ nM) and PS1 ($K_{i(app)} = 182$ nM) are similarly potent SKI-1 inhibitors. When PS2 was digested with carboxypeptidase B to eliminate the His-tag, its inhibitory potency was not affected (*not shown*), confirming that this tag is not responsible for the observed inhibition. We also tested the inhibitory activity of the RP-HPLC-fractionated native prosegment (*see Fig. 21*). Only, the material from fraction IV, which included the full-length ~24 kDa prosegment, was inhibitory, whereas that of the others, including the ~14 kDa peptide alone or in combination with smaller fragments, were not inhibitory (*not shown*).

DISCUSSION

Limited proteolysis of inactive precursor proteins at sites marked by paired or multiple basic residues is a widespread process (1,2). Less common is the recent finding that bioactive peptides or proteins can also be generated by limited proteolysis after either hydrophobic or small residues (3). SKI-1 represents the first mammalian member of subtilisin-like processing enzymes with such substrate specificity (10,11). It is a widely expressed enzyme (10) that may play a crucial role in cholesterol and

fatty acid metabolism (11). Due to its very recent discovery, information regarding its enzymatic properties, substrate specificity, and the function of its proregion have only begun to be addressed.

Many peptidyl hydrolases, including subtilases, possess a prodomain which acts both as an intramolecular chaperone and a highly potent inhibitor of its associated protease (24,25). Activation of the enzyme typically requires release of the prosegment in an organelle-specific manner. For furin (26) the release occurs in the TGN, whereas for PC1 and PC2 (27) it occurs in immature secretory granules. The data presented in this report demonstrate that SKI-1 is unique among the mammalian subtilases, since both the C-terminal and internal cleavages of its prosegment occur in the ER. Hence, this enzyme does not appear to require an acidic environment for activation, assuming, by analogy with other subtilases (3), that prosegment release is the crucial step leading to zymogen activation. We propose the following sequence of events presumably leading to SKI-1 activation: 1) The signal peptide is removed in the ER by a signal peptidase cleavage at LVVLLC¹⁷↓GKKHLG (Fig. 21C). 2) The prosegment is processed into a non-N-glycosylated polypeptide with an apparent molecular mass of ~24-26 kDa (Fig. 20). 3) This prosegment is further processed into 14, 10 and 8 kDa intermediates (Fig. 20). While these multiple cleavages may be catalyzed by SKI-1 itself, the participation of other proteases cannot be excluded. The major cleavages leading to the formation of the ~24 and ~14 kDa products occur within 10 min, and the other secondary ones within 30 min (*not shown*). Since treatment of cells with BFA did not significantly alter these processing events, they most likely occur in the ER (Fig. 20). It is possible that the generation of prosegment fragments from the ~24-26 kDa pro-form leads to a loss of inhibition in a fashion similar to that of subtilisin E (24,25). Indeed, our results demonstrate that while the full-length prosegment is inhibitory, its ~14 kDa product is not. Surprisingly, some pro-region-derived polypeptides are found associated with SKI-1 in cell culture media. Thus, in contrast to furin (26), the low pH and high Ca²⁺ concentrations prevailing in the TGN do not lead to propeptide dissociation. High ionic concentrations (up to 1M NaCl) such as those used in immunoprecipitation (Fig. 19B) and metal chelation protein purification (Fig. 19C) also do not disrupt the complex. It is only during RP-HPLC purification (Fig. 21A), in the presence of strong acids and organic solvents, that the prosegment peptides dissociate from SKI-1. These data suggest that hydrophobic interactions may be critical, as is the case for subtilisin (24,25).

To distinguish the SKI-1 prosegment autoprocessing sites (C-terminal and internal) from several closely situated candidate sites, we employed a combination of mass spectrometry and synthetic peptide digestion. In the case of the C-terminal site, only one of three candidate peptides (III) was processed by SKI-1 (Table II-A), indicating that RRL¹⁸⁶↓RAIP is the most likely autoprocessing site. For the internal site, preliminary mass spectrometric data suggested three distinct cleavages occurring within the sequence PQRKVFRSLKYAESD¹⁴² (Fig. 21E). Two of the three possible sites (PQRKVF¹³³↓RSLKYAESD and PQRKVFR¹³⁴↓SLKYAESD) appeared to satisfy the proposed SKI-1 recognition motif requiring a P4 basic residue (8). The third possibility (PQRKVERSL¹³⁶↓KYAESD) could be considered by assuming the cleavage actually occurred at PQRKVFRSLK¹³⁷↓YAESD, followed by endogenous, basic carboxypeptidase removal of the C-terminal Lys residue (23). Assays carried out *in vitro* with synthetic peptides corresponding to this region of the prosegment (peptides VIII and IX) produced the same cleavage products (*not shown*), but only the PQRKVFRSLK¹³⁷↓YAESD cleavage was unique to SKI-1. Thus, we propose that the aforementioned site is the most likely internal autoprocessing site, with the qualification that PQRKVF¹³³↓RSLKYAESD may occur to a lesser extent (see Results and Fig. 22).

Other information regarding the substrate preferences of SKI-1 was obtained by replacing the P3' and P4' Ile and Pro residues of the C-terminal cleavage site peptide (III) by Leu and Glu (peptides IV and V) to create a very well processed SKI-1 substrate. While it would appear that the presence of an acidic residue at P4' significantly enhances the rate of substrate hydrolysis, it is also possible that the presence of Pro at P4' hinders efficient substrate processing. The presence of similar acidic residues at the P3' or P4' position of the two confirmed substrates of SKI-1 (peptides I and II) as well as in the prosegment internal cleavage site RSLK¹³⁷↓YAES (Table II-A) lends support to the first argument. In addition to these residues, others also appear to play a role in SKI-1 substrate cleavage catalysis. The peptide pairs IV/V and X/XI both point to influences of positions N-terminal to the P4 residue. Interestingly, the efficiency of the truncated C-terminal peptide V is lower than that of peptide IV, whereas that of the truncated internal (quenched) peptide XI is higher. Taken together, these data indicate the importance of aa at both the P and P' positions in SKI-1-mediated substrate hydrolysis.

The data presented in Fig. 24 indicate that SKI-1 functions most efficiently near neutral pH and at 2-3 mM Ca²⁺. This is in general agreement with the conditions that

reportedly prevail in the ER (28,29). However, closer examination of the data reveal that the pH optimum of SREBP-2 cleavage (peptide II, Fig. 24A) is actually 6.5, an observation that we confirmed using our purified SKI-1 preparation (*not shown*). This suggests that the processing of SREBP might occur outside of the ER, perhaps in the Golgi where pH values of ~6.5 have recently been reported (30,31). Indeed, there is now cellular evidence suggesting that SREBP cleavage may occur in the Golgi rather than in the ER (32,33). The pH optimum of SKI-1 appears to be dependent on the substrate employed; proBDNF (10) and its related peptide (I), appear to be well cleaved even at pH 5.5, suggesting that it could cleave this (and possibly other substrates) in acidic endosome-like compartments where it was previously localized (10). On the other hand, cleavage of the internal, autocatalytic, prosegment processing site PQRKVFRSLK¹³⁷↓YAESD (Fig. 22B) is optimal at pH 8 (*not shown*), implying that this event, as we concluded from our biosynthesis assays, takes place most effectively in the ER. Overall, the pH and Ca²⁺ profiles of SKI-1 resemble those of the constitutively secreted PCs (1,13). The inhibitor profile of SKI-1 (10, Table III), showing that enzymatic activity is significantly inhibited by EDTA, EGTA and only high concentrations of o-phenanthroline, tend to discount the likelihood that SKI-1 is a transition metal-dependent proteinase. In fact, SKI-1 activity is inhibited by low concentrations of certain transition metals, such as Cu²⁺ and Zn²⁺.

Directed by the observation that peptides containing the primary processing site of the prosegment of PC1 are potent inhibitors of its activity, and that the C-terminal basic residues of furin and PC7 are essential for enzyme inhibition (34,35), we assessed the inhibitory potency of three SKI-1 recombinant propeptides. All of these end at sequences near the RRLL¹⁸⁶RA cleavage site. Interestingly, the three prosegments displayed comparable inhibitory potencies (Table V). Compared to proPC1 (34), pro-furin and proPC7 (35), the K_{i(app)} values (Table V) are up to 250 fold higher. This suggests that the prosegment of SKI-1, although potentially inhibitory *in vivo*, may function more as a chaperone, catalyzing the productive folding of SKI-1. Indeed, since SKI-1 may be active in the ER (10,11), whereas the PCs are not (13,26), the lower inhibitory potency of the prosegment of SKI-1 may be adapted to the conditions prevailing in this cellular compartment. In the case of PCs, highly effective inhibition by the prosegment may be needed in order to ensure that these enzymes are activated only when they reach the TGN or secretory granules (1-3). The 14 kDa fragment, which represents the major secreted form of the prosegment, is tightly

associated with SKI-1 (Fig. 19C) yet it is not inhibitory (*not shown*). Accordingly, this segment may serve a chaperonin-like function similar to that reported for the N-terminal 150 aa of 7B2 towards proPC2 (36,37).

Two articles describing the processing, purification and *in vitro* activity of hamster SKI-1/S1P were published (38,39). On most points, our results are in close agreement with those recently published. Thus, these authors characterized the processing of the SKI-1/S1P prosegment, proposing that the ER is the major site of autocatalytic activation of SKI-1 at the same cleavage sites as we present here. They also went on to purify a soluble form of the enzyme, showing that it correctly processes SREBP-2 derived peptides as well as a 16 residue peptide spanning the internal prosegment cleavage site. In addition, they find that cleavage of fluorogenic RSLK-MCA peptide derived from the same sequence is optimal at ~3 mM Ca^{2+} at slightly alkaline pH. Discrepancies such as the lack of detectable shed SKI-1/S1P, multiple secreted prosegment forms, and a different signal peptidase site can most likely be attributed to the different cell types and species employed in the two studies.

In conclusion, the present work firmly establishes that SKI-1 is a Ca^{2+} -dependent subtilase with a reasonably neutral pH optimum, depending on the substrate employed. We also demonstrate that SKI-1 can cleave substrates C-terminal to Thr, Leu and Lys residues, thus providing direct, *in vitro* evidence that it is a candidate converting enzyme responsible for the generation of 28 kDa proBDNF (10) and SREBP-2 processing at site 1 (11). For efficient cleavage, it appears that substrates should contain a basic residue at P4 and an aliphatic one at P2 (Table II-A). Furthermore, aa at the P3' and P4' positions seem to exert an important discriminatory effect. The best substrate tested so far is the quenched fluorogenic substrate Abz-RSLK_YAESDY(NO_2), thereby providing a convenient and sensitive assay for SKI-1 activity. The present data demonstrate that only the full length SKI-1 prosegment is inhibitory. Thus, overexpression of this prosegment in cell lines may provide a novel method for inhibiting the cellular activity of this enzyme in a fashion similar to the that of over-expressed profurin and proPC7 (35). Finally, it is anticipated that precursor substrates other than the sterol regulating SREBPs (8) and the neurotrophin proBDNF (10) will be identified, thereby extending the spectrum of activity of this unique and versatile enzyme.

Table II-A

Synthetic peptide substrates

Peptides were first reacted with approximately equal quantities of BTMD-SKI-1 medium for 2-18 h as described in "Experimental Procedures". When cleavage was not detected, a 10-fold concentrated enzyme preparation was tested. Arrow thickness is a qualitative estimate of the cleavage efficacy.

| | Peptide | P16 | P12 | P8 | P4 | P1 | P4' | P8' |
|----|-------------------|-------------|---------------------------|---------------------|-----------|----------------------------------|-----|-----|
| 10 | I | | | K A G S R G L T | | S L A D T F | | |
| | II | G G A H D S | D Q H P H S G S G R S V L | | | S F E S G S G G | | |
| | III | | W H A T G R H S S R R L L | | | R A I P R | | |
| | IV | | W H A T G R H S S R R L L | | | R A L E | | |
| | V | | | | S R R L L | R A L E | | |
| 15 | VI ¹ | | W Q S S R P L R R A S L | | | S L G S G | | |
| | VII ¹ | | | R A I P R Q V A | | Q T L Q A D V | | |
| | VIII ² | | | P Q R K V F | | R S L | | |
| | IX ^{2,3} | | | P Q R K V F R S L K | | Y A E S D | | |
| | X | | | Abz-V F R S L K | | Y A E S D Y(NO ₂) -A | | |
| 20 | XI | | | Abz-R S L K | | Y A E S D Y(NO ₂) -A | | |

¹ No cleavage detected even with a 10-fold excess of enzyme.

² Cleavage detected but not attributable to SKI-1.

³ Kinetic determinations of this peptide were not attempted due to the presence of multiple cleavages.

Table II-B

Kinetic constants for the hydrolysis of peptide substrates by BTMD-hSKI-1

Increasing concentrations of peptides were reacted with identical quantities of BTMD-SKI-1 medium for times chosen to produce 5-30 % substrate hydrolysis. Data analysis was carried out as described in "Experimental Procedures". The values are averages of duplicate assays.

| Peptide | $K_{m(app)}$ (nM*1000) | $V_{max(app)}$ (nmol/h) | $V_{max(app)} / K_{m(app)}$ (h ⁻¹ L ⁻¹) |
|---------|---------------------------|----------------------------|---|
| I | 169 | 0.4 | 0.002 |
| II | 124 | 0.5 | 0.004 |
| IV | 17 | 0.4 | 0.023 |
| V | 109 | 1.1 | 0.010 |

Table III

Effect of selected protease inhibitors on BTMD-hSKI-1 activity

Digestion reactions using BTMD-SKI-1 medium plus peptide II were carried out as described in "Experimental Procedures". The agents were preincubated with the enzyme for 30 min.

| | Inhibitor | Concentration (mM) | Hydrolysis of SREBP-2 peptide (% of control) ¹ |
|----|-------------------|-----------------------|---|
| 10 | Control | - | 100 |
| | APMSF | 1.0 | 95 |
| | PMSF | 1.0 | 85 |
| | TPCK | 1.0 | 71 |
| | TLCK | 1.0 | 100 |
| 15 | SBTI | 0.5 ² | 100 |
| | Cystatin | 0.01 | 100 |
| | Antipain | 1.0 | 100 |
| | Chymostatin | 1.0 | 100 |
| | Leupeptin | 1.0 | 100 |
| 20 | Pepstatin | 0.1 | 97 |
| | E-64 | 0.01 | 100 |
| | O-Phenanthroline | 0.05 | 135 |
| | | 1.0 | 90 |
| | | 5.0 | 0 |
| 25 | EDTA | 10.0 | 0 |
| | EGTA | 10.0 | 15 |
| | Dithiothreitol | 10.0 | 92 |
| | CuSO ₄ | 1.0 | 0 |
| | ZnSO ₄ | 1.0 | 0 |
| 30 | NiSO ₄ | 1.0 | 93 |
| | MgCl ₂ | 1.0 | 100 |
| | CoCl ₂ | 1.0 | 100 |

¹ Values represent averages of duplicate assays (variation is ± 5 %).

² Concentration in mg/ml.

Table IV

Kinetic constants for the hydrolysis of quenched fluorogenic substrates by shed-hSKI-1

Assays and data analysis were carried out as described in Table II-A. The values are averages of duplicate assays.

| | Peptide | $K_{m(app)}$ (μ M) | $V_{max(app)}$ (μ moles/h) | $V_{max(app)} / K_{m(app)}$ ($h^{-1} L^{-1}$) |
|---|---------|----------------------------|------------------------------------|--|
| 5 | X | 31.3 | 34.0 | 1.1 |
| | XI | 8.7 | 56.9 | 6.5 |

Table V

Effect of pro-segment peptide constructs on BTMD-hSKI-1 activity

10 Digestion reactions using BTMD-SKI-1 medium plus peptide IV were carried out as described in "Experimental Procedures". The prosegment peptides were preincubated with the enzyme for 30 min. Values were deduced from the Dixon plots obtained from three separate experiments.

| | Pro-segment construct | $K_{i(app)}$ (nM) |
|----|-----------------------|----------------------|
| 15 | PS1 | 182.0 \pm 0.5 |
| | PS2 | 97.5 \pm 4.5 |
| | PS3 | 127.3 \pm 6.2 |

EXAMPLE 4**SIMILARITY OF ANATOMICAL DISTRIBUTION OF SKI-1 mRNA TO THAT OF APP**

25 β -amyloid precursor protein (β -APP) is a member of a highly conserved gene family, which includes amyloid precursor-like protein-1 and amyloid precursor-like protein-2 { McNamara, M.J. et al. (1998) Brain Research 804, 45-51; Rassoulzadegan, M. et al. (1998) The EMBO Journal 17, 4647-4656 }. Mammalian subtilases, exemplified by SKI-1, may be responsible for limited cleavage at hydrophobic residues present in biologically important precursor proteins such as β -amyloid precursor protein (β -APP) (TableVI). SKI-1 has recently been identified as the enzyme which

30 cleaves sterol-regulatory element-binding protein (SREBP) in a fashion analogous to the β -secretase cleavage of APP { Sakai, J. et al. (1998) Molecular Cell 2, 505-514 }. The cleavage of SREBP by SKI-1 (Site 1 protease) at a position 20 residues to the luminal side of the first membrane-spanning segment is analogous to the β -secretase

35 cleavage of β -APP at a position 28 amino acids from the membrane { Brown, M.S. and Goldstein, J.L. (1997) Cell 89, 331-340 }.

Similarity of anatomical distribution of SKI-1 mRNA to that of APP suggests a functional link between both proteins.

In situ hybridization performed in 4-day-mouse provides evidence of a similar distribution of mRNA coding for the membrane proteins SKI-1 and APP (Fig. 25).

5 Their spatial distribution was observed to be significantly overlapping within different tissues such as brain and spinal cord, cranial and spinal ganglia, submaxillary gland, thymus, kidney, bones, skin and many other. Their mRNA distribution was partially similar to that of two other proteases, namely the convertase furin and the peptidase neprilysin. A much different distribution was observed with convertases PC1, PC2 and
10 PC5. It is clearly established that an increase in cellular cholesterol levels results in the inhibition of activity of SKI-1 / S1P { reviewed in Edwards, P.A., and Ericsson, J. (1999) Annu. Rev. Biochem. 68, 157-185 }. In a similar fashion, an increase in dietary cholesterol leads to significant reductions in brain levels of secreted APP derivatives, including sAPP α , sAPP β , A β 1-40 and A β 1-42 { Howland, D.S. et al. (1998) J. Biol.
15 Chem. 273, 16576-16582 }. The nature of the relationships between cholesterol, SKI-1 and APP metabolism are complex.

Cellular association between SKI-1 and APP in lacrimal gland. Potential use of shed SKI-1 in tears as diagnostic tool.

20 Results of immunocytochemistry performed in mouse lacrimal glands provides evidence for the presence of SKI-1 and APP in the same cells types, including intralobular duct epithelial cells and some acinar cells (Fig. 26). The finding of SKI-1 in the lacrimal gland suggests the possibility of developing a diagnostic assay
25 analyzing tears; perhaps based on two -dimensional polyacrylamide gel electrophoresis for disease diagnosis { Molley, M.P. et al. (1997) Electrophoresis 18, 2811-2815; Glasson, M.J. et al. (1998) Electrophoresis 19, 852-855; Grus, F.H., and Augustin, A.J. (1999) Electrophoresis 20, 875-880; Iskeleli, G. et al. (1999) Electrophoresis 20, 875-880 }.

TABLE VI
PRECURSOR CLASSIFICATION BASED ON HYDROPHOBIC AND/OR SMALL AMINO ACID CLEAVAGE

| Precursor protein | Cleavage site sequence |
|--------------------------------|---|
| (h) proBDNF | Lys-Ala-Gly-Ser-Arg-Gly-Leu-Thr-Ser-Leu-Ala-Asp-Thr-Phe-Glu-His |
| (r) proBDNF | Lys-Ala-Gly-Ser-Arg-Gly-Leu-Thr-Thr-Ser-Leu-Ala-Asp-Thr-Phe |
| (h) proSKI-1 | Arg-His-Ser-Ser-Arg-Leu-Leu-Leu-Arg-Ala-Ile-Pro-Arg-Gln-Val-Ala |
| | Arg-Lys-Val-Phe-Arg-Ser-Leu-Lys-Tyr-Ala-Glu-Ser-Asp-Pro-Thr-Val |
| | Thr-Pro-Gln-Arg-Lys-Val-Phe-Arg-Ser-Leu-Lys-Tyr-Ala-Glu-Ser-Asp |
| | Val-Thr-Pro-Gln-Arg-Lys-Val-Phe-Arg-Ser-Leu-Lys-Lys-Tyr-Ala-Glu |
| (h) SREBP-2 | Ser-Gly-Ser-Gly-Arg-Ser-Val-Leu-Ser-Phe-Glu-Ser-Gly-Ser-Gly-Gly |
| (h) SREBP-1a | His-Ser-Pro-Gly-Arg-Asn-Val-Leu-Gly-Thr-Glu-Ser-Arg-Asp-Gly-Pro |
| (r) pro-Relaxin (B-chain) | Ala-Ser-Val-Gly-Arg-Leu-Ala-Leu-Ser-Gln-Glu-Glu-Pro-Ala-Pro-Leu |
| (h) pro-CCK (CCK5) | Arg-Ile-Ser-Asp-Arg-Tyr-Met-Gly-Trp-Met-Asp-Phe-Gly-Arg-Arg |
| (r) pro-Somatostatin (Antrin) | Asp-Pro-Arg-Leu-Arg-Gln-Phe-Leu-Gln-Lys-Ser-Leu-Ala-Ala-Thr |
| (b) Chromogranin A (82183) | Leu-Leu-Lys-Glu-Leu-Gln-Asp-Leu-Ala-Leu-Gln-Gly-Ala-Lys-Glu-Arg |
| (b) Chromogranin A (3091310) | Met-Ala-Arg-Ala-Pro-Gln-Val-Leu-Phe-Arg-Gly-Gly-Lys-Ser-Gly-Glu |
| (b) Chromogranin B (6291630) | Glu-Leu-Glu-Asn-Leu-Ala-Ala-Met-Asp-Leu-Glu-Leu-Gln-Lys-Ile-Ala |
| (b) Chromogranin B (6341635) | Ala-Ala-Met-Asp-Leu-Glu-Leu-Gln-Lys-Ile-Ala-Glu-Lys-Phe-Ser-Gly |
| (r) pro-Renin | Lys-Ser-Ser-Phe-Thr-Asn-Val-Thr-Ser-Pro-Val-Val-Leu-Thr-Asn-Tyr |
| (r) α-Endorphin | Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys |
| (r) γ-Endorphin | Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn |
| (r) pro-AVP (CPP) | Gly-Pro-Ala-Arg-Glu-Leu-Leu-Arg-Leu-Val-Gln-Leu-Ala-Gly-Thr |
| (h) ADAM-10 (kuzbanian) | Leu-Leu-Arg-Lys-Lys-Arg-Thr-Thr-Ser-Ala-Glu-Lys-Asn-Thr-Cys-Gln |
| (h) β-APP | |
| β-Secretase site | Glu-Glu-Ile-Ser-Glu-Val-Lys-Met-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser |
| β-Secretase site (Swedish) | Glu-Glu-Ile-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser |
| β ₁ -Secretase site | Ile-Ser-Glu-Val-Lys-Met-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr |
| β ₂ -Secretase site | Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val |

EXAMPLE 5

Prodomains in general (for example furin and PC7 prodomains) function *in trans* when expressed in mammalian cells to inhibit their cognate subtilisin-like convertase

5 We have recently shown that the prosegment of furin expressed as an independent domain (preprofurin, ppfurin) can specifically inhibit neurotrophin processing. In these assays, successful inhibition requires not only that the prodomain enter the secretory pathway, but that it remain there long enough to interact with the target PC (most likely furin within the TGN). Figures 27 & 28 depict vaccinia virus
10 constructs or transient transfections of prosegments preventing the maturation of the neurotrophins NGF and BDNF in Schwann or COS-1 cells, respectively. The modest inhibition with the prodomain of PC7 (ppPC7) is most likely due to inhibition of furin, since PC7 is a poor effector of proNGF and proBDNF maturation in these cells. The complementary experiment to demonstrate selectivity by the prosegment of PC7 will be carried out once we are able to establish unique *in vivo* PC7 substrates.

15 Most proteases from the four major classes (thiol, aspartic, serine, and metallo) are synthesized as inactive precursor molecules with N-terminal extensions (prosegments) that play critical roles in folding, stability and regulation of enzymatic activity { Khan, A.R., and James, M.N. (1998) Protein Sci. 7, 815-836 }. The proregions
20 of the PCs have been shown to function as potent inhibitors of their cognate enzymes *in vitro*. We present data for the first time showing that the expression of a prosegment as an independent domain in a cell-based (*ex vivo*) assay functions as a PC inhibitor (Figs. 27 and 28). In these assays, successful inhibition requires not only that the prodomain enter the secretory pathway, but that it remain there long enough to interact
25 with the target PC (most likely furin within the TGN).

We have shown that expression of full length SKI-1 prosegment (22-24 kDa with sequence ending at the secondary cleavage sequence RHSSRRLL) inhibits SKI-1 activity in stable HK 293 cell lines (Example 2). However, since the prodomain of SKI-1 is processed at an internal primary cleavage site RKVFRSLK to give a 14 kDa
30 N-terminal fragment (Fig. 29A&B) we predict that mutation of this site will generate an even more effective SKI-1 inhibitor. In fact, in the case of the mouse PC5 prodomain we have shown that mutation of the internal prosegment cleavage site does in fact generate a inhibitor of integrin α_4 150 kDa processing to 80kDa and 70kDa species (Fig. 15).

EXAMPLE 6**SKI-1 Peptide Substrates for fluorescence resonance energy transfer (FRET)
– Based Proteolysis Assays**

A large number of synthetic peptides based on potential cleavage sites in the
5 hSKI-1 prodomain, proBDNF and the loop region of SREBP-2 were synthesized.
These are:

(i) hSKI-1 (156-172)

Trp-Gln-Ser-Ser-Arg-Pro-Leu-Arg-Arg-Ala-Ser-Leu↓ Ser-Leu-Gly-Ser-Gly

(ii) hSKI-1 (174-191)

10 *Trp-His-Ala-Thr-Gly-Arg-His-Ser-Ser-Arg-Arg-Leu-Leu↓ Arg-Ala-Ile-Pro-Arg*

(iii) hSKI-1 (174-188+Leu+Glu)

Trp-His-Ala-Thr-Gly-Arg-His-Ser-Ser-Arg-Arg-Leu-Leu↓ Arg-Ala-Leu-Glu

(iv) hSKI-1 (181-188+Glu)

Ser-Ser-Arg-Arg-Leu-Leu↓ Arg-Ala-Ile-Glu

(v) hSKI-1 (187-201)

15 *Arg-Ala-Ile-Pro-Arg-Gln-Val-Ala↓ Gln-Thr-Leu-Gln-Ala-Asp-Val*

(vi) hSKI-1 (128-136)

Pro-Gln-Arg-Lys-Val-Phe-Arg-Ser-Leu

(vii) hSKI-1 (128-142)

20 *Pro-Gln-Arg-Lys-Val-Phe-Arg-Ser-Leu-Lys↓ Tyr-Ala-Glu-Ser-Asp*

(viii) hProBDNF (50-63)

Lys-Ala-Gly-Ser-Arg-Gly-Leu-Thr↓ Ser-Leu-Ala-Asp-Thr-Phe

(ix) SREBP-2 27 mer

Gly-Gly-Ala-His-Asp-Ser-Asp-Gln-His-Pro-His-Ser-Gly-Ser-Gly-Arg-Ser-Val-

25 *Leu↓ Ser-Phe-Glu-Ser-Gly-Ser-Gly-Gly*

(x) SREBP-2 10 mer

Ser-Gly-Ser-Gly-Arg-Ser-Val-Leu↓ Ser-Phe-Glu-Ser

30 These peptides were examined as possible substrates of SKI-1. Our data indicate
that only the **peptides (iii), (iv), (vii), (viii) (ix) and (x)** are efficiently cleaved by
the recombinant SKI-1.

NOVEL FLUOROGENIC SUBSTRATE BASED ASSAY OF SKI-1 ACTIVITY:

Based on the results reported above with various synthetic peptides we designed a number of internally quenched fluorogenic substrates of SKI-1. *Our main goal was to develop a rapid and a sensitive method for the assay of SKI-1 enzymatic activity.* SKI-1 activity was monitored by following the cleavage of suitable peptide substrates with HPLC that is often extremely slow and cumbersome. The following internally quenched fluorogenic peptides were synthesized and tested as substrates for SKI-1:

10 (a) QSKI (132-142):

Abz-Val-Phe-Arg-Ser-Leu-Lys ↓ Tyr-Ala-Glu-Ser-Asp-Tyr(NO₂)-Ala

(b) QSKI (134-142):

Abz-Arg-Ser-Leu-Lys ↓ Tyr-Ala-Glu-Ser-Asp-Tyr(NO₂)-Ala

15 (c) QSKI (178-188)

Abz-Arg-His-Ser-Ser-Arg-Arg-Leu-Leu ↓ Arg-Ala-Ile-Tyr(NO₂)-Ala

(d) QSKI (181-187+Leu+Glu)

20 Abz-Ser-Arg-Arg-Leu-Leu ↓ Arg-Ala-Leu-Glu-Tyr(NO₂)-Ala

(e) QBDNF (47-58)

Abz-Asn-Gly-Pro-Lys-Ala-Gly-Ser-Arg-Gly-Leu-Thr ↓ Ser-Tyr(NO₂)-Ala

25 The main feature of these peptides is the incorporation of two special amino acids namely **Abz** [Ortho amino benzoic acid also known as anthranalic acid] and **Tyr(NO₂)** [3-nitro Tyrosin] at the amino (N-) and carboxy (C-) terminal end of the peptide chain respectively. **Abz**, an **electron donor**, is a powerful fluorescent moiety whereas **Tyr(NO₂)**, an **electron acceptor**, acts as a

30 fluorescence quench group. All the above peptides exhibit weak fluorescence background values (at $\lambda_{\text{ex}} = 320 \text{ nm}$ and $\lambda_{\text{em}} = 420 \text{ nm}$). It is expected that upon cleavage by the proteolytic action of SKI, these peptides will release two peptide

fragments of which the **Abz-containing N-terminal part** should display a very high degree of fluorescence. The net result will be the increase of fluorescence intensity that can be measured very accurately with a fluorimeter instrument. This technique of measurement of enzymatic activity has been applied to a number of enzymes

5 { F. Jean, A. Boudreault, A. Basak, N. G. Seidah and C. Lazure.,, J. Biol. Chem., 1995, **270**, 19225-19231}

RESULTS

Our data indicates that among the above quenched fluorogenic peptides,

10 **peptide (a)** is most effective as a substrate for SKI-1. In fact the measurement of kinetic parameters (V_{max}/Km) indicted that this peptide is **6-fold** more efficient that the nearest candidate **quenched peptide (b)**. HPLC analysis using both UV and fluorescence detector systems clearly revealed a single site of cleavage in

15 **peptides (a) and (b)** (as indicated above by a vertical arrow ↓), again reenforcing the notion that the preferred sequence motif for SKI-1 is characterized by the presence of an Arg residue at P4 , an alkyl hydrophobic residue at P2 and possibly an aromatic hydrophobic residue at P1'. **Therefore, peptide (a) is a highly specific fluorogenic substrate for monitoring the activity of SKI-1**

This invention has been described in details hereinabove, and it will be

20 readily apparent to the skilled artisan that modifications can be made thereto without departing form the teachings of the present disclosure. These modifications are considered within the scope of the present invention, as defined in the appended claims.

Human SKI-1

cagggcacgctgggtcggcgagctgaggtcccagctgtgggcctcgctggcccggtcg
 gtcccgtgcgacccagccgctcgactccgaggtcgacacccggagcgacccggccagc
 1 -----+-----+-----+-----+-----+-----+ 60
 cccagctctcgcgagagttgggagtaaacagccccgaatggagtgccagggcgtgttcgcc
 gggtcagagcgctctcaaccctcatttgtcggggcttacctcacgggtccgcacaagcgg
 61 -----+-----+-----+-----+-----+-----+ 120
 gcggagggcgccgttatcccggggccgcccgcctgagctcccggggcgagattggctc
 cgcctccgcggaatagggcccgggcgccgggactcgagggccgcccgtctaacccgag
 121 -----+-----+-----+-----+-----+-----+ 180
 acagtggttgattgatcaacccccattggacgttggttctgtgtgtacaaatggagtacagg
 tgtcaccaactaactagttgggtaacctgaaccaagacacccatgtttacctcatgtcc
 181 -----+-----+-----+-----+-----+-----+ 240
 actcagtcgtcacggcctgagtgagagaagccttatttccaagatggagaagaagcggag
 tgagtcagcagtgccggactcactctcttcggaataaagggtctacctcttcttcgcctc
 241 -----+-----+-----+-----+-----+-----+ 300
 aaagaaatgaaagcctctcttcaggtgaaccacaaaaggccatgggatttaacttttat
 tttctttacttttcggagagaagtcgacttggtgtttccggtaccctaaattgaaaata
 301 -----+-----+-----+-----+-----+-----+ 360
 ttatgttgggcaagactgtaagatggctgatcagtaagtgttcagcttttagctgaaaca
 aatacaacccgttctgacattctaccgactagtcattacaacgtcgaaaatcgactttgt
 361 -----+-----+-----+-----+-----+-----+ 420
 aaaattcacttttaatacaagaaaaagtgatttgaaatatatgcaattttatgatc
 ttttaagtgaataatagttcttctttttcacactaaacttatatacgttaaaaatactag
 421 -----+-----+-----+-----+-----+-----+ 480
 1 M K L V N I W L L L L V V L L 15
 atattcgcttgtgacccatgaagcttgtcaacatctggctgcttctgctcgtggttttgc
 tataagcgaacacttggtacttcgaacagttgtgacccgacgaagacgagcaccaaaacga
 481 -----+-----+-----+-----+-----+-----+ 540
 16 C G K K H L G D R L E K K S F E K A P C 35
 ctgtgggaagaaacatctgggcgacagactggaaaagaaatcttttgaaaaggcccatg
 gacacccttctttagacccgctgtctgaccttttcttagaaaacttttccgggggtac
 541 -----+-----+-----+-----+-----+-----+ 600
 36 P G C S H L T L K V E F S S T V V E Y E 55
 ccctgggtgttcccactgactttgaaggtggaattctcatcaacagttgtggaatatga
 gggaccgacaagggtggactgaaactccaccttaagagtagttgtcaacaccttatact
 601 -----+-----+-----+-----+-----+-----+ 660
 56 Y I V A F N G Y F T A K A R N S F I S S 75
 atatattgtggctttcaatggatactttacagccaaagctagaaattcatttatttcaag
 tatataacaccgaaagtacctatgaaatgtcggtttcgatctttaagtaaataaagttc
 661 -----+-----+-----+-----+-----+-----+ 720
 76 A L K S S E V D N W R I I P R N N P S S 95
 tgccctgaagagcagtgaaagtagacaattggagaattatacctcgaaacaatccatccag
 acgggacttctcgtcacttcatctgttaacctcttaatatggagctttgttaggtaggtc
 721 -----+-----+-----+-----+-----+-----+ 780
 96 D Y P S D F E V I Q I K E K Q K A G L L 115
 tgactaccctagtgattttgaggtgattcagataaaagaaaaacagaaagcggggtgct
 actgatgggatcactaaaactccactaagtcctattttcttttcttcttcccccagca
 781 -----+-----+-----+-----+-----+-----+ 840
 116 T L E D H P N I K R V T P Q R K V F R S 135
 aacacttgaagatcatccaaacatcaaacgggtcacgccccaacgaaaagtctttcggtc
 ttgtgaacttctagttagttttagtttgcacgtgcggggtgcttttcagaaagcaag
 841 -----+-----+-----+-----+-----+-----+ 900
 136 L K Y A E S D P T V P C N E T R W S Q K 155
 cctcaagtatgctgaatctgacccccaggtacctgcaatgaaacccgggtggagccagaa
 ggagttcatacgacttagactggggtgcatgggacgttactttgggccacctcggtctt
 901 -----+-----+-----+-----+-----+-----+ 960
 156 W Q S S R P L R R A S L S L G S G F W H 175
 gtggcaatcatcacgtcccctgcgaagagccagcctctccctgggctctggcttctggca
 caccgttagtagtgacggggacgcttctcggtcggagagggacccgagaccgaagaccgt
 961 -----+-----+-----+-----+-----+-----+ 1020

| | | |
|------|---|------|
| 176 | A T G R H S S R R L L R A I P R Q V A Q | 195 |
| | tgctacgggaaggcattcgagcagacggctgctgagagccatcccgcgccaggttgccca | |
| 1021 | acgatgcccttccgtaagctcgtctgccgacgactctcggtagggcgcggtccaacgggt | 1080 |
| 196 | T L Q A D V L W Q M G Y T G A N V R V A | 215 |
| | gacactgcaggcagatgtgctctggcagatgggatatacaggtgctaagtgaagagttgc | |
| 1081 | ctgtgacgtccgtctacacgagaccgtctaccctatatgtccacgattacattctcaacg | 1140 |
| 216 | V F D T G L S E K H P H F K N V K E R T | 235 |
| | tgtttttgacactgggctgagcgagaagcatccccacttcaaaaatgtgaaggagagaac | |
| 1141 | acaaaaactgtgacccgactcgtctctcgtaggggtgaagtttttacacttcctctcttg | 1200 |
| 236 | N W T N E R T L D D G L G H G T F V A G | 255 |
| | caactggaccaacgagcgaacgctggacgatgggttgggccatggcacattcgtggcagg | |
| 1201 | gttgacctggttgctcgtctggacactgctacccaacccggtagcgtgtaagcaccgtcc | 1260 |
| 256 | V I A S M R E C Q G F A P D A E L H I F | 275 |
| | tgtgatagccagcatgagggagtgccaaggatttgcctcagatgcagaacttcacatttt | |
| 1261 | acactatcggtcgtactccctcacggttcctaaacgaggtctacgtcttgaagtgtaaaa | 1320 |
| 276 | R V F T N N Q V S Y T S W F L D A F N Y | 295 |
| | cagggtctttaccaataatcaggtatcttacacatcttggttttggacgccttcaacta | |
| 1321 | gtcccagaaatggttattagtcctagaaatgtgtagaacaaaaacctgcggaagtgtat | 1380 |
| 296 | A I L K K I D V L N L S I G G P D F M D | 315 |
| | tgccattttaaagaagatcgacgtgttaaactcagcatcgccggcccgacttcattgga | |
| 1381 | acggtaaaatttctctagctgcacaatttggagtcgtagccgcccggcctgaagtacct | 1440 |
| 316 | H P F V D K V W E L T A N N V I M V S A | 335 |
| | tcacccgtttgttgacaagggtgtgggaattaacagctaacaatgtaatcatggtttctgc | |
| 1441 | agtaggcaaacaactgttccacacccttaattgtcgattgttacattagtagtaccagagc | 1500 |
| 336 | I G N D G P L Y G T L N N P A D Q M D V | 355 |
| | tattggcaatgacggacctctttatggcactctgaataaccctgctgatcaaatggatgt | |
| 1501 | ataaccgttactgcttgagaaaataccgtgagacttattgggacgactagttacctaca | 1560 |
| 356 | I G V G G I D F E D N I A R F S S R G M | 375 |
| | gattggagtagggcggttgactttgaagataacatcgccgcttttcttcaaggggaat | |
| 1561 | ctaacctcatccgctgaactgaaacttctattgtagcgggcgaaaagaagtccctcta | 1620 |
| 376 | T T W E L P G G Y G R M K P D I V T Y G | 395 |
| | gactacctgggagctaccaggaggtacggctcgcatgaaacctgacattgtcacctatgg | |
| 1621 | ctgatggacctcgatggtcctccgatgccagcgtactttggactgtaacagtggatacc | 1680 |
| 396 | A G V R G S G V K G G C R A L S G T S V | 415 |
| | tgctggcgtgcggggttctggcgtgaaaggggggtgccgggcccctctcagggaccagtgt | |
| 1681 | acgaccgcacgcccgaagaccgcactttccccccacggcccgaggagtccttggtcaca | 1740 |
| 416 | A S P V V A G A V T L L V S T V Q K R E | 435 |
| | tgcttctccagtggttgaggtgctgtcaccttgttagtgagcacagtcagagaagcgtga | |
| 1741 | acgaagaggtcaccaacgtccacgacagtggaacaatcactcgtgtcaggtcttcgcact | 1800 |
| 436 | L V N P A S M K Q A L I A S A R R L P G | 455 |
| | gctggtgaatcccgccagtatgaagcaggccctgatcgcgctcagcccggaggctccccgg | |
| 1801 | cgaccacttagggcggtcactacttcgtccgggactagcgcagtcgggcctccgaggggcc | 1860 |
| 456 | V N M F E Q G H G K L D L L R A Y Q I L | 475 |
| | ggtcaacatgtttgagcaaggccacggcaagctcgatctgctcagagcctatcagatcct | |
| 1861 | ccagttgtacaaactcgttccggtgccgttcgagctagacgagtcctcgatagtcctagga | 1920 |

| | | |
|------|--|------|
| 476 | N S Y K P Q A S L S P S Y I D L T E C P | 495 |
| | caacagctacaagccacaggcaagtttgagccccagctacatagatctgactgagtgtcc | |
| 1921 | gttgctgatgttcggtgtccgttcaaactcggggtcgatgtatctagactgactcacagg | 1980 |
| 496 | Y M W P Y C S Q P I Y Y G G M P T V V N | 515 |
| | ctacatgtggccctactgtctccagcccatctactatggaggaatgccgacagttgttaa | |
| 1981 | gatgtacacccgggatgacgaggggtcggttagatgatacctccttacggctgtcaacaatt | 2040 |
| 516 | V T I L N G M G V T G R I V D K P D W Q | 535 |
| | tgtcaccatcctcaacggcatgggagtcacaggaagaattgtagataagcctgactggca | |
| 2041 | acagtggtaggagttccgtaccctcagtgctcttctaatacatctattcggactgaccgt | 2100 |
| 536 | P Y L P Q N G D N I E V A F S Y S S V L | 555 |
| | gccctattttgccacagaacggagacaacattgaagttgccttctcctactcctcggctctt | |
| 2101 | cggtgataaacgggtgtcttgctctgttgtaacttcaacggaagaggatgaggagccagaa | 2160 |
| 556 | W P W S G Y L A I S I S V T K K A A S W | 575 |
| | atggccttggtcgggtacctggccatctccatttctgtgaccaagaaagcgggtctcctg | |
| 2161 | taccggaaccagcccgatggaccggttagaggtaaagacactggttctttcgccgaaggac | 2220 |
| 576 | E G I A Q G H V M I T V A S P A E T E S | 595 |
| | ggaaggcattgtctcagggccatgtcatgatcactgtggcttccccagcagagacagagtc | |
| 2221 | ccttcgtaacagagtcgccgtacagtactagtacaccgaaggggtcgtctctgtctcag | 2280 |
| 596 | K N G A E Q T S T V K L P I K V K I I P | 615 |
| | aaaaaatggtgcagaaacagacttcaacagtaaaagctccccattaaggtgaagataattcc | |
| 2281 | ttttttaccacgtcttctgtgaagttgtcatttcgaggggtaattccacttctattaagg | 2340 |
| 616 | T P P R S K R V L W D Q Y H N L R Y P P | 635 |
| | tactcccccggaagcaagagagttctctgggatcagtagccacaacctccgctatccacc | |
| 2341 | atgagggggcgcttctctctcaagagaccctagtcagtggtgttgaggcgataggtgg | 2400 |
| 636 | G Y F P R D N L R M K N D P L D W N G D | 655 |
| | tggctattttccccagggataatttaaggatgaagaatgaccttttagactggaatggtga | |
| 2401 | accgataaaggggtccctattaaattcctacttcttactgggaaatctgaccttaccact | 2460 |
| 656 | H I H T N F R D M Y Q H L R S M G Y F V | 675 |
| | tcacatccacaccaatttcagggatatgtaccagcatctgagaagcatgggctactttgt | |
| 2461 | agtgtaggtgtggttaaagtcctatacatgggtcgtagactcttcgtaccgcatgaaca | 2520 |
| 676 | E V L G A P F T C F D A S Q Y G T L L M | 695 |
| | agaggtcctcggggcccccttcacgtgttttgatgccagtcagtaggcactttgtgat | |
| 2521 | tctccaggagccccgggggaagtgcacaaaactacggtcagtcataccgtgaaacgacta | 2580 |
| 696 | V D S E E E Y F P E E I A K L R R D V D | 715 |
| | ggtggacagtgaggaggagtacttccctgaagagatcgccaagctccggaggacgtgga | |
| 2581 | ccacctgtcactcctcctcgaagggacttctctagcgggttcgaggcctcctgcacct | 2640 |
| 716 | N G L S L V I F S D W Y N T S V M R K V | 735 |
| | caacggcctctcgtcgtcatcttcagtgactgggtacaacacttctgttatgagaaaagt | |
| 2641 | gttgccggagagcgagcagtagaagtcactgaccatgttggaagacaataactcttttca | 2700 |
| 736 | K F Y D E N T R Q W W M P D T G G A N I | 755 |
| | gaagttttatgatgaaaacacaggcagtggtggatgccggataccggaggagctaact | |
| 2701 | cttcaaaataactacttttgtgttcggtaccacacctacggcctatggcctcctcgattgta | 2760 |
| 756 | P A L N E L L S V W N M G F S D G L Y E | 775 |
| | cccagctctgaatgagctgctgtctgtgtggaacatgggggttcagcgatggcctgtatga | |
| 2761 | gggtcgagacttactcgacgacagacacaccttgtagcccaagtcgctaccggacatact | 2820 |

SUBSTITUTE SHEET (RULE 26)

tggttctacatgggcctgccctcctgtgatgggcagaggctcctggtacatcgagaagatt
acaagatgtacccggacgggaggacactacccgtctccgaggaccatgtagctcttctaa
3781 -----+-----+-----+-----+-----+-----+ 3840
cctgtggatcccgtcaggagggacttagtggtctctgccgccagtggagacttcccgcggc
ggacacctagggcagtcctcctgaatcacccgagacggcggtcactctgaagggcgggcg
3841 -----+-----+-----+-----+-----+-----+ 3900
agctgtgcgcaccaaagactcgggagaactggaaaggctgtctggggtcttctgactgca
tcgacacgcgtgggttctgagccctcttgaccttccgacagaccccagaagactgacgt
3901 -----+-----+-----+-----+-----+-----+ 3960
ggggaaggatgtactttccaaacaaatgatacaaccctgaccaagctaaaagacgcttgt
cccttccctacatgaaaagggttggtttactatggttgggactgggttcgattttctgcaaca
3961 -----+-----+-----+-----+-----+-----+ 4020
taaaggctattttctatatatttattgttgggaaaagtcactttaagacttgtgctatttg
atttccgataaaaagataataaacaacccttttcagtgaatttctgaacacgataaac
4021 -----+-----+-----+-----+-----+-----+ 4080
gaagcaaagctatttttttgtcagtggaatgcagtttttttactattccatcatgagga
cttcgtttcgataaaaaaacagtcaccttacgtcaaaaaaatgataaggtagtactcct
4081 -----+-----+-----+-----+-----+-----+ 4140
acaacatagattccatgatcttttttaatgacagtacagactgagatttgaaggaaacatg
tgttgtatctaaggtagtagaaaaattactgtcatgtctgactctaaacttcctttgtac
4141 -----+-----+-----+-----+-----+-----+ 4200
cacaaatctgtaaaacatagaccttcgctttatttttgaagtatcacctgccaccatgt
gtgttttagacattttgtatctggaagcgaaataaaaaacattcatagtgacggtgtgaca
4201 -----+-----+-----+-----+-----+-----+ 4260
tttgaatttgaggtcttgatttcaccattgtcggtgaagaaaattttcaataaatatgt
aaacattaaactccagaactaaagtggtaacagccacttcttttaaagttatttataca
4261 -----+-----+-----+-----+-----+-----+ 4320
attacccgtctgaagctt
taatgggcagacttcgaa
4321 -----+----- 4338

Rat SKI-1

| | | |
|-----|---|-----|
| 1 | CGGAGTAAACATCCCCGAATGGATACCCGAGGCGTGTTCGCGGCGGAGGCCCGTTTTC | 60 |
| | CGCTCATTTGTAGGGGGCTTACCTATGGGCTCCGCACAAGCGCCCTCCGGGGCAAAAG | |
| 61 | CCGGGTCCGCCGATCCCGAGCCTGAGGCGACGCAGATCGGCTCAGAGCGGTGGCTTGGGC | 120 |
| | GGCCAGGCGGCTAGGGCTCGGACTCCGCTGCGTCTAGCCGAGTCTCGCCACCGAACCCG | |
| 121 | TCCTGCTAGATTTGGGTCTGTGGTACAAATGGAGTTTAGGACTCAGTGGACTCGGCCCTA | 180 |
| | AGGACGATCTAAACCCAGACACCATGTTTACCTCAAATCCTGAGTCACCTGAGCCGGGAT | |
| 181 | ATGAGAGAAGCCCCCTGTCCAAGATGGAGAAGAAGCGGAGAAAGAAATGAAAGCCTCTTT | 240 |
| | TACTCTCTTCGGGGGACAGGTTCTACCTCTTCTTCGCCTCTTCTTTACTTTTCGGAGAAA | |
| 241 | TTGGGCCAAGCTGTGGGTGACCATGGGACTGAGGTTTTCTTTACGTTGGACAAGTCTGTA | 300 |
| | AACCCGTTTCGACACCCACTGGTACCCTGACTCCAAAAGAAATGCAACCTGTTTCAGACAT | |
| 301 | GGATGGCTGATCAGTAAGGTTGCAGCTTTTAGCGAAAACAGAAATCCACTTCTGATCAAG | 360 |
| | CCTACCGACTAGTCATTCCAACGTCGAAAATCGCTTTTGTCTTTAGGTGAAGACTAGTTC | |
| 1 | | M |
| 361 | GAAGAGCCTAGTGCAATTTGAATTTATGCAATTTTATGACCATATTCAGTTAGGACCATG | 420 |
| | CTTCTCGGATCACGTTAAACTTAAATACGTTAAATACTGGTATAAGTGAATCCTGGTAC | |
| 2 | K L V N I W L L L L V V L L C G K K H L | 21 |
| 421 | AAGCTCGTCAACATCTGGCTTCTTCTGCTGGTGGTTTTGCTCTGTGGGAAAAAGCATCTG | 480 |
| | TTCGAGCAGTTGTAGACCGAAGAAGACGACCACCAAAACGAGACACCCTTTTTCGTAGAC | |
| 22 | G D R L G K K A F E K A P C P S C S H L | 41 |
| 481 | GGTGACAGGCTGGGGAAGAAAGCTTTTGAAAAGGCCCATGCCCGAGCTGTCCACCTG | 540 |
| | CCACTGTCCGACCCCTTCTTTCGAAAACCTTTCCGGGGTACGGGGTCGACAAGGGTGGAC | |
| 42 | T L K V E F S S T V V E Y E Y I V A F N | 61 |
| 541 | ACTTTGAAGGTGGAATTCTCCTCAACTGTGGTGAATATGAATATATTGTGGCTTTCAAC | 600 |
| | TGAAACTTCACCTTAAGAGGAGTTGACACCACCTTATACTTATATAACACCGAAAGTTG | |
| 62 | G Y F T A K A R N S F I S S A L K S S E | 81 |
| 601 | GGATACTTCACAGCCAAAGCTAGAAACTCATTTATTTCAAGTGCTCTAAAAAGCAGTGAA | 660 |
| | CCTATGAAGTGTCCGTTTCGATCTTTGAGTAAATAAAGTTCACGAGATTTTTCGTCACTT | |
| 82 | V D N W R I I P R N N P S S D Y P S D F | 101 |
| 661 | GTGGACAACCTGGAGAATAATACCTCGGAACAACCCATCTAGTGACTACCCTAGTGATTTT | 720 |
| | CACCTGTTGACCTCTTATTATGGAGCCTTGTGGGTAGATCACTGATGGGATCACTAAAA | |
| 102 | E V I Q I K E K Q K A G L L T L E D H P | 121 |
| 721 | GAGGTGATTTCAGATAAAAGAGAGCAGAAGGCGGGGCTGCTCACACTTGAAGATCACCCA | 780 |
| | CTCCACTAAGTCTATTTTCTCTTCGTCTTCCGCCCCGACGAGTGTGAACCTTCTAGTGGGT | |

| | | |
|------|---|------|
| 122 | N I K R V T P Q R K V F R S L K F A E S | 141 |
| 781 | AACATCAAGCGGGTGACACCCAGCGGAAAGTCTTTCGTTCCCTGAAGTTTGCTGAATCC | 840 |
| | TTGTAGTTGCCCCACTGTGGGGTCGCCTTTCAGAAAGCAAGGGACTTCAAACGACTTAGG | |
| 142 | D P I V P C N E T R W S Q K W Q S S R P | 161 |
| 841 | GACCCCATTTGTGCCCTGTAATGAGACCCGGTGGAGCCAGAAGTGGCAGTCATCAGTCCC | 900 |
| | CTGGGGTAACACGGGACATTACTCTGGGCCACCTCGGTCTTCACCGTCAGTAGTGCAGGG | |
| 162 | L K R A S L S L G S G F W H A T G R H S | 181 |
| 901 | CTGAAAAGAGCCAGTCTCTCCCTGGGCTCTGGATTCTGGCATGCAACAGGAAGGCATTCA | 960 |
| | GACTTTTCTCGGTCTAGAGAGGGACCCGAGACCTAAGACCGTACGTTGTCTTCCGTAAGT | |
| 182 | S R R L L R A I P R Q V A Q T L Q A D V | 201 |
| 961 | AGTCGACGATTGCTGAGAGCCATTCTCGCCAGGTTGCCCAGACATTGCAGGCAGATGTG | 1020 |
| | TCAGCTGCTAACGACTCTCGGTAAGGAGCGGTCCAACGGGTCTGTAACGTCGGTCTACAC | |
| 202 | L W Q M G Y T G A N V R V A V F D T G L | 221 |
| 1021 | CTTTGGCAGATGGGATACACAGGTGCTAATGTGAGGGTTGCCGTTTGTGATACTGGGCTC | 1080 |
| | GAAACCGTCTACCTATGTGTCCACGATTACAGTCCCAACGGCAAAAATATGACCCGAG | |
| 222 | S E K H P H F K N V K E R T N W T N E R | 241 |
| 1081 | AGTGAGAAGCATCCACATTTCAAGAATGTGAAGGAAAGAACCACTGGACCAATGAGCGG | 1140 |
| | TCACTCTTCGTAGGTGTAAAGTTCTTACACTTCCTTTCTTGGTTGACCTGGTTACTCGCC | |
| 242 | T L D D G L G H G T F V A G V I A S M R | 261 |
| 1141 | ACCCTGGACGATGGGCTGGGCCATGGCACATTCTGTCAGGTGTGATTGCCAGCATGAGA | 1200 |
| | TGGGACCTGCTACCCGACCCGGTACCGTGTAAGCAACGTCCACACTAACGGTCGTACTCT | |
| 262 | E C Q G F A P D A E L H I F R V F T N N | 281 |
| 1201 | GAGTGCCAAGGATTTGCCCCAGATGCAGAGCTGCACATCTTCAGGGTCTTTACCAACAAT | 1260 |
| | CTCACGGTTCTCTAAACGGGGTCTACGTCTCGACGTGTAGAAGTCCAGAAATGTTGTTA | |
| 282 | Q V S Y T S W F L D A F N Y A I L K K M | 301 |
| 1261 | CAGGTGTCTTACACGTCTTGGTTTTTGGATGCCTTCAACTATGCCATCCTAAAGAAGATG | 1320 |
| | GTCCACAGAATGTGCAGAACCAAAACCTACGGAAGTTGATACGGTAGGATTTCTTCTAC | |
| 302 | D V L N L S I G G P D F M D H P F V D K | 321 |
| 1321 | GACGTTCTGAACCTTAGCATCGGTGGGCCTGACTTCATGGATCACCCCTTTGTGACAAG | 1380 |
| | CTGCAAGACTTGGAATCGTAGCCACCCGGACTGAAGTACCTAGTGGGGAACAACCTGTTT | |
| 322 | V W E L T A N N V I M V S A I G N D G P | 341 |
| 1381 | GTATGGGAATTAACAGCGAACAATGTAATCATGGTTTCTGCTATTGGCAATGATGGACCT | 1440 |
| | CATACCCCTAATTGTCGCTTGTTACATTAGTACCAAAGACGATAACCGTTACTACCTGGA | |
| 342 | L Y G T L N N P A D Q M D V I G V G G I | 361 |
| 1441 | CTCTATGGCACTCTGAATAACCCCTGCTGATCAGATGGATGTGATTGGAGTGGGTGGCATT | 1500 |
| | GAGATACCGTGAGACTTATTGGGACGACTAGTCTACCTACCTAACCTCACCCACCGTAA | |
| 362 | D F E D N I A R F S S R G M T T W E L P | 381 |
| 1501 | GACTTTGAAGACAACATCGCCCGCTTCTCTTCCAGGGGAATGACTACCTGGGAACCTACCG | 1560 |
| | CTGAAACTTCTGTTGTAGCGGGCGAAGAGAAGGTCCCCTTACTGATGGACCCTTGATGGC | |

| | | |
|------|---|------|
| 382 | G G Y G R V K P D I V T Y G A G V R G S | 401 |
| 1561 | GGAGGCTATGGTCGTGTGAAGCCTGACATTGTACCTATGGTGCTGGAGTGCGGGGTTCT | 1620 |
| | CCTCCGATACCAGCACACTTCGGACTGTAACAGTGGATACCACGACCTCACGCCCAAGA | |
| 402 | G V K G G C R A L S G T S V A S P V V A | 421 |
| 1621 | GGTGTGAAAGGGGGCTGCCGTGCACTCTCAGGGACCAGTGTGCGCTCCCCAGTGGTTGCT | 1680 |
| | CCACACTTTCCCCGACGGCACGTGAGAGTCCCTGGTCACAGCGGAGGGGTACCAACGA | |
| 422 | G A V T L L V S T V Q K R E L V N P A S | 441 |
| 1681 | GGGGCTGTCACTTGTTAGTAAGCACAGTACAGAAGCGGGAGCTAGTGAATCCTGCCAGT | 1740 |
| | CCCCGACAGTGGAAACAATCATTCTGTTCATGTCTTCGCCCTCGATCACTTAGGACGGTCA | |
| 442 | V K Q A L I A S A R R L P G V N M F E Q | 461 |
| 1741 | GTGAAGCAAGCTTTGATAGCATCAGCCCGGAGACTTCCTGGTGTCAACATGTTTGAGCAA | 1800 |
| | CACTTCGTTCGAAACTATCGTAGTCGGGCTCTGAAGGACCACAGTTGTACAAACTCGTT | |
| 462 | G H G K L D L L R A Y Q I L S S Y K P Q | 481 |
| 1801 | GGCCATGGCAAGTTGGATCTACTGCGAGCCTATCAGATCCTCAGCAGCTATAAACCGCAG | 1860 |
| | CCGGTACCGTTCAACCTAGATGACGCTCGGATAGTCTAGGAGTCGTGATATTTGGCGTC | |
| 482 | A S L S P S Y I D L T E C P Y M W P Y C | 501 |
| 1861 | GCGAGCCTGAGTCCTAGCTACATCGACCTGACTGAGTGTCCCTACATGTGGCCCTACTGC | 1920 |
| | CGCTCGGACTCAGGATCGATGTAGCTGGACTGACTCACAGGGATGTACACCGGGATGACC | |
| 502 | S Q P I Y Y G G M P T I V N V T I L N G | 521 |
| 1921 | TCCCAGCCCATCTACTATGGAGGAATGCCAACAATTGTTAATGTCACCATCCTCAATGGC | 1980 |
| | AGGGTCGGGTAGATGATACCTCCTTACGGTTGTTAACAATTACAGTGGTAGGAGTTACCG | |
| 522 | M G V T G R I V D K P E W R P Y L P Q N | 541 |
| 1981 | ATGGGAGTTACAGGAAGAATTGTGGATAAGCCTGAGTGGCGACCCTATTTACCACAGAAT | 2040 |
| | TACCCTCAATGTCCTTCTTAACACCTATTTCGGACTACCGCTGGGATAAATGGTGTCTTA | |
| 542 | G D N I E V A F S Y S S V L W P W S G Y | 561 |
| 2041 | GGAGACAACATTGAAGTGGCCTTCTCCTACTCCTCAGTGTGTGGCCTTGGTCAGGTTAC | 2100 |
| | CCTCTGTTGTAACCTCACCGGAAGAGGATGAGGAGTCACAACACCGGAACCAGTCCAATG | |
| 562 | L A I S I S V T K K A A S W E G I A Q G | 581 |
| 2101 | CTTGCCATCTCCATTTCTGTGACCAAGAAGGCAGCTTCTGGGAAGGCATCGCGCAGGGC | 2160 |
| | GAACGGTAGAGGTAAAGACACTGGTTCTTCGTCGAAGGACCCTTCGTCAGCGCGTCCCG | |
| 582 | H I M I T V A S P A E T E L K N G A E H | 601 |
| 2161 | CACATCATGATCACAGTGGCTTCCCCAGCAGAGACGGAATTAAAAAATGGTGCCGAGCAT | 2220 |
| | GTGTAGTACTAGTGTACCGAAGGGGTCGTCTCTGCCTTAATTTTTTACCACGGCTCGTA | |
| 602 | T S T V K L P I K V K I I P T P P R S K | 621 |
| 2221 | ACTTCCACAGTGAAGCTGCCCATCAAGGTGAAGATCATTCCCACCCCTCCTCGGAGCAAG | 2280 |
| | TGAAGGTGTCACTTCGACGGGTAGTTCCACTTCTAGTAAGGGTGGGAGGAGCCTCGTTC | |

| | | |
|------|---|------|
| 622 | R V L W D Q Y H N L R Y P P G Y F P R D | 641 |
| 2281 | AGAGTCCTCTGGGACCAGTACCACAACCTCCGCTACCCACCCGGCTACTTCCCCAGGGAC | 2340 |
| | TCTCAGGAGACCCCTGGTCATGGTGTGGAGGCGATGGGTGGGCCGATGAAGGGGTCCCTG | |
| 642 | N L R M K N D P L D W N G D H V H T N F | 661 |
| 2341 | AACTTGCGGATGAAGAATGATCCTTTAGACTGGAATGGCGACCACGTCCACACCAACTTC | 2400 |
| | TTGAACGCCTACTTCTTACTAGGAAATCTGACCTTACCGCTGGTGCAGGTGTGGTTGAAG | |
| 662 | R D M Y Q H L R S M G Y F V E V L G A P | 681 |
| 2401 | AGGGACATGTACCAGCATCTGCGCAGCATGGGCTACTTTGTGGAGGTGCTTGGTGCCCCA | 2460 |
| | TCCCTGTACATGGTCGTAGACGCGTCGTACCCGATGAAACACCTCCACGAACCAACGGGGT | |
| 682 | F T C F D A T Q Y G T L L M V D S E E E | 701 |
| 2461 | TTCACATGCTTTGACGCCACGCAGTACGGCACTTGCTTATGGTGGACAGTGAGGAAGAG | 2520 |
| | AAGTGTACGAACTGCGGTGCGTCATGCCGTGAGACGAATACCACCTGTCACTCCTTCTC | |
| 702 | Y F P E E I A K L R R D V D N G L S L V | 721 |
| 2521 | TACTTCCTCTGAGGAGATTGCTAAGCTGAGGAGGACGTGGACAATGGCCTTTCCCTTGTC | 2580 |
| | ATGAAGGGACTCCTCTAACGATTGCACTCCTCCTGCACCTGTTACCGAAAGGGAACAG | |
| 722 | V F S D W Y N T S V M R K V K F Y D E N | 741 |
| 2581 | GTCTTCAGTGACTGGTACAACACTTCTGTTATGAGAAAAGTGAAGTTTTACGATGAAAAC | 2640 |
| | CAGAAGTCACTGACCATGTTGTGAAGACAATACTCTTTTCACTTCAAATGCTACTTTTG | |
| 742 | T R Q W W M P D T G G A N V P A L N E L | 761 |
| 2641 | ACAAGGCAGTGGTGGATGCCAGATACTGGAGGAGCCAACGTCCCAGCTCTAAACGAGCTG | 2700 |
| | TGTTCCGTCACCACCTACGGTCTATGACCTCCTCGGTTGCAGGGTCGAGATTGCTCGAC | |
| 762 | L S V W N M G F S D G L Y E G E F A L A | 781 |
| 2701 | CTGTCTGTGTGGAACATGGGGTTCAGTGACGGCCTGTATGAAGGGGAGTTTGCCCTGGCA | 2760 |
| | GACAGACACACCTGTACCCCAAGTCACTGCCGGACATACTTCCCCTCAAACGGGACCGT | |
| 782 | N H D M Y Y A S G C S I A R F P E D G V | 801 |
| 2761 | AACCACGACATGTACTATGCATCGGGGTGCAGCATTGCCAGGTTTCCAGAAGATGGTGTG | 2820 |
| | TTGGTGCTGTACATGATACGTAGCCCCACGTCGTAACGGTCCAAAGGTCTTCTACCACAC | |
| 802 | V I T Q T F K D Q G L E V L K Q E T A V | 821 |
| 2821 | GTGATCACACAGACTTTCAAGGACCAAGGATTGGAAGTCTTAAAACAAGAGACAGCAGTT | 2880 |
| | CAGTAGTGTGTCTGAAAGTTCCTGGTTCCTAACCTTCAGAATTTGTTCTCTGTCTCAA | |
| 822 | V D N V P I L G L Y Q I P A E G G G R I | 841 |
| 2881 | GTCGACAATGTCCCCATTCTGGGGCTATATCAGATTCCAGCTGAAGGTGGAGGCCGGATT | 2940 |
| | CAGCTGTTACAGGGGTAAGACCCGATATAGTCTAAGGTCGACTTCCACCTCCGGCCTAA | |
| 842 | V L Y G D S N C L D D S H R Q K D C F W | 861 |
| 2941 | GTGCTGTATGGAGACTCCAAGTCTTGGATGACAGTCACAGACAGAAGGACTGCTTTTGG | 3000 |
| | CACGACATACCTCTGAGGTTGACGAACCTACTGTCAGTGTCTGTCTTCTGACGAAACC | |

| | | |
|------|--|------|
| 862 | L L D A L L Q Y T S Y G V T P P S L S H | 881 |
| 3001 | CTTCTGGATGCACTCCTTCAGTACACATCCTATGGTGTGACCCCTCCCAGCCTCAGCCAT GAAGACCTACGTGAGGAAGTCATGTGTAGGATACCACTGGGGAGGGTCGGAGTCGGTA | 3060 |
| 882 | S G N R Q R P P S G A G L A P P E R M E | 901 |
| 3061 | TCAGGGAACCGGCAGCGCCACCCAGCGGGGCTGGCTTGGCCCTCCTGAAAGGATGGAA AGTCCCTTGGCCGTCGCGGGTGGGTCGCCCGACCGAACCAGGGGAGGACTTTCCTACCTT | 3120 |
| 902 | G N H L H R Y S K V L E A H L G D P K P | 921 |
| 3121 | GGAAACCACCTTCATCGCTACTCCAAAGTTCTTGAGGCCCACTTGGGAGACCCGAAACCT CCTTTGGTGGAAGTAGCGATGAGGTTTCAAGAACTCCGGGTGAACCTCTGGGCTTTGGA | 3180 |
| 922 | R P L P A C P H L S W A K P Q P L N E T | 941 |
| 3181 | CGGCCCCCTTCCAGCCTGTCCACACTTGTGCTGGGCCAAGCCACAGCCTTTGAATGAGACG GCCGGGGAAGGTCGGACAGGTGTGAACAGCACCCGGTTCGGTGTGGAAACTTACTCTGC | 3240 |
| 942 | A P S N L W K H Q K L L S I D L D K V V | 961 |
| 3241 | GCACCCAGTAATCTTTGGAACACCAGAAGCTGCTCTCCATTGACCTGGACAAAGTAGTG CGTGGGTCTATTAGAAACCTTTTGGTCTTCGACGAGAGGTAAGTGGACCTGTTTCATCAC | 3300 |
| 962 | L P N F R S N R P Q V R P L S P G E S G | 981 |
| 3301 | TTACCCAACTTTTCCTCAAATCGCCCTCAAGTGAGACCTTTGTCCCCTGGAGAAAGTGGT AATGGGTTGAAAGCGAGTTTAGCGGGAGTTCCTCTGGAACAGGGGACCTCTTTCACCA | 3360 |
| 982 | A W D I P G G I M P G R Y N Q E V G Q T | 1001 |
| 3361 | GCCTGGGACATTCTTGGAGGGATCATGCCTGGCCGCTACAACCAGGAAGTAGGCCAGACC CGGACCCTGTAAGGACCTCCCTAGTACGGACCGGCGATGTTGGTCTTCATCCGGTCTGG | 3420 |
| 1002 | I P V F A F L G A M V A L A F F V V Q I | 1021 |
| 3421 | ATCCCTGTTTTTGCCTTCCTTGAGCCATGGTGGCCCTGGCCTTCTTCGTGGTACAGATC TAGGGACAAAAACGGAAGGAACCTCGGTACCACCGGGACCGGAAGAAGCACCATGTCTAG | 3480 |
| 1022 | S K A K S R P K R R R P R A K R P Q L A | 1041 |
| 3481 | AGTAAGGCCAAGAGCCGGCCGAGCGGAGGAGGCCAGGGCAAAGCGTCCACAACCTTGCA TCATTCCGGTTCTCGGCCGGCTTCGCTCCTCCGGGTCCCGTTTCGCAGGTGTTGAACGT | 3540 |
| 1042 | Q Q A H P A R T P S V | 1052 |
| 3541 | CAGCAGGCCACCTGCAAGGACCCCGTCAGTGTGATCATCACAGTGGCCAGACACAGAA GTGCTCCGGGTGGGACGTTCTGGGGCAGTCACACTAGTAGTGTACCGGTCTGTGTCTT | 3600 |
| 3601 | GCTGACAAGCTTTGAACCCCTCTGGTGGCCACACAGCATCAGAGAGCATCCTGGGAAGTG CGACTGTTTCGAACTTGGGGAGACCACCGGTGTGTCGTAGTCTCTCGTAGGACCTTCAC | 3660 |
| 3661 | CCTGTTTCCAAGGAGCCCTATCTCTGGATTGTGGCTGGCTTAGTGTGTTCTGCCAGACG GGACAAAGGTTCTCGGGATAGAGACCTAACACCGACCGAATCACACAAGACGGGTCTGC | 3720 |
| 3721 | TCTATGAGGTACATCCTGCAGTGCTCACTGTGTTTGGCTCTGGCCGAAGGTGCCAGTA AGATACTCCATGTAGGACGTACGGAGTGACACAAACCGAGACCGGCTTCACGGGTCTCAT | 3780 |

3781 GCTCAGCCTCCGGTGGCATCAGGCCCAGTGACAGTGCACCAAAGACACAGAGCCTGGAAG 3840
CGAGTCGGAGGCCACCGTAGTCCGGGTCACTGTCACGTGGTTTCTGTGTCTCGGACCTTC

3841 GGCTGTCGGGACATACTTTCTACATAATGCTACAACCCTGACCAAGCGAAGACAT 3895
CCGACAGCCCTGTATGAAAGATGTATTACGATGTTGGGACTGGTTCGCTTCTGTA

Mouse SKI-1

| | | |
|-----|---|-----|
| 1 | . M K L V S T W L L V L V V L L C G K | 18 |
| | GCATTCCATGAAGCTCGTCAGCACCTGGCTTCTTGTGCTGGTGGTTTGTCTCTGTGGGAA | |
| 1 | CGTAAGGTACTTCGAGCAGTCGTGGACCGAAGAACACGACCACCAAAACGAGACACCCCTT | 60 |
| 19 | R H L G D R L G T R A L E K A P C P S C | 38 |
| | ACGGCACCTGGGCGACAGGCTGGGGACGAGAGCTTTGAAAAGGCCCGTGCCCCAGCTG | |
| 61 | TGCCGTGGACCCGCTGTCCGACCCCTGCTCTCGAAACCTTTTCCGGGGCAGGGGTCGAC | 120 |
| 39 | S H L T L K V E F S S T V V E Y E Y I V | 58 |
| | CTCCACCTGACTTTGAAGGTGGAATTCTTCAACTGTGGTGGAGTACGAATATATTGT | |
| 121 | GAGGGTGGACTGAACTTCCACCTTAAGAGAAGTTGACACCACCTCATGCTTATATAACA | 180 |
| 59 | A F N G Y F T A K A R N S F I S S A L K | 78 |
| | GGCTTTCAACGGATACTTCACAGCCAAAGCTAGAAACTCATTTATTCAAGTGGCTGAA | |
| 181 | CCGAAAGTTGCCTATGAAGTGTGGTTTCGATCTTTGAGTAAATAAAGTTACGGCGACTT | 240 |
| 79 | S S E V E N W R I I P R N N P S S D Y P | 98 |
| | AAGCAGTGAAGTGGAAAAGTGGAGAATAATACCTCGGAACAACCCATCCAGTGACTACCC | |
| 241 | TTGCTCACTTCACCTTTTGACCTCTTATATGGAGCCTTGTTGGGTAGGTCACTGATGGG | 300 |
| 99 | S D F E V I Q I K E K Q K A G L L T L E | 118 |
| | TAGTGATTTTGAGGTGATTCAGATAAAAGAGAAGCAGAAGGCGGGGCTGCTCACACTTGA | |
| 301 | ATCACTAAACTCCACTAAGTCTATTTTCTCTTCGCTTCCGCCCCGACGAGTGTGAACT | 360 |
| 119 | D H P N I K R V T P Q R K V F R S L K F | 138 |
| | AGATCACCCCAACATCAAGCGGGTGACACCCAGCGGAAAGTCTTTCGTTCCCTCAAGTT | |
| 361 | TCTAGTGGGGTTGTAGTTGCGCCACTGTGGGGTCGCTTTCAGAAAGCAAGGGAGTTCAA | 420 |
| 139 | A E S N P I V P C N E T R W S Q K W Q S | 158 |
| | TGCTGAATCCAACCCCATCGTGCCCTGTAATGAAACCGGTGGAGCCAGAAGTGGCAGTC | |
| 421 | ACGACTTAGGTTGGGGTAGCACGGGACATTACTTTGGGCCACCTCGGTCTTCACCGTCAG | 480 |
| 159 | S R P L K R A S L S L G S G F W H A T G | 178 |
| | ATCACGTCCCCTGAAAAGAGCCAGTCTCTCCCTGGGCTCTGGATTCTGGCATGCAACAGG | |
| 481 | TAGTGCAGGGGACTTTTCTCGGTGAGAGGGACCCGAGACCTAAGACCGTACGTTGTCC | 540 |
| 179 | R H S S R R L L R A I P R Q V A Q T L Q | 198 |
| | AAGACATTCAAGTCGGCGATTGCTGAGAGCCATTCCCTCGCCAGGTGCGCCAGACACTGCA | |
| 541 | TTCTGTAAGTTACGCCGTAACGACTCTCGGTAAGGAGCGGTCCAGCGGGTCTGTGACGT | 600 |
| 199 | A D V L W Q M G Y T G A N V R V A V F D | 218 |
| | GGCAGATGTGCTGTGGCAGATGGGATACACAGGTGCTAATGTGAGAGTTGCTGTTTTGA | |
| 601 | CCGTCTACACGACACCGTCTACCCATGTGTCCACGATTACAGTCTCAACGACAAAACT | 660 |
| 219 | T G L S E K H P H F K N V K E R T N W T | 238 |
| | TACTGGGCTCAGTGAGAAGCATCCGCATTTTAAGAATGTGAAGGAGAGAACCAACTGGAC | |
| 661 | ATGACCCGAGTCACTCTTCGTAGGCGTAAAATTCTTACACTTCCTCTCTTGTTGACCTG | 720 |

| | | |
|------|--|------|
| 239 | N E R T L D D G L G H G T F V A G V I A | 258 |
| | CAATGAGCGGACCCTGGATGATGGGCTAGGCCATGGCACATTTCGTTGCAGGTGTGATTGC | |
| 721 | GTTACTCGCCTGGGACCTACTACCCGATCCGGTACCGTGTAAAGCAACGTCCACACTAACG | 780 |
| 259 | S M R E C Q G F A P D A E L H I F R V F | 278 |
| | CAGCATGAGGGAGTGCCAAGGATTTGCTCCAGATGCAGAGCTGCACATCTTCAGGGTCTT | |
| 781 | GTCGTACTCCCTCAGGTTCTTAAACGAGGTCTACGTCTCGACGTGTAGAAGTCCAGAA | 840 |
| 279 | T N N Q V S Y T S W F L D A F N Y A I L | 298 |
| | TACCAACAATCAGGTGTCTTACACATCTTGGTTTCTGGATGCCTTCAACTATGCCATCCT | |
| 841 | ATGGTTGTTAGTCCACAGAATGTGTAGAACCAAAGACCTACGGAAGTTGATACGGTAGGA | 900 |
| 299 | K K M D V L N L S I G G P D F M D H P F | 318 |
| | AAAGAAGATGGACGTTCTCAACCTTAGCATCGGTGGGCCCCGACTTCATGGATCATCCGTT | |
| 901 | TTTCTTCTACCTGCAAGAGTTGGAATCGTAGCCACCCGGGCTGAAGTACCTAGTAGGCAA | 960 |
| 319 | V D K V W E L T A N N V I M V S A I G N | 338 |
| | TGTTGACAAGGTGTGGGAATTAACAGCTAACAATGTAATTATGGTTTCTGCTATTGGCAA | |
| 961 | ACAACCTGTTCCACACCCTTAATTGTCGATTGTTACATTAATACCAAAGACGATAACCGTT | 1020 |
| 339 | D G P L Y G T L N N P A D Q M D V I G V | 358 |
| | TGATGGACCTCTCTATGGCACTCTGAATAACCCTGCTGATCAGATGGATGTGATGGAGT | |
| 1021 | ACTACCTGGAGAGATACCGTGAGACTTATTTGGGACGACTAGTCTACCTACCTAACCTCA | 1080 |
| 359 | G G I D F E D N I A R F S S R G M T T W | 378 |
| | GGGTGGCATTGACTTTGAAGATAACATCGCTCGCTTTTCTTCCAGGGGAATGACTACCTG | |
| 1081 | CCCACCGTAAGTAACTTCTATTGTAGCGAGCGAAAAGAAGGTCCCCTTACTGATGGAC | 1140 |
| 379 | E L P G G Y G R V K P D I V T Y G A G V | 398 |
| | GGAATTACCAGGAGGCTATGGTCTGTGAAGCCTGACATTGTCCACCTATGGTGTGGAGT | |
| 1141 | CCTTAATGGTCTCCGATACCAGCACACTTCGGACTGTAACAGTGGATACCACGACCTCA | 1200 |
| 399 | R G S G V K G G C R A L S G T S V A S P | 418 |
| | GCGGGGTTCCGGTGTGAAAGGGGGCTGCCGTGCACTCTCAGGGACCAGTGTGCTTCCCC | |
| 1201 | CGCCCCAAGGCCACACTTTCCCCCGACGGCACGTGAGAGTCCCTGGTCACAGCGAAGGGG | 1260 |
| 419 | V V A G A V T L L V S T V Q K R E L V N | 438 |
| | AGTGGTCTGCTGGGGCCGTACCTTGTAGTAAGCACAGTACAGAAGCGGGAGCTGGTGAA | |
| 1261 | TCACCAGCGACCCCGGAGTGAACAATCATTTCGTGTCATGTCTTCGCCCTCGACCACTT | 1320 |
| 439 | P A S V K Q A L I A S A R R L P G V N M | 458 |
| | TCCTGCCAGTGTGAAGCAAGCTTTGATAGCGTCAGCCCGGAGACTTCCTGGGGTCAACAT | |
| 1321 | AGGACGGTCACTTTCGTTTCGAACTATCGCAGTCGGGCCTCTGAAGGACCCAGTTGTA | 1380 |
| 459 | F E Q G H G K L D L L R A Y Q I L S S Y | 478 |
| | GTTTCGAGCAAGGTCTATGGCAAGTTGGATCTGCTGCGAGCTTATCAGATCCTCAGCAGCTA | |
| 1381 | CAAGCTCGTTCCAGTACCGTTCAACCTAGACGACGCTCGAATAGTCTAGGAGTCGTGAT | 1440 |

| | | |
|------|--|------|
| 479 | K P Q A S L S P S Y I D L T E C P Y M W | 498 |
| | TAAACCGCAGGCAAGCCTGAGTCCTAGCTACATCGACCTGACTGAGTGTCCCTACATGTG | |
| 1441 | ATTTGGCGTCCGTTCCGACTCAGGATCGATGTAGCTGGACTGACTCACAGGGATGTACAC | 1500 |
| 499 | P Y C S Q P I Y Y G G M P T I V N V T I | 518 |
| | GCCCTACTGCTCCCAGCCTATCTACTATGGAGGAATGCCAACAATCGTTAATGTCAACCAT | |
| 1501 | CGGGATGACGAGGGTCCGATAGATGATACCTCCTTACGGTTGTTAGCAATTACAGTGGTA | 1560 |
| 519 | L N G M G V T G R I V D K P E W R P Y L | 538 |
| | CCTCAATGGCATGGGCGTCACAGGAAGAATTGTGGATAAGCCTGAGTGGCGACCCATTATTT | |
| 1561 | GGAGTTACCGTACCCGAGTGTCTTCTTAACACCTATTCCGACTCACCGCTGGGATAAA | 1620 |
| 539 | P Q N G D N I E V A F S Y S S V L W P W | 558 |
| | ACCACAGAATGGAGACAACATTGAAGTGGCCTTCTCCTACTCCTCAGTGTGTGGCCCTG | |
| 1621 | TGGTGTCTTACCTCTGTGTAACTTCACCGGAAGAGGATGAGGAGTCACAACACCGGGAC | 1680 |
| 559 | S G Y L A I S I S V T K K A A S W E G I | 578 |
| | GTCAGGTTACCTTGCCATCTCCATTTCTGTGACCAAGAAGGCAGCTTCTGGGAAGGCAT | |
| 1681 | CAGTCCAATGGAACGGTAGAGGTAAGACACTGGTTCTTCCGTCGAAGGACCCTTCCGTA | 1740 |
| 579 | A Q G H I M I T V A S P A E T E L H S G | 598 |
| | CGCTCAGGGCCACATCATGATCACAGTGGCGTCCCCAGCAGAGACAGAGTTACACAGTGG | |
| 1741 | GCGAGTCCCGGTGTAGTACTAGTGTACCGCAGGGGTGCTCTGTCTCAATGTGTCAAC | 1800 |
| 599 | A E H T S T V K L P I K V K I I P T P P | 618 |
| | TGCGGAGCACACTTCCACCGTGAAGCTGCCCATCAAGGTGAAGATCATTTCCACCCCTCC | |
| 1801 | ACGCCTCGTGTGAAGGTGGCACTTCGACGGGTAGTTCCACTTCTAGTAAGGGTGGGGAGG | 1860 |
| 619 | R S K R V L W D Q Y H N L R Y P P G Y F | 638 |
| | TCGGAGCAAGAGAGTCTCTGGGACCAGTACCACAACCTCCGCTACCCACCTGGCTACTT | |
| 1861 | AGCCTCGTCTCTCAGGAGACCCTGGTCATGGTGTGGAGGCGATGGGTGGACCGATGAA | 1920 |
| 639 | P R D N L R M K N D P L D W N G D H V H | 658 |
| | CCCCAGGGACAACCTTGGCGATGAAGAATGACCCTTTAGACTGGAATGGCGACCACGTCCA | |
| 1921 | GGGGTCCCTGTTGAACGCCTACTTCTTACTGGGAAATCTGACCTTACCGCTGGTGCAGGT | 1980 |
| 659 | T N F R D M Y Q H L R S M G Y F V E V L | 678 |
| | CACCAACTTCAGGGACATGTACCAGCATCTGCGCAGCATGGGCTACTTCGTGGAGGTGCT | |
| 1981 | GTGGTTGAAGTCCCTGTACATGGTCTGAGCGCGTACCCGATGAAGCACCTCCACGA | 2040 |
| 679 | G A P F T C F D A T Q Y G T L L L V D S | 698 |
| | CGGCGCCCCATTACATGTTTTGACGCCACACAGTATGGCACTTTGCTGCTGGTGGACAG | |
| 2041 | GCCGCGGGGTAAGTGTACAAAACCTGCGGTGTGTACACCGTGAAACGACGACCACCTGTC | 2100 |
| 699 | E E E Y F P E E I A K L R R D V D N G L | 718 |
| | TGAGGAAGAGTACTTCCCTGAGGAGATTGCTAAGCTGAGGAGGGATGTGGACAATGGCCT | |
| 2101 | ACTCCTTCTCATGAAGGGACTCCTCTAACGATTGACTCCTCCCTACACCTGTTACCGGA | 2160 |
| 719 | S L V I F S D W Y N T S V M R K V K F Y | 738 |
| | TTCCCTCGTCATCTTCAGTGACTGGTACAACACTTCTGTTATGAGAAAAGTGAAGTTTAA | |
| 2161 | AAGGGAGCAGTAGAAGTCACTGACCATGTTGTGAAGACAATACTCTTTTCACTTCAAAT | 2220 |

| | | |
|------|---|------|
| 739 | D E N T R Q W W M P D T G G A N I P A L | 758 |
| | TGATGAAAACACCAGGCAGTGGTGGATGCCAGACACCGGAGGAGCGAACATCCCAGCTCT | |
| 2221 | ACTACTTTTGTGGTCCGTCACCACCTACGGTCTGTGGCCTCCTCGCTTGTAGGGTCGAGA | 2280 |
| 759 | N E L L S V W N M G F S D G L Y E G E F | 778 |
| | GAATGAGCTGCTGTCTGTGTGGACATGGGGTTCAGTGACGGCCTATATGAAGGGGAGTT | |
| 2281 | CTTACTCGACGACAGACACACCTTGTACCCCAAGTCACTGCCGGATATACTTCCCCTCAA | 2340 |
| 779 | V L A N H D M Y Y A S G C S I A K F P E | 798 |
| | TGTCCTGGCAAACCATGACATGTACTATGCGTCGGGGTGCAGCATCGCCAAAGTTTCCAGA | |
| 2341 | ACAGGACCGTTTGGTACTGTACATGATACGACGCCCCACGTCGTAGCGGTTCAAAGGTCT | 2400 |
| 799 | D G V V I T Q T F K D Q G L E V L K Q E | 818 |
| | AGATGGCGTCGTGATCACACAGACTTTCAGGACCAAGGATTGGAGGTCTTAAACAAGA | |
| 2401 | TCTACCGCAGCACTAGTGTGTCTGAAAGTTCCTGGTTCCTAACCTCCAGAATTTTGTCT | 2460 |
| 819 | T A V V E N V P I L G L Y Q I P S E G G | 838 |
| | GACAGCAGTTGTGGAAATGTTCCATTTTGGGGCTTTATCAGATTCCATCTGAAGGTGG | |
| 2461 | CTGTCTCAACACCTTTTACAAGGTTAAACCCCGAAATAGTCTAAGGTAGACTTCCACC | 2520 |
| 839 | G R I V L Y G D S N C L D D S H R Q K D | 858 |
| | AGGCCGGATCGTGCTGTATGGAGACTCCAAGTCTTGGATGACAGTCACAGACAGAAGGA | |
| 2521 | TCCGGCCTAGCACGACATACCTCTGAGGTTGACGAACCTACTGTCAAGTGTGTCTTCT | 2580 |
| 859 | C F W L L D A L L Q Y T S Y G V T P P S | 878 |
| | CTGCTTTTGGCTTCTGGATGCGCTCCTTCAGTACACATCCTATGGCGTGACCCCTCCAG | |
| 2581 | GACGAAAACCGAAGACCTACGCGAGGAAGTCATGTGTAGGATACCGCACTGGGGAGGGTC | 2640 |
| 879 | L S H S G N R Q R P P S G A G L A P P E | 898 |
| | CCTCAGCCATTACAGGAACCGGCAGCGCCACCTAGCGGAGCCGGCTTGGCCCCTCCTGA | |
| 2641 | GGAGTCGGTAAGTCCCTTGGCCGTCGCGGTGGATCGCCTCGGCCGAACCGGGGAGGACT | 2700 |
| 899 | R M E G N H L H R Y S K V L E A H L G D | 918 |
| | AAGGATGGAAGGAAACACCTCCATCGGTACTCCAAAGTTCTTGAAGCCCACTTGGGAGA | |
| 2701 | TTCTACCTTCTTTGGTGGAGGTAGCCATGAGGTTTCAAGAACTTCGGGTGAACCTCT | 2760 |
| 919 | P K P R P L P A C P H L S W A K P Q P L | 938 |
| | CCCGAAACCTCGGCCCTGCCAGCCTGTCCACATTTGTATGGGCCAAGCCACAGCCTTT | |
| 2761 | GGGCTTTGGAGCCGGGACGGTCGGACAGGTGTAAACAGTACCCGGTTCGGTGTGGAAA | 2820 |
| 939 | N E T A P S N L W K H Q K L L S I D L D | 958 |
| | GAATGAGACGGCACCCAGTAATCTTTGGAACATCAGAAGCTGCTCTCCATTGACCTGGA | |
| 2821 | CTTACTCTGCCGTGGGTCATTAGAAACCTTTGTAGTCTTCGACGAGAGGTAAGTGGACCT | 2880 |
| 959 | K V V L P N F R S N R P Q V R P L S P G | 978 |
| | CAAAGTAGTGTTACCCAACCTTTGATCCAATCGCCCTCAAGTGAGACCTTTGTCCCCTGG | |
| 2881 | GTTTCATCACAAATGGGTTGAAAGCTAGGTTAGCGGGAGTTCACTCTGGAACAGGGGACC | 2940 |

979 E S G A W D I P G G I M P G R Y N Q E V 998
AGAGAGTGGTGCCTGGGACATTCTGGAGGGATCATGCCTGGCCGCTACAACCAGGAGGT
2941 TCTCTCACCACGGACCCTGTAAGGACCTCCCTAGTACGGACCGGCGATGTTGGTCTCTCCA 3000

999 G Q T I P V F A F L G A M V A L A F F V 1018
GGGACAGACCATCCCCGTCTTCGCCTTCCTCGGAGCCATGGTGGCCCTGGCCTTCTTTGT
3001 CCCTGTCTGGTAGGGGCGAGAAGCGGAAGGAGCCTCGGTACCACCGGGACCGGAAGAAACA 3060

1019 V Q I S K A K S R P K R R R P R A K R P 1038
GGTACAGATCAGCAAGGCCAAGAGCCGCGGCGAAGCGGAGGAGGCCAGGGCAAAGCGTCC
3061 CCATGTCTAGTCGTTCCGGTTCTCGGCCGGCTTCGCCTCCTCCGGGTCCCGTTTCGCAGG 3120

1039 Q L A Q Q A H P A R T P S V 1052
ACAACTTGACAGCAGGCCCCACCTGCAAGGACCCCATCAGTGTGAGCATCGCAGTAGCC
3121 TGTGAAACGTGTCGTCGCGGTGGGACGTTCTCGGGGTAGTCACACTCGTAGCGTCATCGG 3180

AGCCACAGAAGCTAACAAGCCTTGAACCACTCTGGTGGCCACACAGCGCCTCAGAGAGCA
3181 TCGGTGTCTTCGATTCGTTTCGGAACCTTGGTGTGAGACCACCGGTGTGTCGCGGAGTCTCTCGT 3240

TTCTGGGAAGTGCCTGTTTCCGAGGACCCTGTCTCCAGCTTGTGGCTATCTTACTGTGTT
3241 AAGACCCCTTCACGGACAAAGGCTCCTGGGACAGAGGTGCAACACCGATAGAATGACACAA 3300

CTGCCCAGGCACCTGATGAGGTACATCCTGCAGTGCCTCTCTGTGCTTGGCTCTGGCAGA
3301 GACGGGTCCGTGGACTACTCCATGTAGGACGTCACGGAGAGACACGAACCGAGACCGTCT 3360

AGGCACCCAGTGACATCAGGCATCAGGCCCAGTGACAGTGCACCAAAGACACAGAGCCTG
3361 TCCGTGGGTCACTGTAGTCCGTAGTCCGGGTCACTGTACGTGGTTTTCTGTGTCTCGGAC 3420

GAAGGGCTGTGCGGACATACTTTCTACATAACGCTACAACCCTGACCAAGCAAAGACATG
3421 CTTCGCGACAGCCCTGTATGAAAGATGTATTGCGATGTTGGGACTGGTTTCGTTTCTGTAC 3480

CTTGTTACAGGCTATTTTCTATATTTATTGTGGGAGAGTCACTTTAAAGACTGTGCTAGT
3481 GAACAATGTCCGATAAAAGATATAAATAACACCCTCTCAGTGAAATTTCTGACACGATCA 3540

TGGAACAGAGCTGTTGCTGTTGTGTCAGTGCAGTTCAGTTTTCTGCAGCGATGTCATAAGG
3541 ACCTTTGTCTCGACAACGACAACAGTCAGCTCACGTCAAAGACGTGCTACAGTATTCC 3600

AGTCAGATTCCGTGACCTCCTCTTTGATGGAGGACACACTGAACTGAAGGGGACTTGCGC
3601 TCAGTCTAAGGCACTGGAGGAGAACTACCTCCTGTGTGACTTGACTTCCCCTGAACGCG 3660

GGATGTGGGAGATGCAAGCCTTCGCTTTATTTTTTATACTATCAACTGCCATCATGTT
3661 CCTACACCCTCTACGTTTCGGAAGCGAAATAAAAAATATTGATAGTTGACGGTAGTACAA 3720

TTGTAATTTGGGGATCTTGATTTACCGTTGTTGGTGAAGGAAATTTCAATAAATATGC
3721 AACATTAAACCCTAGAACTAAAGTGGCAACAACCACTTCCTTTAAAGTTATTTATACG 3780

ATAACCTT
3781 TATTGGAA 3788

REFERENCES

Example 1

1. Seidah, N.G., Day, R., Marcinkiewicz, M., & Chrétien, M. (1998) *Ann. N.Y. Acad. Sci.* **839**, 9-24.
- 5 2. Steiner, D.F. (1998) *Curr. Opin. Chem. Biol.* **2**, 31-39.
3. Seidah, N.G., Mbikay, M., Marcinkiewicz, M., & Chrétien, M. (1998) in *Proteolytic and Cellular Mechanisms in Prohormone and Neuropeptide Precursor Processing*, ed. Hook, V.Y.H. (R.G. Landes Company, Georgetown, TX), pp. 49-76.
- 10 4. Ling, N., Burgus, R., & Guillemin, R. (1976) *Proc. Natl. Acad. Sci. USA* **73**, 3042-3046.
5. Burbach, J.P.H., Seidah, N.G., & Chrétien, M. (1986) *Eur. J. Biochem.* **156**, 137-142.
6. Gupta, S.K., Hassel, T., & Singh, J.P. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 7799-7803.
- 15 7. O'Reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses, M., Lane, W.S., Cao, Y., Sage, E.H., & Folkman, J. (1994) *Cell* **79**, 315-328.
8. Rosendahl, M.S., Christine Ko, S., Long, D.L., Brewer, M.T., Rosenzweig, B., Hedl, E., Anderson, L., Pyle, S.M., Moreland, J., Meyers, M.A., Kohno, T.,
- 20 9. Lyons, D., & Lichenstein, H.S. (1997) *J. Biol. Chem.* **272**, 24588-24593.
9. Duncan, E.A., Brown, M.S., Goldstein, J.L., & Sakai, J. (1997) *J. Biol. Chem.* **272**, 12778-12785.
10. Checler, F. (1995) *J. Neurochem.* **65**, 1431-1444.
11. Seidah, N.G. (1995) *Methods Neurosci.* **23**, 3-15.
- 25 12. Nagase, T., Miyajima, N., Tanaka, A., Sazuka, T., Seki, N., Sato, S., Tabata, S., Ishikawa, K-I., Kawarabayasi, Y., Kotani, H., & Nomura, N. (1995) *DNA Res.* **2**, 37-43.
13. Edwards, J.B.D.M., Delort, J., & Mallet, J. (1991) *Nucl. Acid. Res.* **19**, 5227-5232.
- 30 14. Lusson, J., Vieau, D., Hamelin, J., Day, R., Chrétien, M., & Seidah, N.G. (1993) *Proc Natl Acad Sci USA* **90**, 6691-6695.

15. Seidah, N.G., Benjannet, S., Pareek, S., Chrétien, M., & Murphy, R.A. (1996) *FEBS Lett.* **379**, 247-250.
16. Marcinkiewicz, M., Savaria, D., & Marcinkiewicz, J. (1998) *Mol. Brain Res.* **59**, 229-246.
- 5 17. Lippincott-Schwartz, J., Youan, L.C., Bonifacino, J.S., & Klausner, R.D. (1989) *Cell* **56**, 801-813.
18. Anderson, E.D., Thomas, L., Hayflick, J.S., & Thomas, G. (1993) *J. Biol. Chem.* **268**, 24887-24891.
19. Yan, Q., Rosenfeld, R.D., Matheson, C.R., Hawkins, N., Lopez, O.T., Bennett, L., & Welcher, A.A. (1997) *Neuroscience* **78**, 431-448.
- 10 20. Paquet, L., Bergeron, F., Seidah, N.G., Chrétien, M., Mbikay, M., & Lazure, C. (1994) *J. Biol. Chem.* **269**, 19279-19285.
21. Seidah, N.G., Hamelin, J., Mamarbachi, M., Dong, W., Tadros, H., Mbikay, M., Chrétien, M., & Day, R. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 3388-3393.
- 15 22. Siezen, R.J., & Leunissen, J.A.M. (1997) *Protein Sci.* **6**, 501-523.
23. Seidah, N.G., Day, R., & Chrétien, M. (1994) *Biochimie* **76**, 197-209.
24. de Bie, I., Marcinkiewicz, M., Malide, D., Lazure, C., Nakayama, K., Bendayan, M., & Seidah, N.G. (1996) *J. Cell Biol.* **135**, 1261-1275.
25. Reeves, J.P., Decker, R.S., Crie, J.S., & Wildenthal, K. (1981) *Proc. Natl. Acad. Sci. USA* **78**, 4426-4429.
- 20 26. Benjannet, S., Savaria, D., Laslop, A., Chrétien, M., Marcinkiewicz, M., & Seidah, N.G. (1997) *J. Biol. Chem.* **272**, 26210-26218.
27. Maisonpierre, P.C., Le Beau, M.M., Espinosa, R., Ip, N.Y., Belluscio, L., de la Monte, S.M., Squinto, S., Furth, M.E. & Yancopoulos, G.D. (1991) *Genomics* **10**, 558-568.
- 25

EXAMPLE 2

1. Seidah, N.G. *et al.* - Mammalian subtilisin/kexin isozyme SKI-1: A widely expressed proprotein convertase with a unique cleavage specificity and cellular localization. - Proceedings of the National Academy of Sciences of the United States of America 1999; 96: 1321-1326.
- 30

2. Sakai, J. *et al.* - Molecular identification of the sterol-regulated luminal protease that cleaves SREBPs and controls lipid composition of animal cells. - *Molecular Cell* 1998; 2:505-514.
3. Brown, M. S. and Goldstein, J. L. A proteolytic pathway that controls the
5 cholesterol content of membranes, cells, and blood. *Proceedings of the National Academy of Sciences of the United States of America* 1999; 96: 11041-11048.
4. Wang, X., Sato, R., Brown, M.S., Hua, X., and Goldstein, J.L. SREBP-1, a
10 membrane-bound transcription factor released by sterol-regulated proteolysis [see comments]. *Cell* 1994; 77: 53-62.
5. Hua, X. *et al.* SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. *Proceedings of the National Academy of Sciences of the United States of America* 1993; 90, 11603-11607.
6. Sakai, J. *et al.* - Sterol-regulated release of SREBP-2 from cell membranes
15 requires two sequential cleavages, one within a transmembrane segment. - *Cell* 1996 ; 85: 1037-1046.
7. Rawson, R.B. *et al.* - Complementation cloning of S2P, a gene encoding a putative metalloprotease required for intramembrane cleavage of SREBPs.
20 - *Molecular Cell* 1997; 1:47-57.
8. Anderson, E.D., VanSlyke, J.K., Thulin, C.D., Jean, F., and Thomas, G. - Activation of the furin endoprotease is a multiple-step process: requirements for acidification and internal propeptide cleavage. - *EMBO Journal* 1997, 16: 1508-1518.
9. Power, S.D., Adams, R.M., and Wells, J.A. - Secretion and autoproteolytic
25 maturation of subtilisin. - *Proceedings of the National Academy of Sciences of the United States of America* 1986 83: 3096-3100.
10. Seidah, N.G., Mbikay, M., Marcinkiewicz, M. and Chrétien, M., The mammalian precursor convertases: paralogs of the subtilisin/kexin family of calcium-
30 dependent serine proteinases. In: Hook, V.Y.H. (Ed.), *Proteolytic and Cellular Mechanisms in Prohormone and Neuropeptide Precursor*

Processing. R.G. Landes Company, Georgetown, TX, USA, 1998, pp. 49-76.

11. Chiron, M.F., Fryling, C.M., and FitzGerald, D.J. - Cleavage of pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. - Journal of Biological Chemistry 1994; 269: 18167-18176.
- 5 12. Volchkov, V.E., Feldmann, H., Volchkova, V.A., and Klenk, H.D. - Processing of the Ebola virus glycoprotein by the proprotein convertase furin. - Proceedings of the National Academy of Sciences of the United States of America 1998; 95: 5762-5767.
- 10 13. Hallenberger, S., Moulard, M., Sordel, M., Klenk, H.D., and Garten, W. - The role of eukaryotic subtilisin-like endoproteases for the activation of human immunodeficiency virus glycoproteins in natural host cells. - Journal of Virology 1997;71: 1036-1455.
14. Chrétien, M., Mbikay, M., Gaspar, L. and Seidah, N.G., Proprotein convertases and the pathophysiology of human diseases: prospective considerations. 15 Proc. Assoc. Am. Physicians., 107 (1995) 47-66.
- 15 15. Decroly, E., Benjannet, S., Savaria, D., and Seidah, N.G. - Comparative functional role of PC7 and furin in the processing of the HIV envelope glycoprotein gp160. - FEBS Letters 1997; 405: 68-72.
- 16 16. Abrami, L. *et al.* - The pore-forming toxin proaerolysin is activated by furin. - 20 Journal of Biological Chemistry 1998; 273: 32656-32661.
17. Jean, F., Boudreault, A., Basak, A., Seidah, N.G., and Lazure, C. - Fluorescent peptidyl substrates as an aid in studying the substrate specificity of human prohormone convertase PC1 and human furin and designing a potent irreversible inhibitor. - Journal of Biological Chemistry 1995; 270: 19225- 25 19231.
18. Hallenberger, S. *et al.* - Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. - Nature 1992; 360: 358-361.
19. Sakai, J., Duncan, E.A., Rawson, R.B., Hua, X., Brown, M.S. and Goldstein, J. L. Sterol-regulated release of SREBP-2 from cell membranes requires 30 two sequential cleavages, one within a transmembrane segment. Cell 1996; 85: 1037-1046.

20. Laufs, U. and Liao, J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. *Journal of Biological Chemistry* 1998; 273: 24266-24271.
- 5 21. Endres, M. *et al.* Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. *Proceedings of the National Academy of Sciences of the United States of America* 1998; 95: 8880-8885.
- 10 22. Laufs, U., La, F.V., Plutzky, J., and Liao, J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. *Circulation* 1998; 97: 1129-1135.
23. Laufs, U., Fata, V.L., and Liao, J.K. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. *Journal of Biological Chemistry* 1997; 272: 31725-31729.
- 15 24. Raiteri, M. *et al.* Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation. *Journal of Pharmacology & Experimental Therapeutics* 1997; 281:1144-1153.
- 20 25. Soma, M.R., Corsini, A., and Paoletti, R. Cholesterol and mevalonic acid modulation in cell metabolism and multiplication. *Toxicology Letters* 1992; 64-65 Spec No, 1-15.
26. Mutoh, T., Kumano, T., Nakagawa, H., and Kuriyama, M. - Role of tyrosine phosphorylation of phospholipase C gamma1 in the signaling pathway of HMG-CoA reductase inhibitor-induced cell death of L6 myoblasts. - *FEBS Letters* 1999; 446: 91-94.
- 25 27. Mutoh, T., Kumano, T., Nakagawa, H., and Kuriyama, M. - Involvement of tyrosine phosphorylation in HMG-CoA reductase inhibitor-induced cell death in L6 myoblasts. - *FEBS Letters* 1999; 444: 85-89.
28. Bellosta, S. *et al.* - Direct vascular effects of HMG-CoA reductase inhibitors. *Atherosclerosis* 1998; 137 Suppl:S101-S109.
- 30 29. Shimomura, I., Hammer, R. E., Ikemoto, S., Brown, M. S., and Goldstein, J. L. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. *Nature* 1999; 401:73-76.

30. Shimomura, I. *et al.* - Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. - *Genes & Development* 1998; 12:3182-3194.
31. Kim, J.B. *et al.* - Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. - *Journal of Clinical Investigation* 1998; 101: 1-9.
32. Kim, J.B. and Spiegelman, B.M. - ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. - *Genes & Development* 1996; 10: 1096-1107.
33. Kim, J.B., Wright, H.M., Wright, M., and Spiegelman, B.M. - ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. - *Proceedings of the National Academy of Sciences of the United States of America* 1998; 95: 4333-4337.
34. Shimomura, I., Bashmakov, Y. and Horton, J.D. - Increased Levels of Nuclear SREBP-1c Associated with Fatty Livers in Two Mouse Models of Diabetes Mellitus. - *Journal of Biological Chemistry* 1999; 274:30028-30032.

EXAMPLE 3

Seidah, N.G., Day, R., Marcinkiewicz, M., and Chrétien, M. (1998) *Ann. NY Acad. Sci.* **839**, 9-24

Steiner, D.F. (1998) *Curr. Opin. Chem. Biol.* **2**, 31-39

Seidah, N.G., Mbikay, M., Marcinkiewicz, M., and Chrétien, M. (1998) in *Proteolytic and Cellular Mechanisms in Prohormone and Neuropeptide Precursor Processing*. (Hook, V.Y.H, ed) pp. 49-76, R.G. Landes Co., Georgetown, TX

Ling, N., Burgus, R., and Guillemin, R. (1976) *Proc. Natl. Acad. Sci. USA* **73**, 3042-3046

Burbach, J.P.H., Seidah, N.G, and Chrétien, M. (1986) *Eur. J. Biochem.* **156**, 137-142

Hudson, P., Haley, J., Cronk, M., Shine, J., and Niall, H. (1981) *Nature* **291**, 127-131

- Gupta, S.K., Hassel, T., and Singh, J.P. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 7799-7803
- Duncan, E.A., Brown, M.S., Goldstein, J.L., and Sakai, J. (1997) *J. Biol. Chem.* **272**, 12778-12785
- 5 Siezen, R.J., and Leunissen, J.A. (1997) *Protein Sci.* **6**, 501-523
- Seidah, N.G., Mowla, S.J., Hamelin, J., Mamarbachi, A.M., Benjannet, S., Toure, B.B., Basak, A., Munzer, J.S., Marcinkiewicz, J., Zhong, M., Barale, J.C., Lazure, C., Murphy, R.A., Chrétien, M., and Marcinkiewicz, M. (1999) *Proc. Natl. Acad. Sci. USA* **96**, 1321-1326
- 10 Sakai, J., Rawson, R.B., Espenshade, P.J., Cheng, D., Seegmiller, A.C., Goldstein, J.L., and Brown, M.S. (1998) *Mol. Cell* **2**, 505-514
- Nagase, T., Miyajima, N., Tanaka, A., Sazuka, T., Seki, N., Sato, S., Tabata, S., Ishikawa, K., Kawarabayashi, Y., and Kotani, H. (1995) *DNA Res.* **2**, 37-43
- Munzer, J.S., Basak, A., Zhong, M., Mamarbachi, A., Hamelin, J., Savaria, D.,
15 Lazure, C., Benjannet, S., Chrétien, M., and Seidah, N.G. (1997) *J. Biol. Chem.* **272**, 19672-19681
- Rovère, C., Luis, J., Lissitzky, J.-C., Basak, A., Marvaldi, J., Chrétien, M., and Seidah, N.G. (1999) *J. Biol. Chem.* **274**, 12461-12467
- Basak, A., Boudreault, A., Chen, A., Chrétien, M., Seidah, N.G., and Lazure, C.
20 (1995) *J. Pept. Sci.* **1**, 385-395
- Basak, A., Ernst, B., Brewer, D., Seidah, N.G., Munzer, J.S., Lazure, C., and Lajoie, G.A. (1997) *J. Pept. Res.* **49**, 596-603
- Jean, F., Boudreault, A., Basak, A., Seidah, N.G., and Lazure, C. (1995) *J. Biol. Chem.* **270**, 19225-19231
- 25 Hooper, N.M., Karran, E.H., and Turner, A.J. (1997) *Biochem. J.* **321**, 265-279
- Lippincott-Schwartz, J., Yuan, L., Tipper, C., Amherdt, M., Orci, L., and Klausner, R.D. (1991) *Cell* **67**, 601-616
- Gram, H., Ramage, P., Memmert, K., Gamse, R. and Kocher, P. (1994) *Biotechnology* **12**, 1017-1023
- 30 Rittenhose, J., and Marcus, F. (1984) *Anal. Biochem.* **138**, 442-448
- Mizuno, K., Nakamura, T., Ohshima, T., Tanaka, S., and Matsuo, H. (1989) *Biochem. Biophys. Res. Commun.* **159**, 305-311

- Lei, Y., Xin, X., Morgan, D., Pintar, J. E., and Fricker, L. D. (1999) *DNA Cell Biol.* **18**, 175-185
- Inouye, M. (1991) *Enzyme* **45**, 314-321
- Gallagher, T., Gilliland, G., Wang, L., and Bryan, P. (1995) *Structure* **3**, 907-914
- 5 Anderson, E.D., Vanslyke, J.K., Thulin, C.D., Jean, F., and Thomas, G. (1997) *EMBO J.* **16**, 1508-1518
- Malide, D., Seidah, N.G., Chrétien, M., and Bendayan, M. (1995) *J. Histochem. Cytochem.* **43**, 11-19
- Kendall, J.M., Badminton, M.N., Dormer, R.L., and Campbell, A.K. (1994) *Anal.*
10 *Biochem.* **221**, 173-181
- Sambrook, J.F. (1990) *Cell* **61**, 197-199
- Llopis, J, McCaffery, J.M., Miyawaki, A, Farquhar, M.G., and Tsien, R.Y. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 6803-6808
- Kim, J.H., Johannes, L., Goud, B., Antony, C., Lingwood, C.A., Daneman, R., and
15 Grinstein, S. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 2997-3002
- Nohturfft A, DeBose-Boyd, R.A., Scheek, S., Goldstein, J.L., and Brown, M.S. (1999) *Proc. Natl. Acad. Sci. USA* **96**, 11235-11240
- Nohturfft, A, Brown, M.S., and Goldstein, J.L. (1998) *Proc. Natl. Acad. Sci. USA*
95, 12848-12853
- 20 Boudreault, A., Gauthier, D., and Lazure, C. (1998) *J. Biol. Chem.* **273**, 31574-31580
- Zhong, M., Munzer, J.S., Basak, A., Benjannet, S., Mowla, S.J., Decroly, E., Chrétien, M. and Seidah, N.G. (1999) *J. Biol. Chem.* (in press).
- Muller, L., Zhu, X.R., and Lindberg, I. (1997) *J. Cell Biol.* **139**, 625-638
- 25 Benjannet, S., Mamarbachi, A.M., Hamelin, J., Savaria, D., Munzer, J.S., Chrétien, M., and Seidah, N.G. (1998) *FEBS Letters* **428**, 37-42
- Espenshade, P.J., Cheng, D., Goldstein, J. L., and Brown, M. S. (1999) *J. Biol. Chem.* **274**, 22795-22804
- Cheng, D., Espenshade, P. J., Slaughter, C. A., Jaen, J. C., Brown, M. S., and
30 Goldstein J. L. (1999) *J. Biol. Chem.* **274**, 22805-22812

AMENDED SHEET

- 75 -

What is claimed is:

1. A soluble proteic fragment of a subtilisin-kexin isoenzyme named SKI-1 which has the amino acid sequence defined by amino acids 187 to 996 of any one of SEQ ID NOs. 2, 4 and 6, and a variant thereof, which is enzymatically active.
- 5 2. A proteic fragment of a subtilisin-kexin isoenzyme named SKI-1, which has the amino acid sequence defined by amino acids 18 to 137 of any one of SEQ ID NOs: 2, 4 and 6, and a variant thereof, which is capable of binding with amino acids 18 to 1052 of SKI-1 in whole or in part.
- 10 3. The proteic fragment of claim 2, wherein said part has a molecular weight of about 14 KDa and forms a tight complex with the soluble fragment of SKI-1 as defined in claim 1.
4. The proteic fragment of claim 2, which is an inhibitor of SKI-1 activity.
- 15 5. The proteic fragment of claim 4, wherein the SKI-1 amino acid sequence that is modified to prevent further enzymatic processing in a cell expressing said proteic fragment.
6. The proteic fragment of claim 5, which is modified by amino acid substitution, deletion or rearrangement.
7. An isolated nucleic acid encoding a protein fragment as defined in claim 1.
8. An isolated nucleic acid encoding a proteic fragment as defined in claim 2.
- 20 9. An isolated nucleic acid encoding a proteic fragment as defined in claim 3.
10. An isolated nucleic acid encoding a proteic fragment as defined in any one of claims 4 to 6.
11. A recombinant vector comprising the nucleic acid defined in any one of claims 7 to 10.
- 25 12. The recombinant vector of claim 11, which is an expression vector.

1/33

↓

| | | |
|-------|--|----|
| Rat | MKLVNIWLLLLLVLLCGKKHLGDRLGKKAFAKAPCPSCSHLTLKVEFSSTVVEYIYVAFNGYFTAKARNSFISS | 75 |
| Mouse | ST V R TR L | |
| Human | E S G | |

| | | |
|-------|---|-----|
| Rat | ALKSSEVDNWRIIPRNNPSSDYPSPDFEVIQIKEKQKAGLLTLEDHPNKRVTQPKVFRSLKFAESDPVPCNET | 150 |
| Mouse | E N | |
| Human | Y T | |

| | | |
|-------|--|-----|
| Rat | RWSQKWQSSRPLKRASLSLGS GFWHATGRHSSRLLRAIPRQVAQTLOADVLWQMGYTGANVRVAVE DTGLSEKH | 225 |
| Mouse | | |
| Human | R | |

| | | |
|-------|--|-----|
| Rat | PHFKNVKERTNWTNERTLDDGLG HGT FVAGVIASMRQC GFAPDAELHIFRVFTNNQVSYTSWFLDAFN YAILKK | 300 |
| Mouse | | |
| Human | | |

| | | |
|-------|---|-----|
| Rat | MDVLNLSIGGPDFMDHPFVDK VWELTANNVINVSAIGN DGPLYGTLNNPADQMDVIGVGGIDFEDNIARFSSRGM | 375 |
| Mouse | | |
| Human | I | |

▼

| | | |
|-------|--|-----|
| Rat | TTWELPGGYGRVKPDIVTYGAGVRGSGVKGCCRALSGT SVASPVVAGAVTLLVSTVQKRELVNPASVKQALIASA | 450 |
| Mouse | | |
| Human | M M | |

▼

| | | |
|-------|--|-----|
| Rat | RRLPGVNMFEQGHGKDLLRAYQILSSYKPQASLSPSYIDLTECPYMWPYCSQPIYYGGMPTIVNVTILNGMGVT | 525 |
| Mouse | | |
| Human | N V | |

715 - 1A

2/33

Rat GRIVDKPEWRPYLPQNGDNIEVAFSYSSVLWPWSGYLAISISVTKKAASWEGIAQGHIMITVASPAETELKNGAE 600

Mouse HS

Human D Q V S

Rat HTSTVKLPIKVKIIPPPRSKRVLWDQYHNLRYPPGYFPRDNLRMKNDPLDWNGDHVHTNFRDMYQHLRSMGYFV 675

Mouse

Human Q I

Rat EVLGAPFTCFDATQYGTLLMVDSEEEYFPEEIAKLRRDNDGLSLVVFSDWYNTSVMRKVKFYDENTRQWMPDT 750

Mouse L I

Human S I

Rat GGANVPALNELLSVWNMGFSGLYEGEFALANHDMYYASGCCSIARFPEDGVVITQTFKDQGLEVLKQETAVVDNV 825

Mouse I V K E

Human I V K E

Rat PILGLYQIPAEGGGRIVLYGDSNCLDDSHRQKDCFLLDALLQYTSYGVTPPSLSHSGNRQRPPSGAGLAPPERM 900

Mouse S

Human SVT

Rat EGNHLHRYSKVLEAHLGDPKPRPLPACPHLSWAKPQPLNETAPSNLWKHKLLSIDLDKVVLNFRSNRPQVRPL 975

Mouse

Human R


Rat SPGESGAWDIPGGIMPGRYNQEVGQTIPVFAFLGAMVALAFFVVQISKAKSRPKRRRPRAKRQLAQQAHPARTPSV 1052

Mouse


Human V N K V M V PK

FIIS - 1 B


3/33




4/33




5/33





6/33




7/33







9/33




10/33

FIG. 1aFIG. 1b

11/33









TIE-9a





TIE-9b



12/33



13/33



14/33




12D

12E


DRG Cx Cb Hip SpC Thyr Adr Stom

F — 4 KB



12F

15/33

Fig 13Fig 14



16/33

| | | | | | | | | | |
|-------------------|---|---|---|---|-------------------|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 1 | 2 | 3 | 4 | 5 |
| HMG CoA reductase | | | | | HMG CoA reductase | | | | |
| 18 S | | | | | 18 S | | | | |

FEF-15B

FEF-15A

17/33

Fig. 16Fig. 17

6% PAGE

10% PAGE

7-18

(-) Sterols

(+) Sterols

proSREBP-1

↑
intSREBP-1



LA

proSREBP-1 ↑


intSREBP-1 ↑

SUBSTITUTE SHEET (RULE 26)


19/33





20/33

FIG. 19C



21/33




22/33

FIG. 21AFIG. 21B


23/33

Figure 21CFigure 21D


24/33




QRKVF↓R↓SL↓KYAE

FIG. 21E

25/33
(%) CH_3CN









FIG. 23B

28/33

DPKK-[REDACTED]-RASL¹⁶⁷SLEH₆...RRLL¹⁸⁶RALEH₆...RQVA¹⁹⁴QTLEH₆

FIG. 24A

PS1 PS2 PS3 PS1 PS2 PS3

kDa

21 →





Ab P


Western

Coomassie

FIG. 24B



30/33

FIG. 27

31/33






FIG. 2B

32/33



33/33




FIG. 30

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

(Includes Reference to PCT International Applications)

ATTORNEY DOCKET NUMBER

480848.9002*

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

MAMMALIAN SUBTILISIN/KEXIN ISOZYME SKI-1: A PROPROTEIN CONVERTASE WITH A UNIQUE CLEAVAGE SPECIFICITY

the specification of which (check only one item below):

☐ is attached hereto.

☐ was filed as U.S. Patent Application Serial Number ____
on ____,
as amended on ____ (if applicable).

☒ was filed as a PCT international application number PCT/CA99/01058 on 04 Nov 1999
as amended under PCT Article 19 on ____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the applications for which priority is claimed:

PRIOR FOREIGN PATENT APPLICATION(S) AND ANY PRIORITY CLAIMED UNDER 35 U.S.C. §119:

| COUNTRY (If PCT Indicate PCT) | APPLICATION NUMBER | DATE OF FILING (Day, Month, Year) | PRIORITY CLAIMED UNDER 35 USC 119 |
|----------------------------------|--------------------|--------------------------------------|---|
| PCT | PCT/CA99/01058 | 04 November 1999 | <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO |
| Canada | 2,249,648 | 04 November 1998 | <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO |
| | | | <input type="checkbox"/> YES <input type="checkbox"/> NO |
| | | | <input type="checkbox"/> YES <input type="checkbox"/> NO |
| | | | <input type="checkbox"/> YES <input type="checkbox"/> NO |

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

(Includes Reference to PCT International Applications)

ATTORNEY DOCKET NUMBER

480848.9002*

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application.

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:

| U.S. APPLICATIONS | | STATUS (Check One) | | |
|-------------------------|------------------|--------------------|-----------|---------|
| U.S. APPLICATION NUMBER | U.S. FILING DATE | PATENTED | ABANDONED | PENDING |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

PCT APPLICATIONS DESIGNATING THE U.S.

| PCT APPLICATION NUMBER | PCT FILING DATE | U.S. SERIAL NUMBERS | | | |
|------------------------|-----------------|---------------------|--|--|--|
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the U.S. Patent and Trademark Office connected therewith (List names and registration numbers):

Send Correspondence to:

Jean C. BakerQuarles & Brady LLP411 East Wisconsin Ave. Suite 2550Milwaukee, WI 53202-4497

Direct Telephone Calls to:

(414) 277-5000

| | | | | |
|-----|-------------------------|--|---------------------------------------|--|
| 201 | FULL NAME OF INVENTOR | FAMILY NAME SEIDAH | FIRST GIVEN NAME Nabil | SECOND GIVEN NAME G |
| | RESIDENCE & CITIZENSHIP | CITY Ile-des-Soeurs | STATE OR COUNTRY Canada CAX | COUNTRY OF CITIZENSHIP Canada |
| | POST OFFICE ADDRESS | POST OFFICE ADDRESS 200 de Gaspé, Apt. 1412 | CITY Ile-des-Soeurs | STATE & ZIP CODE/COUNTRY CANADA H3E 1E6 |
| 202 | FULL NAME OF INVENTOR | FAMILY NAME CHRETIEN | FIRST GIVEN NAME Michel | SECOND GIVEN NAME |
| | RESIDENCE & CITIZENSHIP | CITY Outremont | STATE OR COUNTRY Canada CAX | COUNTRY OF CITIZENSHIP Canada |
| | POST OFFICE ADDRESS | POST OFFICE ADDRESS 195, chemin de la Cote-Ste-Catherine, Apt. 2208 | CITY Outremont | STATE & ZIP CODE/COUNTRY CANADA H2V 2B1 |
| 203 | FULL NAME OF INVENTOR | FAMILY NAME MARCINKIEWICZ | FIRST GIVEN NAME Mieczyslaw | SECOND GIVEN NAME |
| | RESIDENCE & CITIZENSHIP | CITY Outremont | STATE OR COUNTRY Canada CAX | COUNTRY OF CITIZENSHIP Canada |
| | POST OFFICE ADDRESS | POST OFFICE ADDRESS 6184, avenue Durocher | CITY Outremont | STATE & ZIP CODE/COUNTRY Canada H2V 3Y6 |

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.


SIGNATURE OF INVENTOR 201



DATE

17/08/2001


SIGNATURE OF INVENTOR 202



DATE

21/08/2001

SIGNATURE OF INVENTOR 203



DATE

20/08/2001

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

(Includes Reference to PCT International Applications)

ATTORNEY DOCKET NUMBER

480848.9002*

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application.

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:

| U.S. APPLICATIONS | | STATUS (Check One) | | |
|-------------------------|------------------|--------------------|-----------|---------|
| U.S. APPLICATION NUMBER | U.S. FILING DATE | PATENTED | ABANDONED | PENDING |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

PCT APPLICATIONS DESIGNATING THE U.S.

| PCT APPLICATION NUMBER | PCT FILING DATE | U.S. SERIAL NUMBERS | | | |
|------------------------|-----------------|---------------------|--|--|--|
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the U.S. Patent and Trademark Office connected therewith (List names and registration numbers):

Send Correspondence to:

Jean C. Baker

Quarles & Brady LLP

411 East Wisconsin Ave. Suite 2550



Milwaukee, WI 53202-4497

Direct Telephone Calls to:

(414) 277-5000

| | | | | |
|-----|-------------------------|---|---------------------------------------|--|
| 204 | FULL NAME OF INVENTOR | FAMILY NAME LAAKSONEN | FIRST GIVEN NAME Rejo | SECOND GIVEN NAME |
| | RESIDENCE & CITIZENSHIP | CITY Montreal | STATE OR COUNTRY Canada CAX | COUNTRY OF CITIZENSHIP Finland |
| | POST OFFICE ADDRESS | POST OFFICE ADDRESS 4566, avenue Hampton | CITY Montreal | STATE & ZIP CODE/COUNTRY CANADA H4A 2L4 |
| 205 | FULL NAME OF INVENTOR | FAMILY NAME DAVIGNON | FIRST GIVEN NAME Jean | SECOND GIVEN NAME |
| | RESIDENCE & CITIZENSHIP | CITY Outremont | STATE OR COUNTRY Canada CAX | COUNTRY OF CITIZENSHIP Canada |
| | POST OFFICE ADDRESS | POST OFFICE ADDRESS 768 Hartland Avenue | CITY Outremont | STATE & ZIP CODE/COUNTRY CANADA H2V 2X6 |
| 206 | FULL NAME OF INVENTOR | FAMILY NAME | FIRST GIVEN NAME | SECOND GIVEN NAME |
| | RESIDENCE & CITIZENSHIP | CITY | STATE OR COUNTRY | COUNTRY OF CITIZENSHIP |
| | POST OFFICE ADDRESS | POST OFFICE ADDRESS | CITY | STATE & ZIP CODE/COUNTRY |

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

| | | |
|--|--|--------------------------------|
| SIGNATURE OF INVENTOR 204  | SIGNATURE OF INVENTOR 205  | SIGNATURE OF INVENTOR 206 — |
| DATE 16 September 2001 | DATE 16 August 2001 | DATE — |

SEQUENCE LISTING

10 Nov 2001 18 OCT 2001

<110> Institut de Recherches Cliniques de Montreal
 SEIDAH, Nabil
 CHRÉTIEN, Michel
 MARCINKIEWICZ, Mieczyslaw
 LAAKSONEN, Reijo
 DAVIGNON, Jean

<120> MAMMALIAN SUBTILISIN/KEXIN ISOZYME SKI-1: A PROPROTEIN
 CONVERTASE WITH A UNIQUE CLEAVAGE SPECIFICITY

<130> IRCM

<140> PCT/CA99/01058

<141> 1999-11-04

<150> CA 2,249,648

<151> 1998-11-04

<160> 76

<170> PatentIn Ver. 2.1

<210> 1

<211> 3895

<212> DNA

<213> Rattus sp.

<220>

<221> CDS

<222> (418)..(3573)

<400> 1

gcgagtaaac atcccccgaa tggatacccg aggcgtgttc gcggcggagg ccccgttttc 60

ccgggtccgc cgatcccag cctgaggcga cgcagatcgg ctgagagcgg tggcttgggc 120

tcctgctaga tttgggtctg tggtaaaaat ggagtttagg actcagtgga ctcgcccta 180

atgagagaag cccctgtcc aagatggaga agaagcggag aaagaaatga aagcctcttt 240

ttgggccaag ctgtgggtga ccatgggact gaggttttct ttacgttga caagtctgta 300

ggatggctga tcagtaaggt tgcagctttt agcgaaaaca gaaatccact tctgatcaag 360

gaagagccta gtgcaatttg aatttatgca attttatgac catattcact taggacc 417

| | |
|---|-----|
| atg aag ctc gtc aac atc tgg ctt ctt ctg ctg gtg gtt ttg ctc tgt | 465 |
| Met Lys Leu Val Asn Ile Trp Leu Leu Leu Leu Val Val Leu Leu Cys | |
| 1 5 10 15 | |
| ggg aaa aag cat ctg ggt gac agg ctg ggg aag aaa gct ttt gaa aag | 513 |
| Gly Lys Lys His Leu Gly Asp Arg Leu Gly Lys Lys Ala Phe Glu Lys | |
| 20 25 30 | |
| gcc cca tgc ccc agc tgt tcc cac ctg act ttg aag gtg gaa ttc tcc | 561 |
| Ala Pro Cys Pro Ser Cys Ser His Leu Thr Leu Lys Val Glu Phe Ser | |
| 35 40 45 | |
| tca act gtg gtg gaa tat gaa tat att gtg gct ttc aac gga tac ttc | 609 |
| Ser Thr Val Val Glu Tyr Glu Tyr Ile Val Ala Phe Asn Gly Tyr Phe | |
| 50 55 60 | |
| aca gcc aaa gct aga aac tca ttt att tca agt gct cta aaa agc agt | 657 |
| Thr Ala Lys Ala Arg Asn Ser Phe Ile Ser Ser Ala Leu Lys Ser Ser | |
| 65 70 75 80 | |
| gaa gtg gac aac tgg aga ata ata cct cgg aac aac cca tct agt gac | 705 |
| Glu Val Asp Asn Trp Arg Ile Ile Pro Arg Asn Asn Pro Ser Ser Asp | |
| 85 90 95 | |
| tac cct agt gat ttt gag gtg att cag ata aaa gag aag cag aag gcg | 753 |
| Tyr Pro Ser Asp Phe Glu Val Ile Gln Ile Lys Glu Lys Gln Lys Ala | |
| 100 105 110 | |
| ggg ctg ctc aca ctt gaa gat cac cca aac atc aag cgg gtg aca ccc | 801 |
| Gly Leu Leu Thr Leu Glu Asp His Pro Asn Ile Lys Arg Val Thr Pro | |
| 115 120 125 | |
| cag cgg aaa gtc ttt cgt tcc ctg aag ttt gct gaa tcc gac ccc att | 849 |
| Gln Arg Lys Val Phe Arg Ser Leu Lys Phe Ala Glu Ser Asp Pro Ile | |
| 130 135 140 | |
| gtg ccc tgt aat gag acc cgg tgg agc cag aag tgg cag tca tca cgt | 897 |
| Val Pro Cys Asn Glu Thr Arg Trp Ser Gln Lys Trp Gln Ser Ser Arg | |
| 145 150 155 160 | |
| ccc ctg aaa aga gcc agt ctc tcc ctg ggc tct gga ttc tgg cat gca | 945 |
| Pro Leu Lys Arg Ala Ser Leu Ser Leu Gly Ser Gly Phe Trp His Ala | |
| 165 170 175 | |
| aca gga agg cat tca agt cga cga ttg ctg aga gcc att cct cgc cag | 993 |
| Thr Gly Arg His Ser Ser Arg Arg Leu Leu Arg Ala Ile Pro Arg Gln | |
| 180 185 190 | |

| | |
|---|------|
| gtt gcc cag aca ttg cag gca gat gtg ctt tgg cag atg gga tac aca | 1041 |
| Val Ala Gln Thr Leu Gln Ala Asp Val Leu Trp Gln Met Gly Tyr Thr | |
| 195 200 205 | |
| ggt gct aat gtc agg gtt gcc gtt ttt gat act ggg ctc agt gag aag | 1089 |
| Gly Ala Asn Val Arg Val Ala Val Phe Asp Thr Gly Leu Ser Glu Lys | |
| 210 215 220 | |
| cat cca cat ttc aag aat gtg aag gaa aga acc aac tgg acc aat gag | 1137 |
| His Pro His Phe Lys Asn Val Lys Glu Arg Thr Asn Trp Thr Asn Glu | |
| 225 230 235 240 | |
| cgg acc ctg gac gat ggg ctg ggc cat ggc aca ttc gtt gca ggt gtg | 1185 |
| Arg Thr Leu Asp Asp Gly Leu Gly His Gly Thr Phe Val Ala Gly Val | |
| 245 250 255 | |
| att gcc agc atg aga gag tgc caa gga ttt gcc cca gat gca gag ctg | 1233 |
| Ile Ala Ser Met Arg Glu Cys Gln Gly Phe Ala Pro Asp Ala Glu Leu | |
| 260 265 270 | |
| cac atc ttc agg gtc ttt acc aac aat cag gtg tct tac acg tct tgg | 1281 |
| His Ile Phe Arg Val Phe Thr Asn Asn Gln Val Ser Tyr Thr Ser Trp | |
| 275 280 285 | |
| ttt ttg gat gcc ttc aac tat gcc atc cta aag aag atg gac gtt ctg | 1329 |
| Phe Leu Asp Ala Phe Asn Tyr Ala Ile Leu Lys Lys Met Asp Val Leu | |
| 290 295 300 | |
| aac ctt agc atc ggt ggg cct gac ttc atg gat cac ccc ttt gtt gac | 1377 |
| Asn Leu Ser Ile Gly Gly Pro Asp Phe Met Asp His Pro Phe Val Asp | |
| 305 310 315 320 | |
| aag gta tgg gaa tta aca gcg aac aat gta atc atg gtt tct gct att | 1425 |
| Lys Val Trp Glu Leu Thr Ala Asn Asn Val Ile Met Val Ser Ala Ile | |
| 325 330 335 | |
| ggc aat gat gga cct ctc tat ggc act ctg aat aac cct gct gat cag | 1473 |
| Gly Asn Asp Gly Pro Leu Tyr Gly Thr Leu Asn Asn Pro Ala Asp Gln | |
| 340 345 350 | |
| atg gat gtg att gga gtg ggt ggc att gac ttt gaa gac aac atc gcc | 1521 |
| Met Asp Val Ile Gly Val Gly Gly Ile Asp Phe Glu Asp Asn Ile Ala | |
| 355 360 365 | |
| cgc ttc tct tcc agg gga atg act acc tgg gaa cta ccg gga ggc tat | 1569 |
| Arg Phe Ser Ser Arg Gly Met Thr Thr Trp Glu Leu Pro Gly Gly Tyr | |
| 370 375 380 | |

| | |
|---|------|
| ggt cgt gtg aag cct gac att gtc acc tat ggt gct gga gtg cgg ggt | 1617 |
| Gly Arg Val Lys Pro Asp Ile Val Thr Tyr Gly Ala Gly Val Arg Gly | |
| 385 390 395 400 | |
| tct ggt gtg aaa ggg ggc tgc cgt gca ctc tca ggg acc agt gtc gcc | 1665 |
| Ser Gly Val Lys Gly Gly Cys Arg Ala Leu Ser Gly Thr Ser Val Ala | |
| 405 410 415 | |
| tcc cca gtg gtt gct ggg gct gtc acc ttg tta gta agc aca gta cag | 1713 |
| Ser Pro Val Val Ala Gly Ala Val Thr Leu Leu Val Ser Thr Val Gln | |
| 420 425 430 | |
| aag cgg gag cta gtg aat cct gcc agt gtg aag caa gct ttg ata gca | 1761 |
| Lys Arg Glu Leu Val Asn Pro Ala Ser Val Lys Gln Ala Leu Ile Ala | |
| 435 440 445 | |
| tca gcc cgg aga ctt cct ggt gtc aac atg ttt gag caa ggc cat ggc | 1809 |
| Ser Ala Arg Arg Leu Pro Gly Val Asn Met Phe Glu Gln Gly His Gly | |
| 450 455 460 | |
| aag ttg gat cta ctg cga gcc tat cag atc ctc agc agc tat aaa ccg | 1857 |
| Lys Leu Asp Leu Leu Arg Ala Tyr Gln Ile Leu Ser Ser Tyr Lys Pro | |
| 465 470 475 480 | |
| cag gcg agc ctg agt cct agc tac atc gac ctg act gag tgt ccc tac | 1905 |
| Gln Ala Ser Leu Ser Pro Ser Tyr Ile Asp Leu Thr Glu Cys Pro Tyr | |
| 485 490 495 | |
| atg tgg ccc tac tgc tcc cag ccc atc tac tat gga gga atg cca aca | 1953 |
| Met Trp Pro Tyr Cys Ser Gln Pro Ile Tyr Tyr Gly Gly Met Pro Thr | |
| 500 505 510 | |
| att gtt aat gtc acc atc ctc aat ggc atg gga gtt aca gga aga att | 2001 |
| Ile Val Asn Val Thr Ile Leu Asn Gly Met Gly Val Thr Gly Arg Ile | |
| 515 520 525 | |
| gtg gat aag cct gag tgg cga ccc tat tta cca cag aat gga gac aac | 2049 |
| Val Asp Lys Pro Glu Trp Arg Pro Tyr Leu Pro Gln Asn Gly Asp Asn | |
| 530 535 540 | |
| att gaa gtg gcc ttc tcc tac tcc tca gtg ttg tgg cct tgg tca ggt | 2097 |
| Ile Glu Val Ala Phe Ser Tyr Ser Ser Val Leu Trp Pro Trp Ser Gly | |
| 545 550 555 560 | |
| tac ctt gcc atc tcc att tct gtg acc aag aag gca gct tcc tgg gaa | 2145 |
| Tyr Leu Ala Ile Ser Ile Ser Val Thr Lys Lys Ala Ala Ser Trp Glu | |
| 565 570 575 | |

| | |
|---|------|
| ggc atc gcg cag ggc cac atc atg atc aca gtg gct tcc cca gca gag | 2193 |
| Gly Ile Ala Gln Gly His Ile Met Ile Thr Val Ala Ser Pro Ala Glu | |
| 580 585 590 | |
| acg gaa tta aaa aat ggt gcc gag cat act tcc aca gtg aag ctg ccc | 2241 |
| Thr Glu Leu Lys Asn Gly Ala Glu His Thr Ser Thr Val Lys Leu Pro | |
| 595 600 605 | |
| atc aag gtg aag atc att ccc acc cct cct cgg agc aag aga gtc ctc | 2289 |
| Ile Lys Val Lys Ile Ile Pro Thr Pro Pro Arg Ser Lys Arg Val Leu | |
| 610 615 620 | |
| tgg gac cag tac cac aac ctc cgc tac cca ccc ggc tac ttc ccc agg | 2337 |
| Trp Asp Gln Tyr His Asn Leu Arg Tyr Pro Pro Gly Tyr Phe Pro Arg | |
| 625 630 635 640 | |
| gac aac ttg cgg atg aag aat gat cct tta gac tgg aat ggc gac cac | 2385 |
| Asp Asn Leu Arg Met Lys Asn Asp Pro Leu Asp Trp Asn Gly Asp His | |
| 645 650 655 | |
| gtc cac acc aac ttc agg gac atg tac cag cat ctg cgc agc atg ggc | 2433 |
| Val His Thr Asn Phe Arg Asp Met Tyr Gln His Leu Arg Ser Met Gly | |
| 660 665 670 | |
| tac ttt gtg gag gtg ctt ggt gcc cca ttc aca tgc ttt gac gcc acg | 2481 |
| Tyr Phe Val Glu Val Leu Gly Ala Pro Phe Thr Cys Phe Asp Ala Thr | |
| 675 680 685 | |
| cag tac ggc act ctg ctt atg gtg gac agt gag gaa gag tac ttc cct | 2529 |
| Gln Tyr Gly Thr Leu Leu Met Val Asp Ser Glu Glu Glu Tyr Phe Pro | |
| 690 695 700 | |
| gag gag att gct aag ctg agg agg gac gtg gac aat ggc ctt tcc ctt | 2577 |
| Glu Glu Ile Ala Lys Leu Arg Arg Asp Val Asp Asn Gly Leu Ser Leu | |
| 705 710 715 720 | |
| gtc gtc ttc agt gac tgg tac aac act tct gtt atg aga aaa gtg aag | 2625 |
| Val Val Phe Ser Asp Trp Tyr Asn Thr Ser Val Met Arg Lys Val Lys | |
| 725 730 735 | |
| ttt tac gat gaa aac aca agg cag tgg tgg atg cca gat act gga gga | 2673 |
| Phe Tyr Asp Glu Asn Thr Arg Gln Trp Trp Met Pro Asp Thr Gly Gly | |
| 740 745 750 | |
| gcc aac gtc cca gct cta aac gag ctg ctg tct gtg tgg aac atg ggg | 2721 |
| Ala Asn Val Pro Ala Leu Asn Glu Leu Leu Ser Val Trp Asn Met Gly | |
| 755 760 765 | |

| | |
|---|------|
| ttc agt gac ggc ctg tat gaa ggg gag ttt gcc ctg gca aac cac gac | 2769 |
| Phe Ser Asp Gly Leu Tyr Glu Gly Glu Phe Ala Leu Ala Asn His Asp | |
| 770 775 780 | |
| atg tac tat gca tcg ggg tgc agc att gcc agg ttt cca gaa gat ggt | 2817 |
| Met Tyr Tyr Ala Ser Gly Cys Ser Ile Ala Arg Phe Pro Glu Asp Gly | |
| 785 790 795 800 | |
| gtg gtg atc aca cag act ttc aag gac caa gga ttg gaa gtc tta aaa | 2865 |
| Val Val Ile Thr Gln Thr Phe Lys Asp Gln Gly Leu Glu Val Leu Lys | |
| 805 810 815 | |
| caa gag aca gca gtt gtc gac aat gtc ccc att ctg ggg cta tat cag | 2913 |
| Gln Glu Thr Ala Val Val Asp Asn Val Pro Ile Leu Gly Leu Tyr Gln | |
| 820 825 830 | |
| att cca gct gaa ggt gga ggc cgg att gtg ctg tat gga gac tcc aac | 2961 |
| Ile Pro Ala Glu Gly Gly Gly Arg Ile Val Leu Tyr Gly Asp Ser Asn | |
| 835 840 845 | |
| tgc ttg gat gac agt cac aga cag aag gac tgc ttt tgg ctt ctg gat | 3009 |
| Cys Leu Asp Asp Ser His Arg Gln Lys Asp Cys Phe Trp Leu Leu Asp | |
| 850 855 860 | |
| gca ctc ctt cag tac aca tcc tat ggt gtg acc cct ccc agc ctc agc | 3057 |
| Ala Leu Leu Gln Tyr Thr Ser Tyr Gly Val Thr Pro Pro Ser Leu Ser | |
| 865 870 875 880 | |
| cat tca ggg aac cgg cag cgc cca ccc agc ggg gct ggc ttg gcc cct | 3105 |
| His Ser Gly Asn Arg Gln Arg Pro Pro Ser Gly Ala Gly Leu Ala Pro | |
| 885 890 895 | |
| cct gaa agg atg gaa gga aac cac ctt cat cgc tac tcc aaa gtt ctt | 3153 |
| Pro Glu Arg Met Glu Gly Asn His Leu His Arg Tyr Ser Lys Val Leu | |
| 900 905 910 | |
| gag gcc cac ttg gga gac ccg aaa cct cgg ccc ctt cca gcc tgt cca | 3201 |
| Glu Ala His Leu Gly Asp Pro Lys Pro Arg Pro Leu Pro Ala Cys Pro | |
| 915 920 925 | |
| cac ttg tcg tgg gcc aag cca cag cct ttg aat gag acg gca ccc agt | 3249 |
| His Leu Ser Trp Ala Lys Pro Gln Pro Leu Asn Glu Thr Ala Pro Ser | |
| 930 935 940 | |
| aat ctt tgg aaa cac cag aag ctg ctc tcc att gac ctg gac aaa gta | 3297 |
| Asn Leu Trp Lys His Gln Lys Leu Leu Ser Ile Asp Leu Asp Lys Val | |
| 945 950 955 960 | |

gtg tta ccc aac ttt cgc tca aat cgc cct caa gtg aga cct ttg tcc 3345
 Val Leu Pro Asn Phe Arg Ser Asn Arg Pro Gln Val Arg Pro Leu Ser
 965 970 975

 cct gga gaa agt ggt gcc tgg gac att cct gga ggg atc atg cct ggc 3393
 Pro Gly Glu Ser Gly Ala Trp Asp Ile Pro Gly Gly Ile Met Pro Gly
 980 985 990

 cgc tac aac cag gaa gta ggc cag acc atc cct gtt ttt gcc ttc ctt 3441
 Arg Tyr Asn Gln Glu Val Gly Gln Thr Ile Pro Val Phe Ala Phe Leu
 995 1000 1005

 gga gcc atg gtg gcc ctg gcc ttc ttc gtg gta cag atc agt aag gcc 3489
 Gly Ala Met Val Ala Leu Ala Phe Phe Val Val Gln Ile Ser Lys Ala
 1010 1015 1020

 aag agc cgg ccg aag cgg agg agg ccc agg gca aag cgt cca caa ctt 3537
 Lys Ser Arg Pro Lys Arg Arg Arg Pro Arg Ala Lys Arg Pro Gln Leu
 1025 1030 1035 1040

 gca cag cag gcc cac cct gca agg acc ccg tca gtg tgatcatcac 3583
 Ala Gln Gln Ala His Pro Ala Arg Thr Pro Ser Val
 1045 1050

 agtggccaga cacagaagct gacaagcttt gaaccctct ggtggccaca cagcatcaga 3643
 gagcatcctg ggaagtgcct gtttccaagg agccctatct ctggattgtg gctggcttag 3703
 tgtgttctgc ccagacgtct atgaggtaca tctgcagtg cctcactgtg tttggctctg 3763
 gccgaagggtg cccagtagct cagcctccgg tggcatcagg cccagtgaca gtgcaccaaa 3823
 gacacagagc ctggaagggc tgtcgggaca tactttctac ataatgctac aaccctgacc 3883
 aagcgaagac at 3895

<210> 2
 <211> 1052
 <212> PRT
 <213> Rattus sp.

<400> 2
 Met Lys Leu Val Asn Ile Trp Leu Leu Leu Leu Val Val Leu Leu Cys
 1 5 10 15
 Gly Lys Lys His Leu Gly Asp Arg Leu Gly Lys Lys Ala Phe Glu Lys
 20 25 30

Ala Pro Cys Pro Ser Cys Ser His Leu Thr Leu Lys Val Glu Phe Ser
 35 40 45
 Ser Thr Val Val Glu Tyr Glu Tyr Ile Val Ala Phe Asn Gly Tyr Phe
 50 55 60
 Thr Ala Lys Ala Arg Asn Ser Phe Ile Ser Ser Ala Leu Lys Ser Ser
 65 70 75 80
 Glu Val Asp Asn Trp Arg Ile Ile Pro Arg Asn Asn Pro Ser Ser Asp
 85 90 95
 Tyr Pro Ser Asp Phe Glu Val Ile Gln Ile Lys Glu Lys Gln Lys Ala
 100 105 110
 Gly Leu Leu Thr Leu Glu Asp His Pro Asn Ile Lys Arg Val Thr Pro
 115 120 125
 Gln Arg Lys Val Phe Arg Ser Leu Lys Phe Ala Glu Ser Asp Pro Ile
 130 135 140
 Val Pro Cys Asn Glu Thr Arg Trp Ser Gln Lys Trp Gln Ser Ser Arg
 145 150 155 160
 Pro Leu Lys Arg Ala Ser Leu Ser Leu Gly Ser Gly Phe Trp His Ala
 165 170 175
 Thr Gly Arg His Ser Ser Arg Arg Leu Leu Arg Ala Ile Pro Arg Gln
 180 185 190
 Val Ala Gln Thr Leu Gln Ala Asp Val Leu Trp Gln Met Gly Tyr Thr
 195 200 205
 Gly Ala Asn Val Arg Val Ala Val Phe Asp Thr Gly Leu Ser Glu Lys
 210 215 220
 His Pro His Phe Lys Asn Val Lys Glu Arg Thr Asn Trp Thr Asn Glu
 225 230 235 240
 Arg Thr Leu Asp Asp Gly Leu Gly His Gly Thr Phe Val Ala Gly Val
 245 250 255
 Ile Ala Ser Met Arg Glu Cys Gln Gly Phe Ala Pro Asp Ala Glu Leu
 260 265 270
 His Ile Phe Arg Val Phe Thr Asn Asn Gln Val Ser Tyr Thr Ser Trp
 275 280 285

| | | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Phe | Leu | Asp | Ala | Phe | Asn | Tyr | Ala | Ile | Leu | Lys | Lys | Met | Asp | Val | Leu | 290 | 295 | 300 | |
| Asn | Leu | Ser | Ile | Gly | Gly | Pro | Asp | Phe | Met | Asp | His | Pro | Phe | Val | Asp | 305 | 310 | 315 | 320 |
| Lys | Val | Trp | Glu | Leu | Thr | Ala | Asn | Asn | Val | Ile | Met | Val | Ser | Ala | Ile | 325 | 330 | 335 | |
| Gly | Asn | Asp | Gly | Pro | Leu | Tyr | Gly | Thr | Leu | Asn | Asn | Pro | Ala | Asp | Gln | 340 | 345 | 350 | |
| Met | Asp | Val | Ile | Gly | Val | Gly | Gly | Ile | Asp | Phe | Glu | Asp | Asn | Ile | Ala | 355 | 360 | 365 | |
| Arg | Phe | Ser | Ser | Arg | Gly | Met | Thr | Thr | Trp | Glu | Leu | Pro | Gly | Gly | Tyr | 370 | 375 | 380 | |
| Gly | Arg | Val | Lys | Pro | Asp | Ile | Val | Thr | Tyr | Gly | Ala | Gly | Val | Arg | Gly | 385 | 390 | 395 | 400 |
| Ser | Gly | Val | Lys | Gly | Gly | Cys | Arg | Ala | Leu | Ser | Gly | Thr | Ser | Val | Ala | 405 | 410 | 415 | |
| Ser | Pro | Val | Val | Ala | Gly | Ala | Val | Thr | Leu | Leu | Val | Ser | Thr | Val | Gln | 420 | 425 | 430 | |
| Lys | Arg | Glu | Leu | Val | Asn | Pro | Ala | Ser | Val | Lys | Gln | Ala | Leu | Ile | Ala | 435 | 440 | 445 | |
| Ser | Ala | Arg | Arg | Leu | Pro | Gly | Val | Asn | Met | Phe | Glu | Gln | Gly | His | Gly | 450 | 455 | 460 | |
| Lys | Leu | Asp | Leu | Leu | Arg | Ala | Tyr | Gln | Ile | Leu | Ser | Ser | Tyr | Lys | Pro | 465 | 470 | 475 | 480 |
| Gln | Ala | Ser | Leu | Ser | Pro | Ser | Tyr | Ile | Asp | Leu | Thr | Glu | Cys | Pro | Tyr | 485 | 490 | 495 | |
| Met | Trp | Pro | Tyr | Cys | Ser | Gln | Pro | Ile | Tyr | Tyr | Gly | Gly | Met | Pro | Thr | 500 | 505 | 510 | |
| Ile | Val | Asn | Val | Thr | Ile | Leu | Asn | Gly | Met | Gly | Val | Thr | Gly | Arg | Ile | 515 | 520 | 525 | |
| Val | Asp | Lys | Pro | Glu | Trp | Arg | Pro | Tyr | Leu | Pro | Gln | Asn | Gly | Asp | Asn | 530 | 535 | 540 | |

| | | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Glu | Val | Ala | Phe | Ser | Tyr | Ser | Ser | Val | Leu | Trp | Pro | Trp | Ser | Gly | 545 | 550 | 555 | 560 |
| Tyr | Leu | Ala | Ile | Ser | Ile | Ser | Val | Thr | Lys | Lys | Ala | Ala | Ser | Trp | Glu | 565 | 570 | 575 | |
| Gly | Ile | Ala | Gln | Gly | His | Ile | Met | Ile | Thr | Val | Ala | Ser | Pro | Ala | Glu | 580 | 585 | 590 | |
| Thr | Glu | Leu | Lys | Asn | Gly | Ala | Glu | His | Thr | Ser | Thr | Val | Lys | Leu | Pro | 595 | 600 | 605 | |
| Ile | Lys | Val | Lys | Ile | Ile | Pro | Thr | Pro | Pro | Arg | Ser | Lys | Arg | Val | Leu | 610 | 615 | 620 | |
| Trp | Asp | Gln | Tyr | His | Asn | Leu | Arg | Tyr | Pro | Pro | Gly | Tyr | Phe | Pro | Arg | 625 | 630 | 635 | 640 |
| Asp | Asn | Leu | Arg | Met | Lys | Asn | Asp | Pro | Leu | Asp | Trp | Asn | Gly | Asp | His | 645 | 650 | 655 | |
| Val | His | Thr | Asn | Phe | Arg | Asp | Met | Tyr | Gln | His | Leu | Arg | Ser | Met | Gly | 660 | 665 | 670 | |
| Tyr | Phe | Val | Glu | Val | Leu | Gly | Ala | Pro | Phe | Thr | Cys | Phe | Asp | Ala | Thr | 675 | 680 | 685 | |
| Gln | Tyr | Gly | Thr | Leu | Leu | Met | Val | Asp | Ser | Glu | Glu | Glu | Tyr | Phe | Pro | 690 | 695 | 700 | |
| Glu | Glu | Ile | Ala | Lys | Leu | Arg | Arg | Asp | Val | Asp | Asn | Gly | Leu | Ser | Leu | 705 | 710 | 715 | 720 |
| Val | Val | Phe | Ser | Asp | Trp | Tyr | Asn | Thr | Ser | Val | Met | Arg | Lys | Val | Lys | 725 | 730 | 735 | |
| Phe | Tyr | Asp | Glu | Asn | Thr | Arg | Gln | Trp | Trp | Met | Pro | Asp | Thr | Gly | Gly | 740 | 745 | 750 | |
| Ala | Asn | Val | Pro | Ala | Leu | Asn | Glu | Leu | Leu | Ser | Val | Trp | Asn | Met | Gly | 755 | 760 | 765 | |
| Phe | Ser | Asp | Gly | Leu | Tyr | Glu | Gly | Glu | Phe | Ala | Leu | Ala | Asn | His | Asp | 770 | 775 | 780 | |
| Met | Tyr | Tyr | Ala | Ser | Gly | Cys | Ser | Ile | Ala | Arg | Phe | Pro | Glu | Asp | Gly | 785 | 790 | 795 | 800 |

| | | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|------|------|------|
| Val | Val | Ile | Thr | Gln | Thr | Phe | Lys | Asp | Gln | Gly | Leu | Glu | Val | Leu | Lys | 805 | 810 | 815 | |
| Gln | Glu | Thr | Ala | Val | Val | Asp | Asn | Val | Pro | Ile | Leu | Gly | Leu | Tyr | Gln | 820 | 825 | 830 | |
| Ile | Pro | Ala | Glu | Gly | Gly | Gly | Arg | Ile | Val | Leu | Tyr | Gly | Asp | Ser | Asn | 835 | 840 | 845 | |
| Cys | Leu | Asp | Asp | Ser | His | Arg | Gln | Lys | Asp | Cys | Phe | Trp | Leu | Leu | Asp | 850 | 855 | 860 | |
| Ala | Leu | Leu | Gln | Tyr | Thr | Ser | Tyr | Gly | Val | Thr | Pro | Pro | Ser | Leu | Ser | 865 | 870 | 875 | 880 |
| His | Ser | Gly | Asn | Arg | Gln | Arg | Pro | Pro | Ser | Gly | Ala | Gly | Leu | Ala | Pro | 885 | 890 | 895 | |
| Pro | Glu | Arg | Met | Glu | Gly | Asn | His | Leu | His | Arg | Tyr | Ser | Lys | Val | Leu | 900 | 905 | 910 | |
| Glu | Ala | His | Leu | Gly | Asp | Pro | Lys | Pro | Arg | Pro | Leu | Pro | Ala | Cys | Pro | 915 | 920 | 925 | |
| His | Leu | Ser | Trp | Ala | Lys | Pro | Gln | Pro | Leu | Asn | Glu | Thr | Ala | Pro | Ser | 930 | 935 | 940 | |
| Asn | Leu | Trp | Lys | His | Gln | Lys | Leu | Leu | Ser | Ile | Asp | Leu | Asp | Lys | Val | 945 | 950 | 955 | 960 |
| Val | Leu | Pro | Asn | Phe | Arg | Ser | Asn | Arg | Pro | Gln | Val | Arg | Pro | Leu | Ser | 965 | 970 | 975 | |
| Pro | Gly | Glu | Ser | Gly | Ala | Trp | Asp | Ile | Pro | Gly | Gly | Ile | Met | Pro | Gly | 980 | 985 | 990 | |
| Arg | Tyr | Asn | Gln | Glu | Val | Gly | Gln | Thr | Ile | Pro | Val | Phe | Ala | Phe | Leu | 995 | 1000 | 1005 | |
| Gly | Ala | Met | Val | Ala | Leu | Ala | Phe | Phe | Val | Val | Gln | Ile | Ser | Lys | Ala | 1010 | 1015 | 1020 | |
| Lys | Ser | Arg | Pro | Lys | Arg | Arg | Arg | Pro | Arg | Ala | Lys | Arg | Pro | Gln | Leu | 1025 | 1030 | 1035 | 1040 |
| Ala | Gln | Gln | Ala | His | Pro | Ala | Arg | Thr | Pro | Ser | Val | | | | | 1045 | 1050 | | |

<210> 3
 <211> 3788
 <212> DNA
 <213> Mus sp.

<220>
 <221> CDS
 <222> (8)..(3163)

<400> 3

| | |
|---|-----|
| gcattcc atg aag ctc gtc agc acc tgg ctt ctt gtg ctg gtg gtt ttg | 49 |
| Met Lys Leu Val Ser Thr Trp Leu Leu Val Leu Val Val Leu | |
| 1 5 10 | |
| ctc tgt ggg aaa cgg cac ctg ggc gac agg ctg ggg acg aga gct ttg | 97 |
| Leu Cys Gly Lys Arg His Leu Gly Asp Arg Leu Gly Thr Arg Ala Leu | |
| 15 20 25 30 | |
| gaa aag gcc ccg tgc ccc agc tgc tcc cac ctg act ttg aag gtg gaa | 145 |
| Glu Lys Ala Pro Cys Pro Ser Cys Ser His Leu Thr Leu Lys Val Glu | |
| 35 40 45 | |
| ttc tct tca act gtg gtg gag tac gaa tat att gtg gct ttc aac gga | 193 |
| Phe Ser Ser Thr Val Val Glu Tyr Glu Tyr Ile Val Ala Phe Asn Gly | |
| 50 55 60 | |
| tac ttc aca gcc aaa gct aga aac tca ttt att tca agt gcg ctg aaa | 241 |
| Tyr Phe Thr Ala Lys Ala Arg Asn Ser Phe Ile Ser Ser Ala Leu Lys | |
| 65 70 75 | |
| agc agt gaa gtg gaa aac tgg aga ata ata cct cgg aac aac cca tcc | 289 |
| Ser Ser Glu Val Glu Asn Trp Arg Ile Ile Pro Arg Asn Asn Pro Ser | |
| 80 85 90 | |
| agt gac tac cct agt gat ttt gag gtg att cag ata aaa gag aag cag | 337 |
| Ser Asp Tyr Pro Ser Asp Phe Glu Val Ile Gln Ile Lys Glu Lys Gln | |
| 95 100 105 110 | |
| aag gcg ggg ctg ctc aca ctt gaa gat cac ccc aac atc aag cgg gtg | 385 |
| Lys Ala Gly Leu Leu Thr Leu Glu Asp His Pro Asn Ile Lys Arg Val | |
| 115 120 125 | |
| aca ccc cag cgg aaa gtc ttt cgt tcc ctc aag ttt gct gaa tcc aac | 433 |
| Thr Pro Gln Arg Lys Val Phe Arg Ser Leu Lys Phe Ala Glu Ser Asn | |
| 130 135 140 | |

| | |
|---|------|
| ccc atc gtg ccc tgt aat gaa acc cgg tgg agc cag aag tgg cag tca | 481 |
| Pro Ile Val Pro Cys Asn Glu Thr Arg Trp Ser Gln Lys Trp Gln Ser | |
| 145 150 155 | |
| tca cgt ccc ctg aaa aga gcc agt ctc tcc ctg ggc tct gga ttc tgg | 529 |
| Ser Arg Pro Leu Lys Arg Ala Ser Leu Ser Leu Gly Ser Gly Phe Trp | |
| 160 165 170 | |
| cat gca aca gga aga cat tca agt cgg cga ttg ctg aga gcc att cct | 577 |
| His Ala Thr Gly Arg His Ser Ser Arg Arg Leu Leu Arg Ala Ile Pro | |
| 175 180 185 190 | |
| cgc cag gtc gcc cag aca ctg cag gca gat gtg ctg tgg cag atg gga | 625 |
| Arg Gln Val Ala Gln Thr Leu Gln Ala Asp Val Leu Trp Gln Met Gly | |
| 195 200 205 | |
| tac aca ggt gct aat gtc aga gtt gct gtt ttt gat act ggg ctc agt | 673 |
| Tyr Thr Gly Ala Asn Val Arg Val Ala Val Phe Asp Thr Gly Leu Ser | |
| 210 215 220 | |
| gag aag cat ccg cat ttt aag aat gtg aag gag aga acc aac tgg acc | 721 |
| Glu Lys His Pro His Phe Lys Asn Val Lys Glu Arg Thr Asn Trp Thr | |
| 225 230 235 | |
| aat gag cgg acc ctg gat gat ggg cta ggc cat ggc aca ttc gtt gca | 769 |
| Asn Glu Arg Thr Leu Asp Asp Gly Leu Gly His Gly Thr Phe Val Ala | |
| 240 245 250 | |
| ggg gtg att gcc agc atg agg gag tgc caa gga ttt gct cca gat gca | 817 |
| Gly Val Ile Ala Ser Met Arg Glu Cys Gln Gly Phe Ala Pro Asp Ala | |
| 255 260 265 270 | |
| gag ctg cac atc ttc agg gtc ttt acc aac aat cag gtg tct tac aca | 865 |
| Glu Leu His Ile Phe Arg Val Phe Thr Asn Asn Gln Val Ser Tyr Thr | |
| 275 280 285 | |
| tct tgg ttt ctg gat gcc ttc aac tat gcc atc cta aag aag atg gac | 913 |
| Ser Trp Phe Leu Asp Ala Phe Asn Tyr Ala Ile Leu Lys Lys Met Asp | |
| 290 295 300 | |
| gtt ctc aac ctt agc atc ggt ggg ccc gac ttc atg gat cat ccg ttt | 961 |
| Val Leu Asn Leu Ser Ile Gly Gly Pro Asp Phe Met Asp His Pro Phe | |
| 305 310 315 | |
| gtt gac aag gtg tgg gaa tta aca gct aac aat gta att atg gtt tct | 1009 |
| Val Asp Lys Val Trp Glu Leu Thr Ala Asn Asn Val Ile Met Val Ser | |
| 320 325 330 | |

| | |
|---|------|
| gct att ggc aat gat gga cct ctc tat ggc act ctg aat aac cct gct | 1057 |
| Ala Ile Gly Asn Asp Gly Pro Leu Tyr Gly Thr Leu Asn Asn Pro Ala | |
| 335 340 345 350 | |
| gat cag atg gat gtg att gga gtg ggt ggc att gac ttt gaa gat aac | 1105 |
| Asp Gln Met Asp Val Ile Gly Val Gly Gly Ile Asp Phe Glu Asp Asn | |
| 355 360 365 | |
| atc gct cgc ttt tct tcc agg gga atg act acc tgg gaa tta cca gga | 1153 |
| Ile Ala Arg Phe Ser Ser Arg Gly Met Thr Thr Trp Glu Leu Pro Gly | |
| 370 375 380 | |
| ggc tat ggt cgt gtg aag cct gac att gtc acc tat ggt gct gga gtg | 1201 |
| Gly Tyr Gly Arg Val Lys Pro Asp Ile Val Thr Tyr Gly Ala Gly Val | |
| 385 390 395 | |
| cgg ggt tcc ggt gtg aaa ggg ggc tgc cgt gca ctc tca ggg acc agt | 1249 |
| Arg Gly Ser Gly Val Lys Gly Gly Cys Arg Ala Leu Ser Gly Thr Ser | |
| 400 405 410 | |
| gtc gct tcc cca gtg gtc gct ggg gcc gtc acc ttg tta gta agc aca | 1297 |
| Val Ala Ser Pro Val Val Ala Gly Ala Val Thr Leu Leu Val Ser Thr | |
| 415 420 425 430 | |
| gta cag aag cgg gag ctg gtg aat cct gcc agt gtg aag caa gct ttg | 1345 |
| Val Gln Lys Arg Glu Leu Val Asn Pro Ala Ser Val Lys Gln Ala Leu | |
| 435 440 445 | |
| ata gcg tca gcc cgg aga ctt cct ggg gtc aac atg ttc gag caa ggt | 1393 |
| Ile Ala Ser Ala Arg Arg Leu Pro Gly Val Asn Met Phe Glu Gln Gly | |
| 450 455 460 | |
| cat ggc aag ttg gat ctg ctg cga gct tat cag atc ctc agc agc tat | 1441 |
| His Gly Lys Leu Asp Leu Leu Arg Ala Tyr Gln Ile Leu Ser Ser Tyr | |
| 465 470 475 | |
| aaa ccg cag gca agc ctg agt cct agc tac atc gac ctg act gag tgt | 1489 |
| Lys Pro Gln Ala Ser Leu Ser Pro Ser Tyr Ile Asp Leu Thr Glu Cys | |
| 480 485 490 | |
| ccc tac atg tgg ccc tac tgc tcc cag cct atc tac tat gga gga atg | 1537 |
| Pro Tyr Met Trp Pro Tyr Cys Ser Gln Pro Ile Tyr Tyr Gly Gly Met | |
| 495 500 505 510 | |
| cca aca atc gtt aat gtc acc atc ctc aat ggc atg ggc gtc aca gga | 1585 |
| Pro Thr Ile Val Asn Val Thr Ile Leu Asn Gly Met Gly Val Thr Gly | |
| 515 520 525 | |

| | |
|---|------|
| aga att gtg gat aag cct gag tgg cga ccc tat tta cca cag aat gga | 1633 |
| Arg Ile Val Asp Lys Pro Glu Trp Arg Pro Tyr Leu Pro Gln Asn Gly | |
| 530 535 540 | |
| gac aac att gaa gtg gcc ttc tcc tac tcc tca gtg ttg tgg ccc tgg | 1681 |
| Asp Asn Ile Glu Val Ala Phe Ser Tyr Ser Ser Val Leu Trp Pro Trp | |
| 545 550 555 | |
| tca ggt tac ctt gcc atc tcc att tct gtg acc aag aag gca gct tcc | 1729 |
| Ser Gly Tyr Leu Ala Ile Ser Ile Ser Val Thr Lys Lys Ala Ala Ser | |
| 560 565 570 | |
| tgg gaa ggc atc gct cag ggc cac atc atg atc aca gtg gcg tcc cca | 1777 |
| Trp Glu Gly Ile Ala Gln Gly His Ile Met Ile Thr Val Ala Ser Pro | |
| 575 580 585 590 | |
| gca gag aca gag tta cac agt ggt gcg gag cac act tcc acc gtg aag | 1825 |
| Ala Glu Thr Glu Leu His Ser Gly Ala Glu His Thr Ser Thr Val Lys | |
| 595 600 605 | |
| ctg ccc atc aag gtg aag atc att ccc acc cct cct cgg agc aag aga | 1873 |
| Leu Pro Ile Lys Val Lys Ile Ile Pro Thr Pro Pro Arg Ser Lys Arg | |
| 610 615 620 | |
| gtc ctc tgg gac cag tac cac aac ctc cgc tac cca cct ggc tac ttc | 1921 |
| Val Leu Trp Asp Gln Tyr His Asn Leu Arg Tyr Pro Pro Gly Tyr Phe | |
| 625 630 635 | |
| ccc agg gac aac ttg cgg atg aag aat gac cct tta gac tgg aat ggc | 1969 |
| Pro Arg Asp Asn Leu Arg Met Lys Asn Asp Pro Leu Asp Trp Asn Gly | |
| 640 645 650 | |
| gac cac gtc cac acc aac ttc agg gac atg tac cag cat ctg cgc agc | 2017 |
| Asp His Val His Thr Asn Phe Arg Asp Met Tyr Gln His Leu Arg Ser | |
| 655 660 665 670 | |
| atg ggc tac ttc gtg gag gtg ctc ggc gcc cca ttc aca tgt ttt gac | 2065 |
| Met Gly Tyr Phe Val Glu Val Leu Gly Ala Pro Phe Thr Cys Phe Asp | |
| 675 680 685 | |
| gcc aca cag tat ggc act ttg ctg ctg gtg gac agt gag gaa gag tac | 2113 |
| Ala Thr Gln Tyr Gly Thr Leu Leu Leu Val Asp Ser Glu Glu Glu Tyr | |
| 690 695 700 | |
| ttc cct gag gag att gct aag ctg agg agg gat gtg gac aat ggc ctt | 2161 |
| Phe Pro Glu Glu Ile Ala Lys Leu Arg Arg Asp Val Asp Asn Gly Leu | |
| 705 710 715 | |

| | |
|---|------|
| tcc ctc gtc atc ttc agt gac tgg tac aac act tct gtt atg aga aaa | 2209 |
| Ser Leu Val Ile Phe Ser Asp Trp Tyr Asn Thr Ser Val Met Arg Lys | |
| 720 725 730 | |
| gtg aag ttt tat gat gaa aac acc agg cag tgg tgg atg cca gac acc | 2257 |
| Val Lys Phe Tyr Asp Glu Asn Thr Arg Gln Trp Trp Met Pro Asp Thr | |
| 735 740 745 750 | |
| gga gga gcg aac atc cca gct ctg aat gag ctg ctg tct gtg tgg aac | 2305 |
| Gly Gly Ala Asn Ile Pro Ala Leu Asn Glu Leu Leu Ser Val Trp Asn | |
| 755 760 765 | |
| atg ggg ttc agt gac ggc cta tat gaa ggg gag ttt gtc ctg gca aac | 2353 |
| Met Gly Phe Ser Asp Gly Leu Tyr Glu Gly Glu Phe Val Leu Ala Asn | |
| 770 775 780 | |
| cat gac atg tac tat gcg tcg ggg tgc agc atc gcc aag ttt cca gaa | 2401 |
| His Asp Met Tyr Tyr Ala Ser Gly Cys Ser Ile Ala Lys Phe Pro Glu | |
| 785 790 795 | |
| gat ggc gtc gtg atc aca cag act ttc aag gac caa gga ttg gag gtc | 2449 |
| Asp Gly Val Val Ile Thr Gln Thr Phe Lys Asp Gln Gly Leu Glu Val | |
| 800 805 810 | |
| tta aaa caa gag aca gca gtt gtg gaa aat gtt ccc att ttg ggg ctt | 2497 |
| Leu Lys Gln Glu Thr Ala Val Val Glu Asn Val Pro Ile Leu Gly Leu | |
| 815 820 825 830 | |
| tat cag att cca tct gaa ggt gga ggc cgg atc gtg ctg tat gga gac | 2545 |
| Tyr Gln Ile Pro Ser Glu Gly Gly Gly Arg Ile Val Leu Tyr Gly Asp | |
| 835 840 845 | |
| tcc aac tgc ttg gat gac agt cac aga cag aag gac tgc ttt tgg ctt | 2593 |
| Ser Asn Cys Leu Asp Asp Ser His Arg Gln Lys Asp Cys Phe Trp Leu | |
| 850 855 860 | |
| ctg gat gcg ctc ctt cag tac aca tcc tat ggc gtg acc cct ccc agc | 2641 |
| Leu Asp Ala Leu Leu Gln Tyr Thr Ser Tyr Gly Val Thr Pro Pro Ser | |
| 865 870 875 | |
| ctc agc cat tca ggg aac cgg cag cgc cca cct agc gga gcc ggc ttg | 2689 |
| Leu Ser His Ser Gly Asn Arg Gln Arg Pro Pro Ser Gly Ala Gly Leu | |
| 880 885 890 | |
| gcc cct cct gaa agg atg gaa gga aac cac ctc cat cgg tac tcc aaa | 2737 |
| Ala Pro Pro Glu Arg Met Glu Gly Asn His Leu His Arg Tyr Ser Lys | |
| 895 900 905 910 | |

gtt ctt gaa gcc cac ttg gga gac ccg aaa cct cgg ccc ctg cca gcc 2785
 Val Leu Glu Ala His Leu Gly Asp Pro Lys Pro Arg Pro Leu Pro Ala
 915 920 925

tgt cca cat ttg tca tgg gcc aag cca cag cct ttg aat gag acg gca 2833
 Cys Pro His Leu Ser Trp Ala Lys Pro Gln Pro Leu Asn Glu Thr Ala
 930 935 940

ccc agt aat ctt tgg aaa cat cag aag ctg ctc tcc att gac ctg gac 2881
 Pro Ser Asn Leu Trp Lys His Gln Lys Leu Leu Ser Ile Asp Leu Asp
 945 950 955

aaa gta gtg tta ccc aac ttt cga tcc aat cgc cct caa gtg aga cct 2929
 Lys Val Val Leu Pro Asn Phe Arg Ser Asn Arg Pro Gln Val Arg Pro
 960 965 970

ttg tcc cct gga gag agt ggt gcc tgg gac att cct gga ggg atc atg 2977
 Leu Ser Pro Gly Glu Ser Gly Ala Trp Asp Ile Pro Gly Gly Ile Met
 975 980 985 990

cct ggc cgc tac aac cag gag gtg gga cag acc atc ccc gtc ttc gcc 3025
 Pro Gly Arg Tyr Asn Gln Glu Val Gly Gln Thr Ile Pro Val Phe Ala
 995 1000 1005

ttc ctc gga gcc atg gtg gcc ctg gcc ttc ttt gtg gta cag atc agc 3073
 Phe Leu Gly Ala Met Val Ala Leu Ala Phe Phe Val Val Gln Ile Ser
 1010 1015 1020

aag gcc aag agc cgg ccg aag cgg agg agg ccc agg gca aag cgt cca 3121
 Lys Ala Lys Ser Arg Pro Lys Arg Arg Arg Pro Arg Ala Lys Arg Pro
 1025 1030 1035

caa ctt gca cag cag gcc cac oct gca agg acc cca tca gtg 3163
 Gln Leu Ala Gln Gln Ala His Pro Ala Arg Thr Pro Ser Val
 1040 1045 1050

tgagcatcgc agtagccagc cacagaagct aacaagcctt gaaccactct ggtggccaca 3223

cagcgctca gagagcattc tgggaagtgc ctgtttccga ggaccctgtc tccagcttgt 3283

ggctatctta ctgtgttctg cccaggcacc tgatgaggta catcctgcag tgcctctctg 3343

tgcttggctc tggcagaagg caccagtgta catcaggcat caggcccagt gacagtgcac 3403

caaagacaca gagcctggaa gggctgtcgg gacatacttt ctacataacg ctacaaccct 3463

gaccaagcaa agacatgctt gttacaggct attttctata tttattgtgg gagagtcact 3523

ttaaagactg tgctagttgg aaacagagct gttgctgttg tcagtcgagt gcagttttct 3583
gcagcgatgt cataaggagt cagattccgt gacctcctct ttgatggagg acacactgaa 3643
ctgaagggga cttgcgcgga tgtgggagat gcaagccttc gctttatattt tttataacta 3703
tcaactgccca tcatgttttg taatttgggg atcttgattt caccgttggt ggtgaaggaa 3763
attttcaata aatatgcata acctt 3788

<210> 4
<211> 1052
<212> PRT
<213> Mus sp.

<400> 4
Met Lys Leu Val Ser Thr Trp Leu Leu Val Leu Val Val Leu Leu Cys
1 5 10 15
Gly Lys Arg His Leu Gly Asp Arg Leu Gly Thr Arg Ala Leu Glu Lys
20 25 30
Ala Pro Cys Pro Ser Cys Ser His Leu Thr Leu Lys Val Glu Phe Ser
35 40 45
Ser Thr Val Val Glu Tyr Glu Tyr Ile Val Ala Phe Asn Gly Tyr Phe
50 55 60
Thr Ala Lys Ala Arg Asn Ser Phe Ile Ser Ser Ala Leu Lys Ser Ser
65 70 75 80
Glu Val Glu Asn Trp Arg Ile Ile Pro Arg Asn Asn Pro Ser Ser Asp
85 90 95
Tyr Pro Ser Asp Phe Glu Val Ile Gln Ile Lys Glu Lys Gln Lys Ala
100 105 110
Gly Leu Leu Thr Leu Glu Asp His Pro Asn Ile Lys Arg Val Thr Pro
115 120 125
Gln Arg Lys Val Phe Arg Ser Leu Lys Phe Ala Glu Ser Asn Pro Ile
130 135 140
Val Pro Cys Asn Glu Thr Arg Trp Ser Gln Lys Trp Gln Ser Ser Arg
145 150 155 160

| | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|
| Pro | Leu | Lys | Arg | Ala | Ser | Leu | Ser | Leu | Gly | Ser | Gly | Phe | Trp | His | Ala | | |
| | | | | 165 | | | | | 170 | | | | | 175 | | | |
| Thr | Gly | Arg | His | Ser | Ser | Arg | Arg | Leu | Leu | Arg | Ala | Ile | Pro | Arg | Gln | | |
| | | | 180 | | | | | 185 | | | | | 190 | | | | |
| Val | Ala | Gln | Thr | Leu | Gln | Ala | Asp | Val | Leu | Trp | Gln | Met | Gly | Tyr | Thr | | |
| | | 195 | | | | | 200 | | | | | 205 | | | | | |
| Gly | Ala | Asn | Val | Arg | Val | Ala | Val | Phe | Asp | Thr | Gly | Leu | Ser | Glu | Lys | | |
| | 210 | | | | | 215 | | | | | 220 | | | | | | |
| His | Pro | His | Phe | Lys | Asn | Val | Lys | Glu | Arg | Thr | Asn | Trp | Thr | Asn | Glu | | |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 | | |
| Arg | Thr | Leu | Asp | Asp | Gly | Leu | Gly | His | Gly | Thr | Phe | Val | Ala | Gly | Val | | |
| | | | | 245 | | | | | 250 | | | | | | 255 | | |
| Ile | Ala | Ser | Met | Arg | Glu | Cys | Gln | Gly | Phe | Ala | Pro | Asp | Ala | Glu | Leu | | |
| | | | 260 | | | | | 265 | | | | | | 270 | | | |
| His | Ile | Phe | Arg | Val | Phe | Thr | Asn | Asn | Gln | Val | Ser | Tyr | Thr | Ser | Trp | | |
| | 275 | | | | | | 280 | | | | | 285 | | | | | |
| Phe | Leu | Asp | Ala | Phe | Asn | Tyr | Ala | Ile | Leu | Lys | Lys | Met | Asp | Val | Leu | | |
| | 290 | | | | | 295 | | | | | 300 | | | | | | |
| Asn | Leu | Ser | Ile | Gly | Gly | Pro | Asp | Phe | Met | Asp | His | Pro | Phe | Val | Asp | | |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 | | |
| Lys | Val | Trp | Glu | Leu | Thr | Ala | Asn | Asn | Val | Ile | Met | Val | Ser | Ala | Ile | | |
| | | | 325 | | | | | | 330 | | | | | 335 | | | |
| Gly | Asn | Asp | Gly | Pro | Leu | Tyr | Gly | Thr | Leu | Asn | Asn | Pro | Ala | Asp | Gln | | |
| | | | 340 | | | | | 345 | | | | | 350 | | | | |
| Met | Asp | Val | Ile | Gly | Val | Gly | Gly | Ile | Asp | Phe | Glu | Asp | Asn | Ile | Ala | | |
| | | 355 | | | | | 360 | | | | | 365 | | | | | |
| Arg | Phe | Ser | Ser | Arg | Gly | Met | Thr | Thr | Trp | Glu | Leu | Pro | Gly | Gly | Tyr | | |
| | 370 | | | | | 375 | | | | | | 380 | | | | | |
| Gly | Arg | Val | Lys | Pro | Asp | Ile | Val | Thr | Tyr | Gly | Ala | Gly | Val | Arg | Gly | | |
| 385 | | | | | 390 | | | | | 395 | | | | | 400 | | |
| Ser | Gly | Val | Lys | Gly | Gly | Cys | Arg | Ala | Leu | Ser | Gly | Thr | Ser | Val | Ala | | |
| | | | | 405 | | | | | 410 | | | | | 415 | | | |

Ser Pro Val Val Ala Gly Ala Val Thr Leu Leu Val Ser Thr Val Gln
 420 425 430
 Lys Arg Glu Leu Val Asn Pro Ala Ser Val Lys Gln Ala Leu Ile Ala
 435 440 445
 Ser Ala Arg Arg Leu Pro Gly Val Asn Met Phe Glu Gln Gly His Gly
 450 455 460
 Lys Leu Asp Leu Leu Arg Ala Tyr Gln Ile Leu Ser Ser Tyr Lys Pro
 465 470 475 480
 Gln Ala Ser Leu Ser Pro Ser Tyr Ile Asp Leu Thr Glu Cys Pro Tyr
 485 490 495
 Met Trp Pro Tyr Cys Ser Gln Pro Ile Tyr Tyr Gly Gly Met Pro Thr
 500 505 510
 Ile Val Asn Val Thr Ile Leu Asn Gly Met Gly Val Thr Gly Arg Ile
 515 520 525
 Val Asp Lys Pro Glu Trp Arg Pro Tyr Leu Pro Gln Asn Gly Asp Asn
 530 535 540
 Ile Glu Val Ala Phe Ser Tyr Ser Ser Val Leu Trp Pro Trp Ser Gly
 545 550 555 560
 Tyr Leu Ala Ile Ser Ile Ser Val Thr Lys Lys Ala Ala Ser Trp Glu
 565 570 575
 Gly Ile Ala Gln Gly His Ile Met Ile Thr Val Ala Ser Pro Ala Glu
 580 585 590
 Thr Glu Leu His Ser Gly Ala Glu His Thr Ser Thr Val Lys Leu Pro
 595 600 605
 Ile Lys Val Lys Ile Ile Pro Thr Pro Pro Arg Ser Lys Arg Val Leu
 610 615 620
 Trp Asp Gln Tyr His Asn Leu Arg Tyr Pro Pro Gly Tyr Phe Pro Arg
 625 630 635 640
 Asp Asn Leu Arg Met Lys Asn Asp Pro Leu Asp Trp Asn Gly Asp His
 645 650 655
 Val His Thr Asn Phe Arg Asp Met Tyr Gln His Leu Arg Ser Met Gly
 660 665 670

Tyr Phe Val Glu Val Leu Gly Ala Pro Phe Thr Cys Phe Asp Ala Thr
 675 680 685
 Gln Tyr Gly Thr Leu Leu Leu Val Asp Ser Glu Glu Glu Tyr Phe Pro
 690 695 700
 Glu Glu Ile Ala Lys Leu Arg Arg Asp Val Asp Asn Gly Leu Ser Leu
 705 710 715 720
 Val Ile Phe Ser Asp Trp Tyr Asn Thr Ser Val Met Arg Lys Val Lys
 725 730 735
 Phe Tyr Asp Glu Asn Thr Arg Gln Trp Trp Met Pro Asp Thr Gly Gly
 740 745 750
 Ala Asn Ile Pro Ala Leu Asn Glu Leu Leu Ser Val Trp Asn Met Gly
 755 760 765
 Phe Ser Asp Gly Leu Tyr Glu Gly Glu Phe Val Leu Ala Asn His Asp
 770 775 780
 Met Tyr Tyr Ala Ser Gly Cys Ser Ile Ala Lys Phe Pro Glu Asp Gly
 785 790 795 800
 Val Val Ile Thr Gln Thr Phe Lys Asp Gln Gly Leu Glu Val Leu Lys
 805 810 815
 Gln Glu Thr Ala Val Val Glu Asn Val Pro Ile Leu Gly Leu Tyr Gln
 820 825 830
 Ile Pro Ser Glu Gly Gly Gly Arg Ile Val Leu Tyr Gly Asp Ser Asn
 835 840 845
 Cys Leu Asp Asp Ser His Arg Gln Lys Asp Cys Phe Trp Leu Leu Asp
 850 855 860
 Ala Leu Leu Gln Tyr Thr Ser Tyr Gly Val Thr Pro Pro Ser Leu Ser
 865 870 875 880
 His Ser Gly Asn Arg Gln Arg Pro Pro Ser Gly Ala Gly Leu Ala Pro
 885 890 895
 Pro Glu Arg Met Glu Gly Asn His Leu His Arg Tyr Ser Lys Val Leu
 900 905 910
 Glu Ala His Leu Gly Asp Pro Lys Pro Arg Pro Leu Pro Ala Cys Pro
 915 920 925

His Leu Ser Trp Ala Lys Pro Gln Pro Leu Asn Glu Thr Ala Pro Ser
 930 935 940
 Asn Leu Trp Lys His Gln Lys Leu Leu Ser Ile Asp Leu Asp Lys Val
 945 950 955 960
 Val Leu Pro Asn Phe Arg Ser Asn Arg Pro Gln Val Arg Pro Leu Ser
 965 970 975
 Pro Gly Glu Ser Gly Ala Trp Asp Ile Pro Gly Gly Ile Met Pro Gly
 980 985 990
 Arg Tyr Asn Gln Glu Val Gly Gln Thr Ile Pro Val Phe Ala Phe Leu
 995 1000 1005
 Gly Ala Met Val Ala Leu Ala Phe Phe Val Val Gln Ile Ser Lys Ala
 1010 1015 1020
 Lys Ser Arg Pro Lys Arg Arg Arg Pro Arg Ala Lys Arg Pro Gln Leu
 1025 1030 1035 1040
 Ala Gln Gln Ala His Pro Ala Arg Thr Pro Ser Val
 1045 1050

<210> 5

<211> 4338

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (497)..(3652)

<400> 5

cagggcacgc tgggtcggcg gagctgaggc tcccagctgt gggcctcgct ggcccggtcg 60
 cccagtctcg cgagagttgg gagtaaacag ccccgaaatgg agtgcccagg cgtgttcgcc 120
 gcggaggcgc cgttatcccg ggcccgcgcg cctgagctc ccggcggcgc agattggctc 180
 acagtggttg attgatcaac cccattggac gttggttctg tggtaaaaat ggagtacagg 240
 actcagtcgt cacggcctga gtgagagaag ccttatttcc aagatggaga agaagcggag 300
 aaagaaatga aagcctctct tcaggctgaa ccacaaaagg ccatgggatt taacttttat 360

ttatgttggg caagactgta agatggctga tcagtaatgt tgcagctttt agctgaaaca 420
 aaaattcact tttaatcaag aagaaaaaag tgtgatttga atatatgcaa ttttatgatc 480
 atattcgctt gtgacc atg aag ctt gtc aac atc tgg ctg ctt ctg ctc gtg 532
 Met Lys Leu Val Asn Ile Trp Leu Leu Leu Leu Val
 1 5 10
 gtt ttg ctc tgt ggg aag aaa cat ctg ggc gac aga ctg gaa aag aaa 580
 Val Leu Leu Cys Gly Lys Lys His Leu Gly Asp Arg Leu Glu Lys Lys
 15 20 25
 tct ttt gaa aag gcc cca tgc cct ggc tgt tcc cac ctg act ttg aag 628
 Ser Phe Glu Lys Ala Pro Cys Pro Gly Cys Ser His Leu Thr Leu Lys
 30 35 40
 gtg gaa ttc tca tca aca gtt gtg gaa tat gaa tat att gtg gct ttc 676
 Val Glu Phe Ser Ser Thr Val Val Glu Tyr Glu Tyr Ile Val Ala Phe
 45 50 55 60
 aat gga tac ttt aca gcc aaa gct aga aat tca ttt att tca agt gcc 724
 Asn Gly Tyr Phe Thr Ala Lys Ala Arg Asn Ser Phe Ile Ser Ser Ala
 65 70 75
 ctg aag agc agt gaa gta gac aat tgg aga att ata cct cga aac aat 772
 Leu Lys Ser Ser Glu Val Asp Asn Trp Arg Ile Ile Pro Arg Asn Asn
 80 85 90
 cca tcc agt gac tac cct agt gat ttt gag gtg att cag ata aaa gaa 820
 Pro Ser Ser Asp Tyr Pro Ser Asp Phe Glu Val Ile Gln Ile Lys Glu
 95 100 105
 aaa cag aaa gcg ggg ctg cta aca ctt gaa gat cat cca aac atc aaa 868
 Lys Gln Lys Ala Gly Leu Leu Thr Leu Glu Asp His Pro Asn Ile Lys
 110 115 120
 cgg gtc acg ccc caa cga aaa gtc ttt cgt tcc ctc aag tat gct gaa 916
 Arg Val Thr Pro Gln Arg Lys Val Phe Arg Ser Leu Lys Tyr Ala Glu
 125 130 135 140
 tct gac ccc aca gta ccc tgc aat gaa acc cgg tgg agc cag aag tgg 964
 Ser Asp Pro Thr Val Pro Cys Asn Glu Thr Arg Trp Ser Gln Lys Trp
 145 150 155
 caa tca tca cgt ccc ctg cga aga gcc agc ctc tcc ctg ggc tct ggc 1012
 Gln Ser Ser Arg Pro Leu Arg Arg Ala Ser Leu Ser Leu Gly Ser Gly
 160 165 170

| | |
|---|------|
| ttc tgg cat gct acg gga agg cat tcg agc aga cgg ctg ctg aga gcc | 1060 |
| Phe Trp His Ala Thr Gly Arg His Ser Ser Arg Arg Leu Leu Arg Ala | |
| 175 180 185 | |
| atc ccg cgc cag gtt gcc cag aca ctg cag gca gat gtg ctc tgg cag | 1108 |
| Ile Pro Arg Gln Val Ala Gln Thr Leu Gln Ala Asp Val Leu Trp Gln | |
| 190 195 200 | |
| atg gga tat aca ggt gct aat gta aga gtt gct gtt ttt gac act ggg | 1156 |
| Met Gly Tyr Thr Gly Ala Asn Val Arg Val Ala Val Phe Asp Thr Gly | |
| 205 210 215 220 | |
| ctg agc gag aag cat ccc cac ttc aaa aat gtg aag gag aga acc aac | 1204 |
| Leu Ser Glu Lys His Pro His Phe Lys Asn Val Lys Glu Arg Thr Asn | |
| 225 230 235 | |
| tgg acc aac gag cga acg ctg gac gat ggg ttg ggc cat ggc aca ttc | 1252 |
| Trp Thr Asn Glu Arg Thr Leu Asp Asp Gly Leu Gly His Gly Thr Phe | |
| 240 245 250 | |
| gtg gca ggt gtg ata gcc agc atg agg gag tgc caa gga ttt gct cca | 1300 |
| Val Ala Gly Val Ile Ala Ser Met Arg Glu Cys Gln Gly Phe Ala Pro | |
| 255 260 265 | |
| gat gca gaa ctt cac att ttc agg gtc ttt acc aat aat cag gta tct | 1348 |
| Asp Ala Glu Leu His Ile Phe Arg Val Phe Thr Asn Asn Gln Val Ser | |
| 270 275 280 | |
| tac aca tct tgg ttt ttg gac gcc ttc aac tat gcc att tta aag aag | 1396 |
| Tyr Thr Ser Trp Phe Leu Asp Ala Phe Asn Tyr Ala Ile Leu Lys Lys | |
| 285 290 295 300 | |
| atc gac gtg tta aac ctc agc atc ggc ggc ccg gac ttc atg gat cat | 1444 |
| Ile Asp Val Leu Asn Leu Ser Ile Gly Gly Pro Asp Phe Met Asp His | |
| 305 310 315 | |
| ccg ttt gtt gac aag gtg tgg gaa tta aca gct aac aat gta atc atg | 1492 |
| Pro Phe Val Asp Lys Val Trp Glu Leu Thr Ala Asn Asn Val Ile Met | |
| 320 325 330 | |
| gtt tct gct att ggc aat gac gga cct ctt tat ggc act ctg aat aac | 1540 |
| Val Ser Ala Ile Gly Asn Asp Gly Pro Leu Tyr Gly Thr Leu Asn Asn | |
| 335 340 345 | |
| cct gct gat caa atg gat gtg att gga gta ggc ggc att gac ttt gaa | 1588 |
| Pro Ala Asp Gln Met Asp Val Ile Gly Val Gly Gly Ile Asp Phe Glu | |
| 350 355 360 | |

| | |
|---|------|
| gat aac atc gcc cgc ttt tct tca agg gga atg act acc tgg gag cta | 1636 |
| Asp Asn Ile Ala Arg Phe Ser Ser Arg Gly Met Thr Thr Trp Glu Leu | |
| 365 370 375 380 | |
| cca gga ggc tac ggt cgc atg aaa cct gac att gtc acc tat ggt gct | 1684 |
| Pro Gly Gly Tyr Gly Arg Met Lys Pro Asp Ile Val Thr Tyr Gly Ala | |
| 385 390 395 | |
| ggc gtg cgg ggt tct ggc gtg aaa ggg ggg tgc cgg gcc ctc tca ggg | 1732 |
| Gly Val Arg Gly Ser Gly Val Lys Gly Gly Cys Arg Ala Leu Ser Gly | |
| 400 405 410 | |
| acc agt gtt gct tct cca gtg gtt gca ggt gct gtc acc ttg tta gtg | 1780 |
| Thr Ser Val Ala Ser Pro Val Val Ala Gly Ala Val Thr Leu Leu Val | |
| 415 420 425 | |
| agc aca gtc cag aag cgt gag ctg gtg aat ccc gcc agt atg aag cag | 1828 |
| Ser Thr Val Gln Lys Arg Glu Leu Val Asn Pro Ala Ser Met Lys Gln | |
| 430 435 440 | |
| gcc ctg atc gcg tca gcc cgg agg ctc ccc ggg gtc aac atg ttt gag | 1876 |
| Ala Leu Ile Ala Ser Ala Arg Arg Leu Pro Gly Val Asn Met Phe Glu | |
| 445 450 455 460 | |
| caa ggc cac ggc aag ctc gat ctg ctc aga gcc tat cag atc ctc aac | 1924 |
| Gln Gly His Gly Lys Leu Asp Leu Leu Arg Ala Tyr Gln Ile Leu Asn | |
| 465 470 475 | |
| agc tac aag cca cag gca agt ttg agc ccc agc tac ata gat ctg act | 1972 |
| Ser Tyr Lys Pro Gln Ala Ser Leu Ser Pro Ser Tyr Ile Asp Leu Thr | |
| 480 485 490 | |
| gag tgt ccc tac atg tgg ccc tac tgc tcc cag ccc atc tac tat gga | 2020 |
| Glu Cys Pro Tyr Met Trp Pro Tyr Cys Ser Gln Pro Ile Tyr Tyr Gly | |
| 495 500 505 | |
| gga atg ccg aca gtt gtt aat gtc acc atc ctc aac ggc atg gga gtc | 2068 |
| Gly Met Pro Thr Val Val Asn Val Thr Ile Leu Asn Gly Met Gly Val | |
| 510 515 520 | |
| aca gga aga att gta gat aag cct gac tgg cag ccc tat ttg cca cag | 2116 |
| Thr Gly Arg Ile Val Asp Lys Pro Asp Trp Gln Pro Tyr Leu Pro Gln | |
| 525 530 535 540 | |
| aac gga gac aac att gaa gtt gcc ttc tcc tac tcc tcg gtc tta tgg | 2164 |
| Asn Gly Asp Asn Ile Glu Val Ala Phe Ser Tyr Ser Ser Val Leu Trp | |
| 545 550 555 | |

| | |
|---|------|
| cct tgg tcg ggc tac ctg gcc atc tcc att tct gtg acc aag aaa gcg | 2212 |
| Pro Trp Ser Gly Tyr Leu Ala Ile Ser Ile Ser Val Thr Lys Lys Ala | |
| 560 565 570 | |
| gct tcc tgg gaa ggc att gct cag ggc cat gtc atg atc act gtg gct | 2260 |
| Ala Ser Trp Glu Gly Ile Ala Gln Gly His Val Met Ile Thr Val Ala | |
| 575 580 585 | |
| tcc cca gca gag aca gag tca aaa aat ggt gca gaa cag act tca aca | 2308 |
| Ser Pro Ala Glu Thr Glu Ser Lys Asn Gly Ala Glu Gln Thr Ser Thr | |
| 590 595 600 | |
| gta aag ctc ccc att aag gtg aag ata att cct act ccc ccg cga agc | 2356 |
| Val Lys Leu Pro Ile Lys Val Lys Ile Ile Pro Thr Pro Pro Arg Ser | |
| 605 610 615 620 | |
| aag aga gtt ctc tgg gat cag tac cac aac ctc cgc tat cca cct ggc | 2404 |
| Lys Arg Val Leu Trp Asp Gln Tyr His Asn Leu Arg Tyr Pro Pro Gly | |
| 625 630 635 | |
| tat ttc ccc agg gat aat tta agg atg aag aat gac cct tta gac tgg | 2452 |
| Tyr Phe Pro Arg Asp Asn Leu Arg Met Lys Asn Asp Pro Leu Asp Trp | |
| 640 645 650 | |
| aat ggt gat cac atc cac acc aat ttc agg gat atg tac cag cat ctg | 2500 |
| Asn Gly Asp His Ile His Thr Asn Phe Arg Asp Met Tyr Gln His Leu | |
| 655 660 665 | |
| aga agc atg ggc tac ttt gta gag gtc ctc ggg gcc ccc ttc acg tgt | 2548 |
| Arg Ser Met Gly Tyr Phe Val Glu Val Leu Gly Ala Pro Phe Thr Cys | |
| 670 675 680 | |
| ttt gat gcc agt cag tat ggc act ttg ctg atg gtg gac agt gag gag | 2596 |
| Phe Asp Ala Ser Gln Tyr Gly Thr Leu Leu Met Val Asp Ser Glu Glu | |
| 685 690 695 700 | |
| gag tac ttc cct gaa gag atc gcc aag ctc cgg agg gac gtg gac aac | 2644 |
| Glu Tyr Phe Pro Glu Glu Ile Ala Lys Leu Arg Arg Asp Val Asp Asn | |
| 705 710 715 | |
| ggc ctc tcg ctc gtc atc ttc agt gac tgg tac aac act tct gtt atg | 2692 |
| Gly Leu Ser Leu Val Ile Phe Ser Asp Trp Tyr Asn Thr Ser Val Met | |
| 720 725 730 | |
| aga aaa gtg aag ttt tat gat gaa aac aca agg cag tgg tgg atg ccg | 2740 |
| Arg Lys Val Lys Phe Tyr Asp Glu Asn Thr Arg Gln Trp Trp Met Pro | |
| 735 740 745 | |

| | |
|---|------|
| gat acc gga gga gct aac atc cca gct ctg aat gag ctg ctg tct gtg | 2788 |
| Asp Thr Gly Gly Ala Asn Ile Pro Ala Leu Asn Glu Leu Leu Ser Val | |
| 750 755 760 | |
| tgg aac atg ggg ttc agc gat ggc ctg tat gaa ggg gag ttc acc ctg | 2836 |
| Trp Asn Met Gly Phe Ser Asp Gly Leu Tyr Glu Gly Glu Phe Thr Leu | |
| 765 770 775 780 | |
| gcc aac cat gac atg tat tat gcg tca ggg tgc agc atc gcg aag ttt | 2884 |
| Ala Asn His Asp Met Tyr Tyr Ala Ser Gly Cys Ser Ile Ala Lys Phe | |
| 785 790 795 | |
| cca gaa gat ggc gtc gtg ata aca cag act ttc aag gac caa gga ttg | 2932 |
| Pro Glu Asp Gly Val Val Ile Thr Gln Thr Phe Lys Asp Gln Gly Leu | |
| 800 805 810 | |
| gag gtt tta aag cag gaa aca gca gtt gtt gaa aac gtc ccc att ttg | 2980 |
| Glu Val Leu Lys Gln Glu Thr Ala Val Val Glu Asn Val Pro Ile Leu | |
| 815 820 825 | |
| gga ctt tat cag att cca gct gag ggt gga ggc cgg att gta ctg tat | 3028 |
| Gly Leu Tyr Gln Ile Pro Ala Glu Gly Gly Gly Arg Ile Val Leu Tyr | |
| 830 835 840 | |
| ggg gac tcc aat tgc ttg gat gac agt cac cga cag aag gac tgc ttt | 3076 |
| Gly Asp Ser Asn Cys Leu Asp Asp Ser His Arg Gln Lys Asp Cys Phe | |
| 845 850 855 860 | |
| tgg ctt ctg gat gcc ctc ctc cag tac aca tcg tat ggg gtg aca ccg | 3124 |
| Trp Leu Leu Asp Ala Leu Leu Gln Tyr Thr Ser Tyr Gly Val Thr Pro | |
| 865 870 875 | |
| cct agc ctc agt cac tct ggg aac cgc cag cgc cct ccc agt gga gca | 3172 |
| Pro Ser Leu Ser His Ser Gly Asn Arg Gln Arg Pro Pro Ser Gly Ala | |
| 880 885 890 | |
| ggc tca gtc act cca gag agg atg gaa gga aac cat ctt cat cgg tac | 3220 |
| Gly Ser Val Thr Pro Glu Arg Met Glu Gly Asn His Leu His Arg Tyr | |
| 895 900 905 | |
| tcc aag gtt ctg gag gcc cat ttg gga gac cca aaa cct cgg cct cta | 3268 |
| Ser Lys Val Leu Glu Ala His Leu Gly Asp Pro Lys Pro Arg Pro Leu | |
| 910 915 920 | |
| cca gcc tgt cca cgc ttg tct tgg gcc aag cca cag cct tta aac gag | 3316 |
| Pro Ala Cys Pro Arg Leu Ser Trp Ala Lys Pro Gln Pro Leu Asn Glu | |
| 925 930 935 940 | |

acg gcg ccc agt aac ctt tgg aaa cat cag aag cta ctc tcc att gac 3364
 Thr Ala Pro Ser Asn Leu Trp Lys His Gln Lys Leu Leu Ser Ile Asp
 945 950 955

ctg gac aag gtg gtg tta ccc aac ttt cga tcg aat cgc cct caa gtg 3412
 Leu Asp Lys Val Val Leu Pro Asn Phe Arg Ser Asn Arg Pro Gln Val
 960 965 970

agg ccc ttg tcc cct gga gag agc ggc gcc tgg gac att cct gga ggg 3460
 Arg Pro Leu Ser Pro Gly Glu Ser Gly Ala Trp Asp Ile Pro Gly Gly
 975 980 985

atc atg cct ggc cgc tac aac cag gag gtg ggc cag acc att cct gtc 3508
 Ile Met Pro Gly Arg Tyr Asn Gln Glu Val Gly Gln Thr Ile Pro Val
 990 995 1000

ttt gcc ttc ctg gga gcc atg gtg gtc ctg gcc ttc ttt gtg gta caa 3556
 Phe Ala Phe Leu Gly Ala Met Val Val Leu Ala Phe Phe Val Val Gln
 1005 1010 1015 1020

atc aac aag gcc aag agc agg ccg aag cgg agg aag ccc agg gtg aag 3604
 Ile Asn Lys Ala Lys Ser Arg Pro Lys Arg Arg Lys Pro Arg Val Lys
 1025 1030 1035

cgc ccg cag ctc atg cag cag gtt cac ccg cca aag acc cct tcg gtg 3652
 Arg Pro Gln Leu Met Gln Gln Val His Pro Pro Lys Thr Pro Ser Val
 1040 1045 1050

tgaccggcag cctggctgac cgtgagggcc agagagagcc ttcacggacg gcgctggtgg 3712

gtgagccgag ctgtggtggc ggctggttta aaagggatcc agtttccagc tgcaggtttg 3772

ttagagtctg ttctacatgg gcctgccctc ctgtgatggg cagaggctcc tggtagatcg 3832

agaagattcc tgtggatccc gtcaggaggg acttagtggc tctgccgcca gtgagacttc 3892

ccgccggcag ctgtgcgcac caaagactcg ggagaactgg aaaggctgtc tggggctctc 3952

tgactgcagg ggaaggatgt actttccaaa caaatgatac aaccctgacc aagctaaaag 4012

acgcttggtta aaggctatctt tctatatctta ttgttgggaa aagtcacttt aaagacttgt 4072

gctatttgga agcaaagcta ttttttttgt cagtggaaatg cagttttttt actattccat 4132

catgaggaac aacatagatt ccatgatctt tttaatgaca gtacagactg agatttgaag 4192

gaaacatgca caaatctgta aaacatagac cttcgcttta tttttgtaag tatcacctgc 4252

caccatgttt tgtaatttga ggtcttgatt tcaccattgt cggatgaagaa aattttcaat 4312

aaatatgtat taccggtctg aagctt 4338

<210> 6

<211> 1052

<212> PRT

<213> Homo sapiens

<400> 6

Met Lys Leu Val Asn Ile Trp Leu Leu Leu Leu Val Val Leu Leu Cys
1 5 10 15

Gly Lys Lys His Leu Gly Asp Arg Leu Glu Lys Lys Ser Phe Glu Lys
20 25 30

Ala Pro Cys Pro Gly Cys Ser His Leu Thr Leu Lys Val Glu Phe Ser
35 40 45

Ser Thr Val Val Glu Tyr Glu Tyr Ile Val Ala Phe Asn Gly Tyr Phe
50 55 60

Thr Ala Lys Ala Arg Asn Ser Phe Ile Ser Ser Ala Leu Lys Ser Ser
65 70 75 80

Glu Val Asp Asn Trp Arg Ile Ile Pro Arg Asn Asn Pro Ser Ser Asp
85 90 95

Tyr Pro Ser Asp Phe Glu Val Ile Gln Ile Lys Glu Lys Gln Lys Ala
100 105 110

Gly Leu Leu Thr Leu Glu Asp His Pro Asn Ile Lys Arg Val Thr Pro
115 120 125

Gln Arg Lys Val Phe Arg Ser Leu Lys Tyr Ala Glu Ser Asp Pro Thr
130 135 140

Val Pro Cys Asn Glu Thr Arg Trp Ser Gln Lys Trp Gln Ser Ser Arg
145 150 155 160

Pro Leu Arg Arg Ala Ser Leu Ser Leu Gly Ser Gly Phe Trp His Ala
165 170 175

Thr Gly Arg His Ser Ser Arg Arg Leu Leu Arg Ala Ile Pro Arg Gln
180 185 190

Val Ala Gln Thr Leu Gln Ala Asp Val Leu Trp Gln Met Gly Tyr Thr

| | | | | |
|---|-----|-----|-----|-----|
| 195 | | 200 | | 205 |
| Gly Ala Asn Val Arg Val Ala Val Phe Asp Thr Gly Leu Ser Glu Lys | | | | |
| 210 | | 215 | | 220 |
| His Pro His Phe Lys Asn Val Lys Glu Arg Thr Asn Trp Thr Asn Glu | | | | |
| 225 | | 230 | | 240 |
| Arg Thr Leu Asp Asp Gly Leu Gly His Gly Thr Phe Val Ala Gly Val | | | | |
| | 245 | | 250 | 255 |
| Ile Ala Ser Met Arg Glu Cys Gln Gly Phe Ala Pro Asp Ala Glu Leu | | | | |
| | 260 | | 265 | 270 |
| His Ile Phe Arg Val Phe Thr Asn Asn Gln Val Ser Tyr Thr Ser Trp | | | | |
| | 275 | | 280 | 285 |
| Phe Leu Asp Ala Phe Asn Tyr Ala Ile Leu Lys Lys Ile Asp Val Leu | | | | |
| | 290 | | 295 | 300 |
| Asn Leu Ser Ile Gly Gly Pro Asp Phe Met Asp His Pro Phe Val Asp | | | | |
| 305 | | 310 | | 315 |
| Lys Val Trp Glu Leu Thr Ala Asn Asn Val Ile Met Val Ser Ala Ile | | | | |
| | 325 | | 330 | 335 |
| Gly Asn Asp Gly Pro Leu Tyr Gly Thr Leu Asn Asn Pro Ala Asp Gln | | | | |
| | 340 | | 345 | 350 |
| Met Asp Val Ile Gly Val Gly Gly Ile Asp Phe Glu Asp Asn Ile Ala | | | | |
| | 355 | | 360 | 365 |
| Arg Phe Ser Ser Arg Gly Met Thr Thr Trp Glu Leu Pro Gly Gly Tyr | | | | |
| | 370 | | 375 | 380 |
| Gly Arg Met Lys Pro Asp Ile Val Thr Tyr Gly Ala Gly Val Arg Gly | | | | |
| 385 | | 390 | | 395 |
| Ser Gly Val Lys Gly Gly Cys Arg Ala Leu Ser Gly Thr Ser Val Ala | | | | |
| | 405 | | 410 | 415 |
| Ser Pro Val Val Ala Gly Ala Val Thr Leu Leu Val Ser Thr Val Gln | | | | |
| | 420 | | 425 | 430 |
| Lys Arg Glu Leu Val Asn Pro Ala Ser Met Lys Gln Ala Leu Ile Ala | | | | |
| | 435 | | 440 | 445 |
| Ser Ala Arg Arg Leu Pro Gly Val Asn Met Phe Glu Gln Gly His Gly | | | | |

| | | | | |
|---|-----|-----|-----|-----|
| 450 | | 455 | | 460 |
| Lys Leu Asp Leu Leu Arg Ala Tyr Gln Ile Leu Asn Ser Tyr Lys Pro | | | | |
| 465 | | 470 | | 480 |
| Gln Ala Ser Leu Ser Pro Ser Tyr Ile Asp Leu Thr Glu Cys Pro Tyr | | | | |
| | 485 | | 490 | 495 |
| Met Trp Pro Tyr Cys Ser Gln Pro Ile Tyr Tyr Gly Gly Met Pro Thr | | | | |
| | 500 | | 505 | 510 |
| Val Val Asn Val Thr Ile Leu Asn Gly Met Gly Val Thr Gly Arg Ile | | | | |
| | 515 | | 520 | 525 |
| Val Asp Lys Pro Asp Trp Gln Pro Tyr Leu Pro Gln Asn Gly Asp Asn | | | | |
| | 530 | | 535 | 540 |
| Ile Glu Val Ala Phe Ser Tyr Ser Ser Val Leu Trp Pro Trp Ser Gly | | | | |
| 545 | | 550 | | 560 |
| Tyr Leu Ala Ile Ser Ile Ser Val Thr Lys Lys Ala Ala Ser Trp Glu | | | | |
| | 565 | | 570 | 575 |
| Gly Ile Ala Gln Gly His Val Met Ile Thr Val Ala Ser Pro Ala Glu | | | | |
| | 580 | | 585 | 590 |
| Thr Glu Ser Lys Asn Gly Ala Glu Gln Thr Ser Thr Val Lys Leu Pro | | | | |
| | 595 | | 600 | 605 |
| Ile Lys Val Lys Ile Ile Pro Thr Pro Pro Arg Ser Lys Arg Val Leu | | | | |
| | 610 | | 615 | 620 |
| Trp Asp Gln Tyr His Asn Leu Arg Tyr Pro Pro Gly Tyr Phe Pro Arg | | | | |
| 625 | | 630 | | 640 |
| Asp Asn Leu Arg Met Lys Asn Asp Pro Leu Asp Trp Asn Gly Asp His | | | | |
| | 645 | | 650 | 655 |
| Ile His Thr Asn Phe Arg Asp Met Tyr Gln His Leu Arg Ser Met Gly | | | | |
| | 660 | | 665 | 670 |
| Tyr Phe Val Glu Val Leu Gly Ala Pro Phe Thr Cys Phe Asp Ala Ser | | | | |
| | 675 | | 680 | 685 |
| Gln Tyr Gly Thr Leu Leu Met Val Asp Ser Glu Glu Glu Tyr Phe Pro | | | | |
| | 690 | | 695 | 700 |
| Glu Glu Ile Ala Lys Leu Arg Arg Asp Val Asp Asn Gly Leu Ser Leu | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 705 | | 710 | | 715 | | 720 | | | | | | | | | |
| Val | Ile | Phe | Ser | Asp | Trp | Tyr | Asn | Thr | Ser | Val | Met | Arg | Lys | Val | Lys |
| | | | | 725 | | | | | 730 | | | | | 735 | |
| Phe | Tyr | Asp | Glu | Asn | Thr | Arg | Gln | Trp | Trp | Met | Pro | Asp | Thr | Gly | Gly |
| | | | 740 | | | | | 745 | | | | | | 750 | |
| Ala | Asn | Ile | Pro | Ala | Leu | Asn | Glu | Leu | Leu | Ser | Val | Trp | Asn | Met | Gly |
| | | | 755 | | | | | 760 | | | | | | 765 | |
| Phe | Ser | Asp | Gly | Leu | Tyr | Glu | Gly | Glu | Phe | Thr | Leu | Ala | Asn | His | Asp |
| | | 770 | | | | | | 775 | | | | 780 | | | |
| Met | Tyr | Tyr | Ala | Ser | Gly | Cys | Ser | Ile | Ala | Lys | Phe | Pro | Glu | Asp | Gly |
| 785 | | | | | | 790 | | | | 795 | | | | | 800 |
| Val | Val | Ile | Thr | Gln | Thr | Phe | Lys | Asp | Gln | Gly | Leu | Glu | Val | Leu | Lys |
| | | | | 805 | | | | | | 810 | | | | | 815 |
| Gln | Glu | Thr | Ala | Val | Val | Glu | Asn | Val | Pro | Ile | Leu | Gly | Leu | Tyr | Gln |
| | | | 820 | | | | | | 825 | | | | | 830 | |
| Ile | Pro | Ala | Glu | Gly | Gly | Gly | Arg | Ile | Val | Leu | Tyr | Gly | Asp | Ser | Asn |
| | | | 835 | | | | | 840 | | | | | 845 | | |
| Cys | Leu | Asp | Asp | Ser | His | Arg | Gln | Lys | Asp | Cys | Phe | Trp | Leu | Leu | Asp |
| | | 850 | | | | | 855 | | | | 860 | | | | |
| Ala | Leu | Leu | Gln | Tyr | Thr | Ser | Tyr | Gly | Val | Thr | Pro | Pro | Ser | Leu | Ser |
| 865 | | | | | | 870 | | | | 875 | | | | | 880 |
| His | Ser | Gly | Asn | Arg | Gln | Arg | Pro | Pro | Ser | Gly | Ala | Gly | Ser | Val | Thr |
| | | | | 885 | | | | | 890 | | | | | 895 | |
| Pro | Glu | Arg | Met | Glu | Gly | Asn | His | Leu | His | Arg | Tyr | Ser | Lys | Val | Leu |
| | | | 900 | | | | | | 905 | | | | | 910 | |
| Glu | Ala | His | Leu | Gly | Asp | Pro | Lys | Pro | Arg | Pro | Leu | Pro | Ala | Cys | Pro |
| | | | 915 | | | | | 920 | | | | | 925 | | |
| Arg | Leu | Ser | Trp | Ala | Lys | Pro | Gln | Pro | Leu | Asn | Glu | Thr | Ala | Pro | Ser |
| | | | 930 | | | | 935 | | | | | 940 | | | |
| Asn | Leu | Trp | Lys | His | Gln | Lys | Leu | Leu | Ser | Ile | Asp | Leu | Asp | Lys | Val |
| 945 | | | | | | 950 | | | | 955 | | | | | 960 |
| Val | Leu | Pro | Asn | Phe | Arg | Ser | Asn | Arg | Pro | Gln | Val | Arg | Pro | Leu | Ser |

| | | |
|---|------|------|
| 965 | 970 | 975 |
| Pro Gly Glu Ser Gly Ala Trp Asp Ile Pro Gly Gly Ile Met Pro Gly | | |
| 980 | 985 | 990 |
| Arg Tyr Asn Gln Glu Val Gly Gln Thr Ile Pro Val Phe Ala Phe Leu | | |
| 995 | 1000 | 1005 |
| Gly Ala Met Val Val Leu Ala Phe Phe Val Val Gln Ile Asn Lys Ala | | |
| 1010 | 1015 | 1020 |
| Lys Ser Arg Pro Lys Arg Arg Lys Pro Arg Val Lys Arg Pro Gln Leu | | |
| 1025 | 1030 | 1035 |
| | | 1040 |
| Met Gln Gln Val His Pro Pro Lys Thr Pro Ser Val | | |
| 1045 | 1050 | |

<210> 7
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Peptide

<220>
 <221> MOD_RES
 <222> (2)
 <223> Xaa represents any amino acid.

<220>
 <221> MOD_RES
 <222> (3)
 <223> Xaa represents an alkyl or an aromatic hydrophobic amino acid.

<220>
 <221> MOD_RES
 <222> (4)..(6)
 <223> Xaa represents any amino acid.

<220>
 <221> MOD_RES
 <222> (7)
 <223> Xaa represents an acidic amino acid.

<400> 7
Arg Xaa Xaa Xaa Xaa Xaa Xaa
1 5

<210> 8
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<220>
<221> MOD_RES
<222> (2)
<223> Xaa represents any amino acid.

<220>
<221> MOD_RES
<222> (3)
<223> Xaa represents an alkyl or an aromatic hydrophobic amino acid.

<220>
<221> MOD_RES
<222> (4)
<223> Xaa represents Lys, Leu, Phe or Thr.

<220>
<221> MOD_RES
<222> (5)..(6)
<223> Xaa represents any amino acid.

<220>
<221> MOD_RES
<222> (7)
<223> Xaa represents an acidic amino acid.

<400> 8
Arg Xaa Xaa Xaa Xaa Xaa Xaa
1 5

<210> 9
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<220>
<221> MOD_RES
<222> (2)
<223> Xaa represents any amino acid.

<220>
<221> MOD_RES
<222> (3)
<223> Xaa represents an alkyl or an aromatic hydrophobic acid.

<220>
<221> MOD_RES
<222> (4)..(7)
<223> Xaa represents any amino acid.

<220>
<221> MOD_RES
<222> (8)
<223> Xaa represents an acidic amino acid.

<400> 9
Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5

<210> 10
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<220>
<221> MOD_RES
<222> (2)
<223> Xaa represents any amino acid.

<220>
<221> MOD_RES
<222> (3)
<223> Xaa represents an alkyl or an aromatic hydrophobic amino acid.

<220>
<221> MOD_RES
<222> (4)
<223> Xaa represents Lys, Leu, Phe or Thr.

<220>
<221> MOD_RES
<222> (5)..(7)
<223> Xaa represents any amino acid.

<220>
<221> MOD_RES
<222> (8)
<223> Xaa represents an acidic amino acid.

<400> 10
Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5

<210> 11
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<220>
<221> MOD_RES
<222> (2)
<223> Xaa represents any amino acid.

<220>
<221> MOD_RES
<222> (3)
<223> Xaa is an alkyl or an aromatic hydrophobic amino acid.

<220>
<221> MOD_RES
<222> (4)..(8)
<223> Xaa represents any amino acid.

<220>
<221> MOD_RES
<222> (9)

<223> Xaa represents an acidic amino acid.

<400> 11

Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5

<210> 12

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Peptide

<220>

<221> MOD_RES

<222> (2)

<223> Xaa represents any amino acid.

<220>

<221> MOD_RES

<222> (3)

<223> Xaa represents an alkyl or an aromatic hydrophobic amino acid.

<220>

<221> MOD_RES

<222> (4)

<223> Xaa represents Lys, Leu, Phe or Thr.

<220>

<221> MOD_RES

<222> (5)..(8)

<223> Xaa represents any amino acid.

<220>

<221> MOD_RES

<222> (9)

<223> Xaa represents an acid amino acid.

<400> 12

Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5

<210> 13

<211> 11

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<400> 13
Val Phe Arg Ser Leu Lys Tyr Ala Glu Ser Asp
1 5 10

<210> 14
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<220>
<221> MOD_RES
<222> (1)
<223> Xaa represents orthoaminobenzoic acid.

<220>
<221> MOD_RES
<222> (13)
<223> Xaa represents 3-nitrotyrosine.

<400> 14
Xaa Val Phe Arg Ser Leu Lys Tyr Ala Glu Ser Asp Xaa
1 5 10

<210> 15
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<220>
<221> modified_base
<222> (3)
<223> i

<220>
<221> modified_base
<222> (9)
<223> i

<220>
<221> modified_base
<222> (12)
<223> i

<220>
<221> modified_base
<222> (18)
<223> i

<220>
<221> modified_base
<222> (21)
<223> i

<400> 15
ggncayggna cnywykkngc ngg

23

<210> 16
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<220>
<221> modified_base
<222> (3)
<223> i

<220>
<221> modified_base
<222> (6)
<223> i

<220>
<221> modified_base
<222> (9)
<223> i

<220>
<221> modified_base
<222> (12)
<223> i

<220>
<221> modified_base
<222> (15)
<223> i

<220>
<221> modified_base
<222> (18)
<223> i

<220>
<221> modified_base
<222> (21)
<223> i

<220>
<221> modified_base
<222> (24)
<223> i

<220>
<221> modified_base
<222> (29)
<223> i

<400> 16
ccngynacnw snggnswngc nacnswgtnc c

31

<210> 17
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<220>
<221> MOD_RES
<222> (5)
<223> Xaa represents histidine or phenylalanine.

<220>

<221> MOD_RES
<222> (6)
<223> Xaa represents valine or cysteine.

<400> 17
Gly His Gly Thr Xaa Xaa Ala Gly
1 5

<210> 18
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<220>
<221> MOD_RES
<222> (4)
<223> Xaa represents valine or methionine.

<220>
<221> MOD_RES
<222> (6)
<223> Xaa represents threonine or serine.

<220>
<221> MOD_RES
<222> (8)
<223> Xaa represents histidine or valine.

<220>
<221> MOD_RES
<222> (10)
<223> Xaa represents alanine or threonine.

<400> 18
Gly Thr Ser Xaa Ala Xaa Pro Xaa Val Xaa Gly
1 5 10

<210> 19
<211> 28
<212> DNA
<213> Homo sapiens

<400> 19

ggatccgaag aaacatctgg gcgacaga

28

<210> 20

<211> 24

<212> DNA

<213> Homo sapiens

<400> 20

ctcgagggt ctcagccgtg tgct

24

<210> 21

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 21

gaggaagaga caggataaa c

21

<210> 22

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 22

gggatatgct tagcattgac

20

<210> 23

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 23

agccctatta cctgaacctg

20

<210> 24

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 24

gaatctgaaa gaactcccc

20

<210> 25

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 25

ttccgagatt ccatacctacg

20

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 26

tgcagctcag caggtctatg

20

<210> 27

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 27
tctcctccaa cctcaaccac 20

<210> 28
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 28
ccagcctgtc atcctcaata tc 22

<210> 29
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 29
ggagccatgg attgcacttt c 21

<210> 30
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 30
aggagctcaa tgtggcagga 20

<210> 31
<211> 27

<212> DNA
 <213> Homo sapiens

 <400> 31
 gtgaccatga agcttgtcaa catctgg 27

 <210> 32
 <211> 26
 <212> DNA
 <213> Homo sapiens

 <400> 32
 acactgggtcc ctgagagggc ccggca 26

 <210> 33
 <211> 21
 <212> DNA
 <213> Homo sapiens

 <400> 33
 attgacctgg acaaggtggt g 21

 <210> 34
 <211> 57
 <212> DNA
 <213> Homo sapiens

 <400> 34
 ggatcctcta gatcagtggg ggtgggtggg gtgggtgctcc tggttgtagc ggccagg 57

 <210> 35
 <211> 24
 <212> DNA
 <213> Homo sapiens

 <400> 35
 ctcgagggag aggctggctc ttcg 24

 <210> 36
 <211> 28
 <212> DNA
 <213> Homo sapiens

<400> 36
ctcgagtgtc tgggcaacct ggcgcggg

28

<210> 37
<211> 14
<212> PRT
<213> Homo sapiens

<400> 37
Lys Ala Gly Ser Arg Gly Leu Thr Ser Leu Ala Asp Thr Phe
1 5 10

<210> 38
<211> 27
<212> PRT
<213> Homo sapiens

<400> 38
Gly Gly Ala His Asp Ser Asp Gln His Pro His Ser Gly Ser Gly Arg
1 5 10 15

Ser Val Leu Ser Phe Glu Ser Gly Ser Gly Gly
20 25

<210> 39
<211> 18
<212> PRT
<213> Homo sapiens

<400> 39
Trp His Ala Thr Gly Arg His Ser Ser Arg Arg Leu Leu Arg Ala Ile
1 5 10 15

Pro Arg

<210> 40
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<400> 40
Trp His Ala Thr Gly Arg His Ser Ser Arg Arg Leu Leu Arg Ala Leu
1 5 10 15

Glu

<210> 41
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Peptide

<400> 41
Ser Arg Arg Leu Leu Arg Ala Leu Glu
1 5

<210> 42
<211> 17
<212> PRT
<213> Homo sapiens

<400> 42
Trp Gln Ser Ser Arg Pro Leu Arg Arg Ala Ser Leu Ser Leu Gly Ser
1 5 10 15

Gly

<210> 43
<211> 15
<212> PRT
<213> Homo sapiens

<400> 43
Arg Ala Ile Pro Arg Gln Val Ala Gln Thr Leu Gln Ala Asp Val
1 5 10 15

<210> 44
<211> 9
<212> PRT
<213> Homo sapiens

<400> 44

Pro Gln Arg Lys Val Phe Arg Ser Leu

1 5

<210> 45

<211> 15

<212> PRT

<213> Homo sapiens

<400> 45

Pro Gln Arg Lys Val Phe Arg Ser Leu Lys Tyr Ala Glu Ser Asp

1 5 10 15

<210> 46

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (1)

<223> Xaa represents orthoaminobenzoic acid.

<220>

<221> MOD_RES

<222> (13)

<223> Xaa represents 3-nitrotyrosine.

<220>

<223> Description of Artificial Sequence: Peptide

<400> 46

Xaa Val Phe Arg Ser Leu Lys Tyr Ala Glu Ser Asp Xaa Ala

1 5 10

<210> 47

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (1)

<223> Xaa represents orthoaminobenzoic acid.

<220>
<221> MOD_RES
<222> (11)
<223> Xaa represent 3-nitrotyrosine.

<220>
<223> Description of Artificial Sequence: Peptide

<400> 47
Xaa Arg Ser Leu Lys Tyr Ala Glu Ser Asp Xaa Ala
1 5 10

<210> 48
<211> 16
<212> PRT
<213> Homo sapiens

<400> 48
Lys Ala Gly Ser Arg Gly Leu Thr Ser Leu Ala Asp Thr Phe Glu His
1 5 10 15

<210> 49
<211> 16
<212> PRT
<213> Rattus sp.

<400> 49
Lys Ala Gly Ser Arg Gly Leu Thr Thr Thr Ser Leu Ala Asp Thr Phe
1 5 10 15

<210> 50
<211> 16
<212> PRT
<213> Homo sapiens

<400> 50
Arg His Ser Ser Arg Arg Leu Leu Arg Ala Ile Pro Arg Gln Val Ala
1 5 10 15

<210> 51
<211> 16
<212> PRT
<213> Homo sapiens

<400> 51

Arg Lys Val Phe Arg Ser Leu Lys Tyr Ala Glu Ser Asp Pro Thr Val
1 5 10 15

<210> 52

<211> 16

<212> PRT

<213> Homo sapiens

<400> 52

Thr Pro Gln Arg Lys Val Phe Arg Ser Leu Lys Tyr Ala Glu Ser Asp
1 5 10 15

<210> 53

<211> 16

<212> PRT

<213> Homo sapiens

<400> 53

Val Thr Pro Gln Arg Lys Val Phe Arg Ser Leu Lys Lys Tyr Ala Glu
1 5 10 15

<210> 54

<211> 16

<212> PRT

<213> Homo sapiens

<400> 54

Ser Gly Ser Gly Arg Ser Val Leu Ser Phe Glu Ser Gly Ser Gly Gly
1 5 10 15

<210> 55

<211> 16

<212> PRT

<213> Homo sapiens

<400> 55

His Ser Pro Gly Arg Asn Val Leu Gly Thr Glu Ser Arg Asp Gly Pro
1 5 10 15

<210> 56

<211> 16

<212> PRT
<213> Rattus sp.

<400> 56
Ala Ser Val Gly Arg Leu Ala Leu Ser Gln Glu Glu Pro Ala Pro Leu
1 5 10 15

<210> 57
<211> 16
<212> PRT
<213> Homo sapiens

<400> 57
Arg Ile Ser Asp Arg Asp Tyr Met Gly Trp Met Asp Phe Gly Arg Arg
1 5 10 15

<210> 58
<211> 16
<212> PRT
<213> Rattus sp.

<400> 58
Asp Pro Arg Leu Arg Gln Phe Leu Gln Lys Ser Leu Ala Ala Ala Thr
1 5 10 15

<210> 59
<211> 16
<212> PRT
<213> Bovis sp.

<400> 59
Leu Leu Lys Glu Leu Gln Asp Leu Ala Leu Gln Gly Ala Lys Glu Arg
1 5 10 15

<210> 60
<211> 16
<212> PRT
<213> Bovis sp.

<400> 60
Met Ala Arg Ala Pro Gln Val Leu Phe Arg Gly Gly Lys Ser Gly Glu
1 5 10 15

<210> 61
<211> 16
<212> PRT
<213> Bovis sp.

<400> 61
Glu Leu Glu Asn Leu Ala Ala Met Asp Leu Glu Leu Gln Lys Ile Ala
1 5 10 15

<210> 62
<211> 16
<212> PRT
<213> Bovis sp.

<400> 62
Ala Ala Met Asp Leu Glu Leu Gln Lys Ile Ala Glu Lys Phe Ser Gly
1 5 10 15

<210> 63
<211> 16
<212> PRT
<213> Rattus sp.

<400> 63
Lys Ser Ser Phe Thr Asn Val Thr Ser Pro Val Val Leu Thr Asn Tyr
1 5 10 15

<210> 64
<211> 16
<212> PRT
<213> Rattus sp.

<400> 64
Lys Ser Gln Thr Pro Leu Val Thr Leu Phe Lys Asn Ala Ile Ile Lys
1 5 10 15

<210> 65
<211> 16
<212> PRT
<213> Rattus sp.

<400> 65
Ser Gln Thr Pro Leu Val Thr Leu Phe Lys Asn Ala Ile Ile Lys Asn
1 5 10 15

<210> 66
<211> 16
<212> PRT
<213> Rattus sp.

<400> 66
Gly Pro Ala Arg Glu Leu Leu Leu Arg Leu Val Gln Leu Ala Gly Thr
1 5 10 15

<210> 67
<211> 16
<212> PRT
<213> Homo sapiens

<400> 67
Leu Leu Arg Lys Lys Arg Thr Thr Ser Ala Glu Lys Asn Thr Cys Gln
1 5 10 15

<210> 68
<211> 16
<212> PRT
<213> Homo sapiens

<400> 68
Glu Glu Ile Ser Glu Val Lys Met Asp Ala Glu Phe Arg His Asp Ser
1 5 10 15

<210> 69
<211> 16
<212> PRT
<213> Homo sapiens

<400> 69
Glu Glu Ile Ser Glu Val Asn Leu Asp Ala Glu Phe Arg His Asp Ser
1 5 10 15

<210> 70
<211> 16
<212> PRT
<213> Homo sapiens

<400> 70

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Ser | Glu | Val | Lys | Met | Asp | Ala | Glu | Phe | Arg | His | Asp | Ser | Gly | Tyr |
| 1 | | | | 5 | | | | 10 | | | | | | 15 | |

<210> 71

<211> 16

<212> PRT

<213> Homo sapiens

<400> 71

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Phe | Arg | His | Asp | Ser | Gly | Tyr | Glu | Val | His | His | Gln | Lys | Leu | Val |
| 1 | | | | 5 | | | | 10 | | | | | | 15 | |

<210> 72

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Peptide

<400> 72

| | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Ser | Arg | Arg | Leu | Leu | Arg | Ala | Ile | Glu |
| 1 | | | | 5 | | | | 10 | |

<210> 73

<211> 12

<212> PRT

<213> Homo sapiens

<400> 73

| | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Gly | Ser | Gly | Arg | Ser | Val | Leu | Ser | Phe | Glu | Ser |
| 1 | | | | 5 | | | | 10 | | | |

<210> 74

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (1)

<223> Xaa represents orthoaminobenzoic acid.

<220>

<221> MOD_RES
 <222> (13)
 <223> Xaa represents 3-nitrotyrosine.

 <220>
 <223> Description of Artificial Sequence: Peptide

 <400> 74
 Xaa Arg His Ser Ser Arg Arg Leu Leu Arg Ala Ile Xaa Ala
 1 5 10

<210> 75
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Peptide

<220>
 <221> MOD_RES
 <222> (1)
 <223> Xaa represents orthoaminobenzoic acid.

<220>
 <221> MOD_RES
 <222> (11)
 <223> Xaa represents 3-nitrotyrosine.

<400> 75
 Xaa Ser Arg Arg Leu Leu Arg Ala Leu Glu Xaa Ala
 1 5 10

<210> 76
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> MOD_RES
 <222> (1)
 <223> Xaa represents orthoaminobenzoic acid.

<220>
 <221> MOD_RES
 <222> (14)

<223> Xaa represents 3-nitrotyrosine.


<220>

<223> Description of Artificial Sequence: Peptide

<400> 76

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Xaa | Asn | Gly | Pro | Lys | Ala | Gly | Ser | Arg | Gly | Leu | Thr | Ser | Xaa | Ala |
| 1 | | | | 5 | | | | | 10 | | | | | 15 |

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

~~/~~ Scanned copy is best available. Some Figures are dark.